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Cervical cancer is one of the most common malignancies 
affect ing women worldwide. The estimated new cancer cervix 
cases per year are 500,000 of which 79% occur in the developing 
countries ( lARC Scientific Publication, 1997). It arises from con-
tinuously progressive premalignant lesions defined as dysplasia. 
These precursor lesions or dysplasia tradit ionally occur a decade 
earlier than does the invasive cancer. Epidemiological studies re-
veal multiple etiologic factors responsible for the development 
of the disease. These include infection with certain oncogenic 
types of human papillomaviruses (HPVs), and other socio-eco-
nomic factors ( lARC, 1995; Bosch et al., 1995; Schi f fman et al 
1996; Walboomers et al., 1999; Franco et al., 1999; Frenczy and 
Franco, 2002). Extensive viral carcinogenesis studies the world 
over point to human papillomavirus as in important factor in cer-
vical carcinogenesis. Certain high-risk HPVs have been found to 
be associated in 80% of cervical cancers (Das et al., 1992). Sev-
eral lines of experimental evidences suggest HPV infection alone 
to be insufficient for transforming a normal cell to malignant one. 
This suggest the involvement of some genetic events either inde-
pendently or in conjunction with HPV infection. Cervical lesions 
accumula te a number of mutat ions as they progress towards 
malignancy and invasion. Therefore, the identif ication of recur-
rent chromosomal location is of utmost importance for the 
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understanding of the biology of this cancer. The genetic alterations in 
cervical cancer might be either a consequence of biological selection for 
specific chromosome locations containing integrated HPV DNA or result 
from other alterations that are recurrently effected in this tumor. The 
recurrent genetic alterations can take several forms such as point mutation, 
viral DNA integration or LOH. LOH has been detected in a wide variety of 
human tumors. It was further postulated that mutations in the critical 
pathways, which maintain the fidelity during the process of DNA 
replication, DNA repair, cell division and cell differentiation, could lead to 
genomic instability. This novel type of genomic instability, called 
microsatellite instability (MSI), first discovered in hereditary non polyposis 
colorectal cancer, indicates the defect in mismatch repair pathway. 
Microsatellite repeat alterations are the result of slippage due to strand 
misalignment during DNA replication in the tumor or dysplastic tissue 
when compared to constitutional DNA of the same individual. Current 
theories of origin of human cancer suggest that cancer arises at least in part, 
from somatic activation of cellular oncogenes and germline or somatic 
inactivation of tumor suppressor genes. It has recently been reported that 
cerb-B2 oncogene is overexpressed in adenocarcinomas of uterine cervix 
(Kihana et al., 1994) and in CIN and invasive cancer of the cervix (Mitra et 
al., 1994b; Soh et al., 2002). Similarly, increased cytoplasmic expression of 
P-catenin has also been observed in several malignancies. 
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In the present study, loss of heterozygosity and microsatelhte 
instability were analyzed in 58 cervical dysplasia cases, using ten different 
polymorphic markers on PGR based assays. Infection with human 
papillomavirus in different grades of lesions in 473 females was done using 
MY09/11 consensus primers and HPV typing for the types 6, 11, 16, 18 and 
33 was done using type specific primers. A new low-cost PCR-RFLP 
method was developed to detect the above five types commonly associated 
with cervical abnormalities. Study of oncogenes erbB-2 and P-catenin was 
done using immunohistochemistry. Microdissection of the paraffin 
embedded tissue of patients with preneoplastic lesions was done under 
dissecting microscope and malignant and subsequent normal areas were 
scraped from the same section with the help of sterile blades taking 
guidance from the stained slide. DNA isolation was done from the 
microdissected material, samples were deparaffinized with Xylene, 
followed by PK digestion and phenol-chloroform extraction. 30-50ng DNA 
was used as the template for PGR. Standard Polymerase chain reaction was 
carried out in a 25|iL reaction volume containing 30-50ng of DNA as 
template, 20pmol of primers. Forward primer was end-labeled with [y^^P] 
ATP. LOH was studied with five markers for the chromosomal arms 3p 
and 5p, which are reported to be firequently involved in many cancers of 
human origin including cervical cancer. Markers that gave a single major 
5 Abstract 
band in the normal DNA were termed "noninformative" (homozygous). 
Complete absence of upper or lower allele compared with constitutional 
alleles was considered evidence for LOH. LOH in precancers was found to 
be insignificant (<25%), as compared to previously obtained results in 
invasive cervical cancers (Mitra et al , 1994a) lesions maximum LOH 
(13.3%) was observed on chromosome 5pl5.1 (D5S406) supporting the 
study of (Mitra et al., 1994a) suggesting the possibility of a novel candidate 
tumor suppressor gene at 5p, present study of 58 precancerous LOH at 
3pl4.2 (fhit gene region) which has been reported to be frequently deleted 
in many cancers showed LOH (10.7%). 
. Analysis of MSI was done using the Bethesda Consensus 
Conference reference panel of five markers, Bat-25, BAT-26, D2S123, 
D5S346 and D17S250 (Boland, et al. 1998). Maximum instability was 
found in the 2pl6 region (D2S123), where the repeat motifs were (CA)i3 
TA (CA)i5 (T/GA)ii . In addition to MSI, LOH was also observed with the 
same primers, BAT 25 which amplifies the (A)n tract located in the intron 
of c-kit oncogene also showed instability in many cases, primer (BAT26) 
from the intron 5 of hMSH2 gene, also showed little instability. 
Conclusively, both mono and dinucleotide repeat markers were equally 
susceptible to instability. HPV infection in both mild and severe dysplasia 
was significantly higher in cases exhibiting MSI as compared to MSS 
cases. Microsatellite instability together with HPV infection appears to be a 
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good prognostic indicator for categorizing female that are at higher risk of 
developing cancer. HPV type 6 was predominantly present in all grades of 
lesions including invasive cancer and co-infection of HPV types 6 and 16 
was also found in 26% of SCC. 
The oncogene c-erbB2 located on chromosome 17q has been 
reported to be frequently amplified and overexpressed in many 
adenocarcinoma and carcinoma of breast (Slamon et al., 1989), stomach 
(Yokota et al., 1988), renal (Freeman et al., 1989) and ovary (Slamon et al., 
1989; Tyson et al., 1991; Hou et al., 1996). Overexpression of beta-catenin 
in the cytoplasm or nucleus is often found in cancers of various organs, 
including the large intestine (Takayama et al., 1998), endometrium, ovaries 
(Davies et al., 1998), esophagus (Yukuta Kimura et al., 1999), thyroid 
(Huang et al., 1998), soft tissue (Alman et al., 1997) and liver (Nhieu et 
al.,1999). Therefore the localization (cell membrane, nuclei or cytoplasm) 
of P-catenin is of considerable importance. It has been reported by Yutaka 
Kimura et al., (1999) that accumulation of free soluble P-catenin in the 
cytoplasm and nuclei frequently occurs during carcinogenesis of squamous 
epithelium of esophagus. P- catenin was expressed on the cell membrane in 
non cancerous epithelial cells while it was frequently expressed in the 
cytoplasm and/or nucleus in cancer cells (Takehiro, et al 2001). P-catenin is 
a structural component of the E-cadherin mediated cell-cell adhesion 
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system as well as signaling molecule of the Wnt/wingless pathway (Miller , 
et al , 1999). In this signaling pathway (Behrens, et al., 1999; Morin, et al., 
1999), p-catenin functions as an activator of T- Cell factor (TCF)/ 
lymphoid enhance factor (LEF), and upregulates the transcription of 
downstream genes including c-myc (He, et al., 1998) and cyclin D1 (Tetsu, 
et al., 1999), which may be involved in human carcinogenesis. Cellular 
localization and expression of erbB-2 (HER-2/neu) and (3-catenin was 
investigated by immunohistochemistry. 3'Diaminobenzidine (DAB) was 
used as chromogen for staining. Prmary antibodies, biotinylated secondary 
antibody and peroxidase conjugated streptavidin were obtained from 
Neomarker [LSAB Kit, (Ready to use)]. In the present study of 58 cervical 
dysplasia cases (25 were mild dysplasia and 33 severe dysplasia) for the 
expression of erbB-2 oncogene. erbB-2 expression was found to be 8% 
(2/25) in mild dysplasia and 9% (3/33) in severe dysplasia (Chart 3). No 
significant correlation was observed in relation to HPV status (Fig 8.1). 
Similarly, Results showed that the abnormal expression of P-catenin 
increases during the progression of mild to severe dysplasia. Out of 58 
dysplasia cases studied, abnormal expression of p-catenin was significantly 
high (p = 0.03) in severe dysplasia as compared to mild/moderate dysplasia. 
In severe dysplasia HPV P-catenin expression was significantly higher in 
HPV positive cases as compared to HPV negative cases. 
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LOH at 5p 15.1 in precancers and cancer suggest the possibility of a 
novel candidate TSG at 5p. Results on the analysis of microsatellite 
instability using five internationally recommended primers showed high 
frequency of MSI in precancers suggesting that both mono and dinucleotide 
repeats are equally susceptible to instability. HPV infection was high in 
cases exhibiting MSI in precancers and invasive cancers, as compared to 
microsatellite stable cases. Both HPV and MSI together appear to be a good 
prognostic indicator for categorizing females that are higher risk of 
developing cancer. High incidence of HPV type 6 in dysplasia and invasive 
cancer was found. On the basis of serological and epidemiological 
evidences it appears that HPV type 6 also has some role in carcinogenesis. 
To understand the biological behavior of HPVs it is important to analyze 
the interaction between different HPV types. Further researches on the 
assessment of oncogenic potential of HPV type 6 are required. HPV type 
16 was significantly high in cancers than precancers. Co-infection of HPV 
types 6 and 16 was also observed in significant number of cases in invasive 
cancer. ErbB2 expression was found low in cervical dysplasia though 
cytoplasmic expression of P-catenin was found to be increased in cervical 
dysplasia. In severe dysplasia cytoplasmic (3-catenin expression (69%) was 
significantly higher (p<0.01) in HPV positive samples as compared to HPV 
negative (35%), whereas, in mild dysplasia no such correlation was 
observed (table 8.1). Cytoplasmic P-catenin staining was found to be 
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significantly high in severe dysplasia than mild dysplasia. Therefore it is 
likely that accumulation of P-catenin in cytoplasm starts in late dysplasia 
and could pass into the nucleus (nuclear translocation) and interact with 
transcription factors causing progression to cancer. 
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1. INTRODUCTION 
Cancer of the uterine cervix is the second most common cancer 
among women worldwide. The estimated new cervical cancer cases per 
year are 5, 00,000, of which 79% occur in the developing countries (lARC 
Scientific Publication, 1997). In India alone approximately 100,000 new 
cases of cervical cancer develop per year. Precursors of cervical cancer 
traditionally occur at least a decade earlier than does the invasive cancer, 
supporting the temporal evolution of cervical cancer from its precursors 
(Koss et al, 1963; Richart 1973; Hellberg et al., 1993). These precursors or 
precancerous lesions are known as dysplasia. The term "dysplasia" which 
literally means bad molding was introduced in the late 1950s (Reagan et al., 
1953). A spectrum of pathological lesions between normal epithelium to 
cancer occurs as mild, moderate, severe dysplastic and carcinoma in-situ, 
before developing uterine cervical cancer. Biological behavior of the 
dysplastic lesions differ, some of these lesions if left untreated, progress to 
cancer while some regress to normal and some other persist for longer 
period. This offers an unique opportunity to study the molecular events 
during the process in the development of cervical cancer. Several lines of 
evidence suggest that tumorigenesis is a multi-step process and that these 
steps reflect genetic alterations that drive the progressive transformation of 
normal human cells into highly malignant derivative (Hanahan, et al, 
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2000). Pathological analyses of a number of organ sites reveal lesions that 
appear to represent the intermediate steps in a process through which cells 
evolve progressively from normalcy via a series of premalignant states into 
invasive cancers (Foulds L, 1954). 
Cancer in general is a multifactorial disease, involving number of 
etiological factors either environmental or genetic. Epidemiological studies 
suggested role multiple risk-factors. Cervical intraepithelial neoplasia 
(CIN) and cervical cancer are strongly associated with certain HPV types 
(lARC Working group, 1995). But a small percentage of women infected 
with human papillomaviruses develop cervical cancer. Recently, large 
series of molecular and epidemiological studies conducted in past two 
decades reveal that cervical infection by certain human papillomavirus 
types is a precursor event in the genesis of cervical neoplasia (zur Hausen, 
1991, 1996, Munoz et al 1992, Schiffman et al 1993, 1995; Bosch et al 
1995, Franco et al 1995). However, experimental evidences also suggest 
infection of HPV alone is not sufficient for transforming a normal cell into 
malignant one. These indicate possible involvement of some genetic 
alterations in the development of cervical cancer either independently or in 
conjunction with other etiological factors including HPV infection. These 
genetic alterations could be a cascade of genetic alterations involving either 
inactivation of tumor suppressor genes (Mitra et al., 1994a; Mullokandov et 
al., 1996) or activation of oncogenes (Bishop and Weinberg, 1996; Peifer et 
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al., 1997), or both. Recently, differential amplification as well as expression 
of erbB-2 and beta-catenin were reported in cervical cancer (Mitra et al., 
1994b; Sharma et al., 1999; Pinion et al., 1991). 
Earlier, two-hit model of carcinogenesis (Knudson 1971) proposed 
that a mutation transmitted as a dominant trait might be recessive at the 
cellular level and lead to cancer when the normal allele is lost or 
inactivated. This mechanism is also applicable to malignancies developing 
as a result of the accumulation of alterations at multiple loci, some of which 
must be activated and some inactivated. Allele loss studies require the 
identification of locus specific polymorphic markers. Studies of 
chromosome specific loss of heterozygosity (LOH) in tumour cells have 
been used to suggest the presence of tumour suppressor genes. The loss of 
function of tumour suppressor genes is now considered to be the critical 
event in the genesis of cancer. Some non-random genetic deletions were 
frequently observed in various human cancers. Recently, microsatellite 
instabilities, which is apparently because of a gene mutation, causing 
multiple errors in DNA replication (Aaltonen et al 1993), were also 
reported in various precancerous and cancerous lesions. 
In view of the above, the aim of the present study was to investigate 
the status of genetic alterations and HPV infection in precancerous lesions 
of the uterine cervix in order to understand the possible molecular events 
involved in the development of cervical cancer. 
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2. AIMS AND OBJECTIVES 
The aims of the present study were: 
1. Analysis of microsatellite instability, using reference panel of five markers, 
Bat-25, BAT-26, D2S123 (AFM093xh3), D5S346 (APC) and D17S250 
(Mfd215 CA) including both mono and dinucleotide repeats and their 
correlation with HPV infection in each cervical dysplasia. 
2. To determine the prevalence of LOH on chromosomes 3p and 5p in the 
precancerous lesions of the uterine cervix. 
3. Detection of Human papillomavirus infection among different grades of 
lesions, and typing of prevalent HPV types (6, 11,16, 18 and 33). 
4. Analysis of expression of the oncogene c-erbB2/Her2neu in preneoplastic 
lesions, which is reported to be over expressed in squamous cell carcinoma 
and adenocarcinoma of uterine cervix , by immunohistochemistry. 
5. Analysis of the expression of cytoplasmic fi-catenin in cervical dysplasia, 
by immunohistochemistry. 
Aims and Objectives 
Heview of 
Literature 
3. REVIEW OF LITERATURE 
Cervical cancer is one of tiie most common malignancies affecting 
women worldwide. It is the eighth commonest cancers in the world and 
the second most common cause of cancer-related mortality in women 
worldwide. The estimated new cancer cervix cases per year are 500,000 
of which 79% occm* in the developing countries (lARC Scientific 
Publication, 1997), with an estimated death of around 203,000 annually 
(Van Ranst et al., 1992). Epidemiological studies revealed multiple 
etiologic factors associated with cervical cancer. This cancer primarily 
arises from continuously progressive premalignant lesions defined as 
mild to severe dysplasia. 
Graph 3.1 Showing International Comparisons- AAR (Age adjusted 
incidence rate) of seven countries and six major cities in India 
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1 ® Review of Literature 
Despite the fact that cervical cancer represents a worldwide problem 
where it remains one of the most common causes for cancer-related 
mortality and morbidity for women, very little is known about the molecular 
etiology of this disease. Since prognosis for the invasive cancer is generally 
poor, the molecular analysis and the dissection of the molecular events that 
mediate the pathological changes from non-invasive to invasive tumors is of 
considerable interest. The higher rates of cervical cancer are generally 
restricted to developing countries especially to South East Asian regions. 
The highest age adjusted incidence rate (AAR) of cancer cervix was seen in 
Africans in Harare, Zimbabwe and in Trujillo, Peru (Graph 3.1). Most of the 
National Cancer Registries have been showing declining or stationary trends 
since 1998. However, changes in sexual behavior among adolescents, 
increase in oral contraceptive use, built-up of HIV epidemic, lack of 
infrastructure to screen, detect and treat pre-cancerous lesions may reverse 
these trends in years to come. It has been estimated that every year about 
0.15 million new cervical cancers are prevalent. The precancerous lesions 
(low grade and high grade squamous intra-epithelial lesions) account for 
about 6 million cases in the country. It occupies either the top rank or second 
among cancers in women in the developing countries, whereas in the 
affluent countries cancer cervix does not even find a place in the top 5 
leading cancers in women. India contributes 100,000, i.e. 1/5 of the world 
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burden. The truncated rate (TR) in the age group 35-64 years in Chennai, 
India, is even higher (99.1/100,000; 1982-95) than rate reported from Cali, 
Colombia (77.4/100,000, 1987-91). The cervical cancer burden in India 
alone is estimated as 100,000 in 2001 AD (Shanta et al., 2000). Carcinoma 
of the uterine cervix is the most common cancer in South Indian women and 
occupies the top rank among cancers in women in most developing 
countries, constituting 34% of all women's cancers. The magnitude of the 
problem is thus more than evident. The world pattern of cervical cancer, 
together with the age adjusted rate and ranking, clearly indicate that cervical 
cancer is predominantly a problem of poorer socio-economic societies. The 
differential pattern of cervical cancer and the wide variation in incidence are 
possibly related to environmental differences (Shanta et al., 2000). 
Cancer of the cervix is the number one cancer in females in 
Bangalore, Barshi, Bhopal and Chennai. While over 50% of cancers in 
females in Barshi were cancers of the cervix, Chennai had the highest AAR 
of 30.7 per 100,000. Incidence rate begins to rise in the early twenties in all 
registries and reach a peak in the 50-54 age group and only slowly 
thereafter. In all the registries over 90% of cases of cancer of cervix were 
squamous cell carcinomas. Adenocarcinoma constituted 2-4% of all cervical 
cancers. According to PBCR report (1990-96) cancer of the cervix was the 
leading site in Bangalore, Barshi, Chennai and second in Delhi and Mumbai 
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after the cancer of breast (Graph 3.2). Most of the National Cancer 
Registries have been showing a declining or stationery trends since 1988. It 
has been estimated that every year 0.15 million new cervical cancer arise 
annually in India.The precancerous lesions (low grade and high grade 
squamous intra-epthelial lesions) account for 6 million cases prevalent in the 
country. 
Graph 32 The bar chart shows the five leading sites of cancer in the five 
registries in females. The leading sites of cancer were decided on the 
basis of crude incidence rat^. 
so-r 
• Cervix 
• Breast 
• Oesophagus 
• Ovary 
• Oral Cavity 
BarshI Bangalore Chennai Delhi Mumbat 
Two sites, cervix and breast together constituted over 40% of cancer of all 
sites in females in urban registries and over 65% of cancers in the rural 
registry at Barshi (Consolidated report of PBCRs: 1990-1996). Cervical 
cancer is the most common malignancy among Indian women was likely to 
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afflict an estimated 1,00,000 women during the year 2001 constituting 18% 
of the world's annual incidence. It has been shown in one of the long term 
prospective study that the natural history of the disease is the same as that 
reported in the West (Luthra et al 1987) and that every alternate severe 
dysplasia would progress to carcinoma-in-situ, every 4"' moderate dysplasia 
and every lO'^  mild dysplasia will show progression (Murthy, et al 1990). 
Cancer of the uterine cervix develops through well-defined 
precursor lesions called dysplasia. These lesions traditionally occur a 
decade earlier than does the invasive cancer. Dysplasia was further 
subdivided into mild, moderate and severe, depending on the thickness of 
squamous epithelium involved by atypical cells. Based on the observations 
of different follow-up studies, it was observed that some cases of dysplasia 
regressed, some persisted and other progressed to carcinoma-in situ. A 
direct correlation with progression and histological grade was observed. On 
the basis of above observations, the term cervical intraepithelial neoplasia 
(CIN) was introduced in 1968. CIN was divided into CIN I corresponding 
to mild dysplasia, CIN II moderate dysplasia and CIN III correspond to 
severe dysplasia/carcinoma in situ (CIS) (Richart, 1973). In 1992, 
Bethesda system (TBS) of nomenclature was introduced. The main features 
of TBS were the creation of the term squamous intraepithelial lesion (SIL), 
and a two-grade scheme consisting of low grade (LSIL) and high grade 
(HSIL) lesions. The histological and cytological classification is given in 
1 ® Review of Literature 
table 3.1 (lARC Monograph, 1995). TBS was reevaluated and revised in a 
2001, representing more than 20 countries (Solomon et al., 2001). For the 
present study the terminology of WHO was used. 
1 ® Review of Literature 
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HISTOLOGY 
Invasive carcinoma of uterine cervix mainly comprises three 
histologic types called squamous cell carcinoma, adenocarcinoma and 
adenosquamous carcinoma. The occurrence of adenocarcinoma and 
adenosquamous carcinoma is relatively low i.e. between 3 and 10% 
whereas squamous cell carcinoma involves 90% of all cervical cancers. 
The development of cervical cancer is gradual and may take many years, 
precancerous lesions representing a spectrum of abnormal epithelial 
changes, commonly termed as dysplasias or precursor lesions, usually 
precede it. Both stratified non-keratinizing squamous and columnar 
epithelium cover the cervix. These two types of epithelium meet at the 
squamocolumnar junction (Fig 3.IB). The histological architecture of 
the squamous epithelium of the cervix reveals, at the bottom, a single 
layer of round basal cells with a large dark staining nuclei and little 
cytoplasm, attached to the basement membrane. The basement 
membrane separates the epithelium from underlying stroma (composed 
of dense fibromuscular tissue). The endocervical canal is lined by 
columnar epithelium (composed of single layer of tall cells with dark 
staining nuclei close to basement membrane) 
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Fig. 3.1 A. Showing the uterus, cervix and vagina and B. 
squamocolunmar junction, place where the columnar epithelium 
changes abruptly into the squamous epithelium. 
The border at which columnar epithelium changes abruptly into the 
squamous epithelium is called 'squamocolumnar junction' and just above the 
squamocolumnar junction lies the "transformation zone" a zone of columnar 
epithelial cells that is undergoing a gradual change into squamous epithelium, 
it is the place where most cervical abnormalities occur, both malignant and 
benign In the zone of exposed columnar epithelium, the first indication of an 
irritation to mucus membrane is the replacement of columnar epithelial cells 
by primitive cytoplasm-poor cells, a process called reserve cell hyperplasia. 
When there is strong irritation the columnar cells are badly damaged and are 
shed. The lack of epithelial lining stimulates a repair process called squamous 
metaplasia and the cells mature into squamous metaplastic epithelium. This is 
a normal physiologic process occurring in all women 
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during their fertile years. In some cases, the maturation is not normal 
and develops abnormal epithelial changes known as precancerous 
lesions. Depending on the extent of abnormal changes in the epithelium 
it can be graded into mild, moderate and severe. In mild dysplasia 1/3"^  
of the epithelial thickness is composed of dysplastic, basaloid type cells 
with an increasing nuclear: cytoplasmic ratio (Figure 3.2). In moderate 
dysplasia alterations cover to of epithelium (Figure 3.3). 
Whereas, almost the entire epithelium is occupied by basaloid-type cells 
in severe dysplasia (Figure 3.4). 
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Fig3 I^VIild dysplasia. 
In mild dysplasia one third of epithelial thickness is composed of basaloid cells (indicated 
by arrow), showing hyperchromatic, enlarged nuclei with spindle or ovoid shape. The 
normal orientation of the cells is disturbed and showing a characteristic vertical polarity. 
In mild dysplasia the cells at the basal layer change first and become chaotically 
arranged. However, in the middle and superficial layers maturation to normal ceils 
continues. Only mild nuclear abnormalities and vacuolization in the cytoplasm can be 
seen 
if"' • dt 
Fig>^Moderate dysplasia 
Two third of the epithelium is occupied by basaioid cells (indicated by arrow), showing 
the cytological abnormalities of transformed cells. Similar morphological alterations are 
discernible in half to two third of the epithelial thickness. Here also like mild dysplasia the 
orientation of the cells is disturbed so that they become vertically oriented. 
Fig3^Severe dysplasia 
In severe dysplasia almost the entire epithelium is occupied by basaloid-type ceils with 
no preferential orientation (indicated by arrow). Cells with large nuclei and vacuolized 
cytoplasm are scattered and enti re thickness of the epithelium is disorganized. Lesion 
could also show penetration into the underlying stroma or endocervical gland opening. 
However, the basement membrane remains intact. If left untreated the ceils may 
eventually break through the skin. 
Most cervical cancer is the end stage of a continuum of progressively 
more atypical changes in which one stage merges imperceptibly with the 
next. The first and apparently earliest change is the appearance of 
atypical cells in the basal layer of squamous epithelium. The atypical 
cells show changes in nucleo-cytoplasmic ratio, loss of polarity, 
increased mitotic figures and pleomorphism, in other words, all the signs 
of malignant cells. As the lesion evolves, there is progressive 
involvement of the epithelium, until it is totally replaced by atypical 
cells, exhibiting no surface differentiation. 
ETIOPATHOGENESIS OF CERVICAL DYSPLASIA 
The differential pattern of cervical cancer and the wide variation 
in incidence are possibly related to environmental differences. Etiologic 
association and possible risk factors for cervical carcinoma have been 
extensively studied. Epidemiological studies suggested role of multiple 
risk factors like Reproductive Tract Infections (RTIs) including human 
papillomavirus virus (HPV) infection and other environmental factors 
like tobacco smoking, bacterial vaginosis and chlamydia infection, in the 
etiology of cervical cancer. 2-3% of all women over the age of 40 years 
will develop some form of cervical cancer. In all registries over 90% of 
cases of the cancer of cervix were squamous cell carcinomas. 
Adenocarcinoma constitute 2-4% of all cervical cancers. The important 
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determinant of risk of progression to malignancy was found to be the 
initial grade/severity of the preneoplastic changes. The rate of 
progression of severe dysplasia (42.0%) was considerably higher than 
progression of initially moderate dysplasia (24.3%) and initially (4.9%) 
to cancer (Murthy et al., 1990b). HPVs can induce immortalization in 
primary cultures of human and rodent cells. In human cells, 
immortalization is restricted to high-risk viruses, whereas in rodent cells, 
low-risk HPV types also possess weak immortalization potential. 
Extensive viral carcinogenesis studies the world over point to human 
papillomavirus virus as an important factor in cervical carcinogenesis. 
Of the many HPV types, types 16 and 18 are documented as high-risk 
HPV associated with genital neoplasia. Although a cause and effect 
relationship between HPV and cervical cancer is yet to be proven, over 
80% of cervical cancers today are associated with HPV infection. 
In the recent past, it has been discovered that cancer is a genetic 
disease. Population studies suggested that for the progression of cervical 
carcinogenesis, HPV infection may not be the detriment of cervical 
cancer incidence rather there is involvement of some genetic event(s) 
either independently or in conjunction with HPV infections and other 
environmental factors. Cervical intraepithelial neoplasia and cervical 
cancer are both strongly associated with persistent presence of some 
types of HPVs. Epidemiology of cervical cancer suggest that besides 
genetic factors the development of uterine cancer is associated with 
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several well-recognized epidemiological risk factors which include 
sociodemographic factors like socio-economic status, religion, 
occupational factors smoking habits, oral contraceptives, genital 
hygiene, number of pregnancies, multiple sex partners Epidemiology of 
cervical cancer suggest that cervical cancer is a sexually transmitted 
disease (WHO, 1986). Several agents have been investigated for 
etiologic link, which can be: 
Chlamydia, Gardnerella vaginalis. Trichomonas vaginalis, Neisseria 
gonorrhoeae. Group B Streptococcus, Candida albicans. Herpes 
simplex, Treponema pallidum (Syphilis), and last but not the least human 
papillomaviruses. 
RISK FACTORS 
Epidemiological studies have identified a number of risk factors that 
contribute to the development of cervical cancer precursors and cervical 
cancer. These include infection with certain oncogenic types of human 
papillomaviruses (HPVs), and other socio-economic factors (lARC, 
1995; Bosch et al., 1995; Schiffman et al., 1996; Walboomers et a l , 
1999; Franco et al., 1999; Frencxzy and Franco, 2002). 
Socio-economic factors 
The exact cause of cervical cancer is still unknown. However, a number 
of predisposing factors have been identified. Major risk-factors for 
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cervical cancer in India are considered to be socio-economic status 
(related to education, low income, personal life style, multiple sexual 
partners and sexual exposure prior to age of 18). Extensive viral 
carcinogenesis studies world over point to Human papillomavirus as an 
important etiological factor. The first lARC-sponsored case control 
study on HPV and cervical cancer in India carried out at Cancer 
Institute, Chennai documented 99% of uterine cervix were HPV positive 
compared to 22% in the controls. Within the country, the highest 
incidence of cervical cancer is found in Chennai and Barshi, rural 
Maharashtra. In urban areas where the level of education is comparative 
high females are at reduced risk of cervical abnormalities (Graph 3.2 
Consolidated report of PBCR: 1990-96). Age at first intercourse, age at 
first child birth, high parity, number of sexual partners, promiscuity 
these all have been identified as possible risk factors. Progression to 
malignancy was found to be influenced by age at consummation of 
marriage (ACM). Women with consummation of marriage under 18 
years of age had a 2.8-fold higher progression than those with ACM 
over 18 years. This may be possibly due sexual insult to the younger 
cervix. Earlier ACM increases the susceptibility of the cervix to the 
further action of carcinogenesis (Brinton and Fraument, 1986; Luthra et 
al., 1987). .But none of these factors attained independent significance. 
Sexual activity and the number of male sex partners have been identified 
as specific risk factors for cervical carcinogenesis. The married women 
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of rural India are most at risk for cervical cancer. The disease has been 
less commonly found in the nun population and high among sex workers 
indicating that the partner also may playing role as a possible risk factor. 
Studies suggest that females with history of sexually transmitted disease 
are more prone to cervical cancer. High parity is also associated with 
increased risk of developing cervical abnormalities. Regular PAP tests 
have drammatically reduced the risk of developing cervical cancer in 
developed countries. Education and income have been accepted as major 
indicators of socio-economic status. The distribution of cervical cancer 
by educational level and income level in the hospital registry and 
demographic registry highlights the inverse relationship of income 
group and educational level. 
Graph 3.3 Percentage distribution of cervical cancer by education: Chennai 
HBCR. 1995 
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Besides other factors, females not maintaining proper hygiene after 
urination and intercourse are found to be at increased risk of cervical 
cancer. Proper washing of genitalia of both partners reduces the risk. 
The Indian registries show significantly lower incidence of cervical 
cancer in the Muslim women compared to other religious groups (Wahi 
et al., 1972; Jussawala et al., 1971). The religion specific incidence rate 
(RSI) of cancer cervix in Hindu is 24.1, Christian 21.0 and Muslim 11.2. 
The religious difference is strikingly marked in penile cancer incidence 
also. The high incidence of cancer cervix among Hindu women has been 
attributed to early age at coitus and poor penile hygiene on the part of 
male partner. The low frequency among Muslim women was attributed 
to the practice of ritual circumcision in Muslim men. 
Human papillomaviruses 
Cervical intraepithelial neoplasia and cervical cancer both are strongly 
associated with HPVs. Over 90% of the cervical carcinoma have been 
shown to contain HPV infection (Bosch et al., 1995). Human 
papillomaviruses have two possible roles in malignant lesions, either 
due to the presence of vial early gene expression or due to the genetic 
damage caused by viral DNA integration (Clavel et al., 1998). After 
infection there is an incubation of 6-8 weeks, certain types of HPV are 
now officially declared to be human carcinogens (lARC 1995) 
representing the most important etiological agents of cervical squamous 
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cell carcinoma and many other cancers related to squamous epithelium 
(zur Hausen 1999). Like any other viral infections HPV infection also 
remain asymptomatic or mildly symptomatic. 
Papillomaviruses are strictly species specific. HPVs need 
keratinocytes capable of terminal differentiation for their support and 
therefore target of the virus is the basal cell of squamous epithelium. 
Site of entry into the host could be any anatomical region having a 
connection to the outside environment, where squamous epithelium is 
available, such portals could include skin, oral cavity and upper 
gastrointestinal tract, larynx, conjunctiva of eye, genital tract and anal 
canal. Because the virus cannot enter through an intact squamous 
epithelium it requires 
a. abrasion or microwounds, or 
b. immature squamous epithelium (Howley 1982, Stanley 1997) 
The potential sites where a transformation zone exists either naturally or 
due to metaplastic process in the preexisting columnar epithelium 
including uterine cervix. Following infection the virus enters the nucleus 
of its target cell and ready to continue its cycle of replication by 
transcription of its DNA into RNA (zur Hausen 1994) following which 
the viral mRNAs are translated into early (E) and late (L) proteins. 
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Genomic organization of HPV 
More than hundred different types of HPVs have been identified 
so far but they share quite similar genomic organization. HPV are 
double stranded DNA tumor viruses with a circular genome of 7800-
SOOObp, which are organized into three major regions: two proteins 
coding region (early and late regions) and non-coding upstream 
regulatory region (URR). The epidemiological evidence of the role of 
HPV in cervical cancer is complemented by equally strong data on the 
role of oncoproteins E6 and E7 of high-risk HPV types in the molecular 
pathogenesis of cervical cancer. The oncoproteins exert their effect by 
forming complexes with he cellular tumour suppressor protein - E6 with 
p53 (Schef&ier M.,1990) and E7 with pRB (Munger K., et al., 1989; 
Wemess B.A., et al., 1990). The transformation potential of the E6 gene 
was required in combination with E7 for efficient immortalization of the 
cells (Hawley-Nelson 1989, Watanabe S., et al. 1989 Munger K., et al 
1989). 
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Though infection with human papillomavirus is an important etiological 
factor in the development of cervical cancer and detection of the viral 
genome is of prognostic importance, particularly for preneoplastic 
lesions. Epidemiological studies reveal multiple etiological factors 
including HPV infection. Cervical intraepithelial neoplasia and cervical 
cancer both are associated strongly with persistence presence of some of 
HPV types. Over 60% of cervical carcinoma have been shown to 
contain particular HPV types. DeVilliers 1989 reported more than 60 
HPV types associated with a variety of clinical lesions 20 of that are 
associated with anogenital tract lesions. However, more than hundred 
HPV types have been identified so far on the basis of differences in 
DNA sequences. They have specificity for different anatomic sites, for 
instance HPV 16 has a preference for mucosal squamous epithelium 
such as that of genital tract. The low risk HPV types such as 6 and 11 
are associated with genital wart lesions rarely progressing to cervical 
cancer. The high risk HPVs viz. 16 and 18 are associated with CIN and 
Cervical cancer and are said to be the persistent types. The other high-
risk types include HPV 31, 33, 35, 39, 45. 
Viral persistence and disease progression 
Viral DNA can be detected in 10-15% of asymptomatic women of 
reproductive age (Fuschs et al.,1988; Schifman M 1993). However when 
additional cervical swabs are taken during their follow-up, the majority 
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of infections were found to be transient, and only a small population of 
women tend to harbour the same HPV type in subsequent specimens 
(Moscicki et al., 1992, 1993; Hildesheim et al., 1994; Franco et al , 
1994; Evander et al., 1995 et al. Villa et al., 1997) persistence was found 
to be higher among females infected with HR-HPV types. 
Human Papillomaviruses and the Development of Cervical 
Carcinoma 
Papillomaviruses are small non-enveloped virions with icosahedral 
capsid composed of 72 capsomeres (Klug and Finch 1965; Pfister, 1987; 
Baker et al.,1991; Pfister & Fuschs, 1994) measuring 55nm in diameter. 
Viruses classified in Papillomaviridae family. Although several 
epidemiological risk factors have been implicated with the development 
of cervical cancer, the infection of HPVs are considered to be the 
principal etiological agent responsible for including cervical cancer (zur 
Hausen 1996; Das et al., 2000). More than 98% of the invasive cervical 
cancer show presence of HPV in India. HPV infection may be 
categorized into clinical and sub clinical infection. Clinical infection 
may be expressed in the form of condyloma accuminata. The subclinical 
infection is usually associated with oncogenic potential. The latent 
infection is usually associated with histological cervical lesion with 
HPV DNA. More than 70 types of HPV types have been characterized 
so far on the basis of differences in their DNA sequences (Favre et al., 
1989a,b,c and d; Heilman et al., 1980; Danos et al., 1982; Kremsford et 
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al , 1980, 1984; Gismann et al., 1977; Durst et al., 1983., Bushart et al., 
1984; Cole 1986; Benndenon et al., 1986; Lorincz et al., 1987, 1989; 
Muller et al., 1987, Nuovo et al., 1988 etc.). Type specific prevalence is 
presented for the eighteen most common HPV types as identified by 
Clifford et al; Lechner et al., 1992 in meta-analysis of HPV types in 
invasive cervical cancers are: HPV types 6, 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 68, 70, 73 and 82 in order of descending 
prevalence for each subgroup analysis. Two third of invasive cervical 
cancer cases included in the meta-analysis were associated with HPV 16 
(51.0%) or 18 (16.2%) infection. Nubia Munoz et al 2003 in their 
epidemiologic classification of human papillomavirus types grouped 
fifteen HPVs as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 68, 73 and 82); three as probable high-risk types (26, 53 and 660 
and 12 were classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 
70, 72, 81, and CP6108). 
Natural History of genital HPV infections 
Clinical findings from a variety of studies suggest cervical cancer to be a 
common HPV-associated malignancy (Krone et al., 1995) because cells 
capable of proliferation at the squamocolumnar junction are exposed to 
the surface and are therefore most susceptible to infection and 
transformation by HPV, but only a small percentage of individuals 
infected with an oncogenic type of HPV develop cancer (zur Hausen, 
1990). 
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HPV types that are preferentially found in cervical cancers have been 
designated as 'high-risk' types and those found primarily in genital warts 
and non-malignant lesions were labeled as 'low-risk' types. The concept 
of low-risk and high-risk HPV types was introduced after the isolation 
and characterization of the most prevalent HPV types in genital warts 
(HPV-6 and 11) (Gissmann & zur Hansen, 1980; Gissmann et al., 1982) 
and cervical cancer (HPV-16 and 18) (Diirst et al; Boshart et al , 1984). 
Initially it was based exclusively on the high prevalence of type 16/18 
viruses in malignant tumors and rarity of cancer biopsies containing 6 or 
11. Later, functional difference between bothy subgroups of 
papillomaviruses became apparent. Characterization of a new HPV type 
as formerly based on reassociation kinetics in liquid hybridization, later 
on comparison of the viral NA from ORFs E6, E7 and LI and currently 
from LI. Variation below 10% is considered as variants and above 10% 
are types. 
HPV Detection 
As HPV cannot be cultured in vitro and no suitable serological 
assays are at present available, current methods are based on the 
detection of HPV DNA in exfoliated cervical cells. These methods 
include the Hybrid capture assay (HCA) using signal amplification and 
the PGR which is based on the in vitro amplification of target sequences 
especially those from the highly conserved LI region of the viral 
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genome. This LI region of the viral genome is present in majority of 
mucosal HPV genotypes and the primers MY09 and M Y l l from this 
region covers a wide range of HPV types. 
Since the infection with human papillomavirus is an important 
etiological factor in the development of cervical cancer, detection of the 
viral genome is of prognostic importance, particularly for pre-neoplastic 
lesions. Cervical intraepithelial neoplasia (CIN) and cervical cancer both 
are associated strongly with persistent presence of some HPV types. It 
has also been demonstrated that dysplastic women infected with HR-
HPV types especially types 16 and 18 show a high rate of progression to 
malignancy (Curzick et al., 1992). Prospective studies have shown that 
15-18% of HPV DNA positive women developed squamous intra 
epithelial neoplasia (SIL) within two years compared to only 1-3% of 
HPV DNA negative women (Niueminen et al., 1991), in particularly the 
risk of progression for HPV types 16 and 18 was greater (approximately 
40%) than for other HPV types. Hence, detection of HPV DNA type in 
clinically normal women appears to have utility in identifying women at 
risk for progression to SIL. These observations demands for an early 
detection of virus with an easy, cost-effective and simple diagnostic 
procedure. HPVs comprise an extremely heterogenous group of viruses. 
Most are associated with proliferative squamous cell lesions (papillomas 
or warts). They can be divided into cutaneous or mucosal types, based 
on heir preferred sites or as high-intermediate- or low-risk types, based 
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on their oncogenic potential (Lorincz et al., 1992). The only rehable 
method for detecting HPV infections is to identify the presence of viral 
DNA or mRNA. HPV types are defined on the basis of the nucleotide 
sequence homology of their genomes. 
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Table 2.2 Comparison of different molecular biological methods to detect HPV. 
[Courtesy:Synjanen KJ, Papillomavirus infections in human pathology, 2000 ] 
Tech Sensitivity 
Copies/cell 
DNA 
needed 
Label and 
Testing time 
Advantages Disadv. 
• 
Southern 
Blot 
0.1 lO^g 32p 
4-5 days 
Detects new types Laborious 
Dot Blot 1.0 500ng do Rapid False +ve 
Reverse Blot 1.0 500ng 32p 
4-5 days 
High/low string 
-ency 
Individual 
labelling 
Tissue in situ 
Relatedness 
only 
20-50 Few 
Gells 
35s 
6-8 days 
Gellular localization 
Filter in situ 
Hybridization 
1-5x10^ Few 
DNA cells 
32p 
1-2 days 
No DNA extrtn. High copy 
number 
Sandwich 
Hybridization 
do 10^  
cells 
32p 
1 day 
Rapid 
Detects with 
Liq. Scintlln. 
One type/ 
sample 
Analyzed 
PGR 1000/^g 300ng 
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Southern Blot Hybridization 
DNA extracted from the biopsies or cell culture are used for the 
detection of HPVs by cleaving the extracted DNA with appropriate 
restriction enzymes and resolving it by electrophoresis and staining the 
gel by EBr and transferring the gel to nitrocellulose membrane for 
hybridization with probe labeled with radio-active or non radioactive 
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compounds. After washing and autoradiography, the labeled probes 
yield distinct bands corresponding to the complementary sequences in 
the cellular DNA. SB hybridization has however, no applicability in the 
routine testing ofHPV. 
Dot Blot Hybridization 
This is more rapid and does not require RE digestion of DNA. Usually it 
is denatured and dotted directly on The membrane, followed by 
hybridization and detection (Syijanen S., 1990). 
Reverse Biot Hybridization 
Introduced by Villers et al (1986a). HPV DNA released from the 
plasmid by RE and is transferred to filter and probed with 500ng of the 
radiolabelled cellular DNA. Any HPV sequence present in he cellular 
NA is will hybridize to HPV type of which they are complementary. 
False positive results were common with this method. 
Filter in situ Hybridization 
This method can be used to analyze smears and crapes. The cells are 
applied directly to the filter, which is pre-treated so hat it can disrupt the 
cells, denature and neutralize the DNA. The advantage is that it does not 
require DNA extraction. 
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Sandwich Hybridization 
It is done by a two fragment probe, each having homology with the 
target. One is bound to the filter catching specific HPV sequences on 
filter the other is labelled and binds to the filter bound hybrid, allowing 
its detection. Here also no DNA extraction is needed. The only 
disadvantage is hat only one HPV type can be analyzed per test. 
In Situ Hybridization 
Histological sections are cut on Poly-L-Lysine treated slides to prevent 
the detachment of tissue sections. After denaturation of target DNA and 
labeling of probe the slides are washed and detection of target probe is 
done by autoradiography or by enzymatic detection methods. Due to 
lack of automation ISH technique is not available for routine 
diagnostics. 
Digene Hybrid Capture Assay -H 
Digene Diagnostics (Bellsville, MD) have developed HPV tests for 
clinical routine. This test has been recently approved in the USA by the 
Food and Drug Administration (FDA). The Digene HPV test using 
Hybrid Capture -II technology is a signal amplified hybridization 
antibody capture microplate assay that utilizes chemiluminiscent 
detection. Specimens containing the target DNA hybridize with a 
specific HPV RNA probe cocktail. The resultant RNA:DNA hybrids are 
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captured onto the surface of a microplate well coated with antibodies 
specific for RNA: DNA hybrids. Immobilized hybrids are then reacted 
with alkaline phosphatase conjugated antibodies specific for RNA: DNA 
hybrids and detected with a chemiluminiscent substrate, several alkaline 
phosphatase molecules are conjugated to each antibody. Multiple 
conjugated antibodies bind to each captured hybrids resulting in 
substantial signal amplification. As the substrate is cleaved by the bound 
alkaline phosphatase, light is emitted which is measured. It is a simple 
technique that could be readily automated for large-scale use if required. 
Polymerase chain reaction 
PCR is currently the most sensitive method to detect human 
papillomavirus DNA in cervical scrapes.(Walboomer et al., 1997) It is 
based on invitro enzymatic DNA amplification and in principle detects 
one copy of a target sequence in a given sample. To date at least 30 
different HPV genotypes have been isolated from anogenital tract 
among which 14 are HR-HPV genotypes (16, 18, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66 and 68) have been defined on the basis of their isolation 
from cervical carcinomas (Bosch et al.,1995; Chaouki et al., 1998). 
Different primers have been used for the detection of wide range of 
HPVs e.g. General primers -mediated (GP) PCR based amplification, 
selected from highly conserved region LI and El of HPV genome. This 
assay is based on three different approaches viz.: 
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a). Use of degenerate primers (mixture of oligonucleotides showing 
nucleotide differences at several intervals) 
b). Degenerate primers in addition contain inosine residues at certain 
ambiguous base positions, 
c). Acceptance of certain degree of mismatch between primers and 
target DNA accomplished by reducing the stringency of primer 
annealing (Snijders et al., 1990) Recently a new method was introduced 
using GP+/GP6+ PGR based procedure which included Southern Blot 
hybridization of PGR products with cocktails of radioactively labeled 
HPV type-specific internal oligonucleotides. There are several reports 
on the efficacy of the two most commonly used primer sets (MY09/11 
and GP5+/GP6+) used for the detection of HPV. Both primer sets 
amplify a wide spectrum of HPV genotypes. There was differential 
amplification sensitivity of HPV types between the MY-PGR and GP+-
PGR primer systems (Qu et al., 1997). It was shown that MY-PGR 
primer set was more robust than GP+-PGR primer set in the 
amplification of multiple HPV DNA types within a given sample. The 
GP+-PGR primers were relatively inefficient in the amplification of 
HPV types 53 and 61 compared to MY-PGR, whereas MY-PGR was 
inefficient in the amplification of HPV 35. 
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HPV Variants 
Based on the DNA sequencing performed on HPV isolates from cervical 
scrapings and cell lines, number of variants have been described in 
which the nucleotide sequence does not vary more than 2% in coding 
and 5% in non-coding regions of the viral genome (Bernard et al., 
1994a; Galloway 1994). The most detailed genomic variability has been 
done with HPV-16 and also 18, 6 and 11. Nucleotide sequence variation 
has been used as the tool for epidemiological studies of viral 
transmission and persistence. Ho, et a l , 1993 studied the sexual 
transmission of HPV-16 among couples in Singapore and found that 
same HPV 16 variant was present in 50% of the couples but other half 
carried mismatch virus. A cohort study of young women, Xi, et al., 
1995, have found 16 different HPV 16 variants, among which one 
variant was persisted over time while the other variants were transiently 
detected. The originally obtained reference sequence, so called 
prototype (Seedorf et al., 1985) belongs to the European subtype 
(Yamada et al., 1997). Preliminary studies suggest that HPV 16 
polymorphism in the URR region may alter the oncogenic potential of 
the virus (Kammer et al., 2002). 
HPV Vaccine 
Therapeutic vaccination may potentially be used to treat patients with 
established HPV infections or HPV-associated precancer or cancer; 
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prophylactic vaccination may potentially protect against HPV infection. 
Theoretically, protection can be achieved by induction of virus-
neutralizing antibodies prior to exposure, and successful therapeutic 
vaccination will depend on stimulation of cellular immune response. 
Neutralizing antibodies are found in sera of HPV-positive patients 
(Christensen & Kreider 1993; Kimbaur et al., 1994), but regression or 
recurrence of HPV-induced lesions have not yet been correlated with 
previously antibody status. Recently, synthetic virus-like particles have 
been developed after expression of papillomavirus structural proteins in 
vitro (Zhou et al., 1991; Hagensee et al, 1993; Kimbauer. et al., 1994). 
Two types of vaccines are being tried experimentally and in clinical 
trials. 
(i) The prophylactic vaccines 
(ii) Therapeutic vaccines. 
As has been well established that of the 75 HPV types identified only 20 
infect the female genital tract of which 4 types (16, 18, 31 and 45) 
account for 80% of cervical cancers. Antibodies against one type do 
not5 provide cross protection against the other types of HPV. Thus there 
is need for developing a polyvalent vaccine. 
Therapeutic vaccine 
The E6 and E7 transforming genes are highly expressed in most cases of 
cervical cancers. These have been utilized for making therapeutic 
vaccines. Therapeutic vaccines against HPV lesions is based on the 
induction of cellular immunity against viral proteins to provoke 
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regression of HPV associated lesions. Several E6 and E7 based vaccines 
are undergoing in human trails with advanced cervical cancer or pre-
cancerous lesions. The following issues need to be resolved before 
undertaking the field trial of the vaccine: 
(i) Age of commencement of vaccination, (ii) Should only the high risk 
or general population be vaccinated, (iii) Should both male and female 
be vaccinated 
For therapeutic vaccine, the target population is symptomatic with 
concomitant better compliance and acceptance of the vaccination. For 
prophylactic vaccine, on the other hand, target population has to be 
asymptomatic with resultant acceptance and compliance. In India, for 
therapeutic vaccine, 6 million women need to be vaccinated with CIN 
lesions or warts. The target population for prophylactic vaccines has to 
be adolescent women before sexual encounter. This population size is as 
large as 50 million. For therapeutic vaccination, male partners of the 
women with CIN lesions or warts can easily be identified and 
vaccinated. However, for prophylactic vaccination it is difficult to 
identify and vaccinate prospective male partners of adolescent females. 
Though the containment of infectious reservoir and to reduce the 
transmission channel of infection in the community prophylactic vaccine 
is desired, yet from the operational point of view and to reduce the load 
of HPV induced disease, therapeutic vaccines seems feasible in the 
Indian context. Institute of Cytology and Preventive Oncology (ICMR) 
is formulating such integrated feasible programs. 
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GENETIC ANALYSIS OF CERVICAL CARCINOMA 
Carcinogenesis is a multi-step process resulting from the interaction of 
several genetic and environmental factors. Cancer is a multigenic 
disease, mostly somatic (Kinzler, and Vogelstein,1996, 1998; Lengauer 
et al., 1988). Cancer related genes fall into two categories: oncogenes 
that have a dominant effect and tumor suppressor genes with a recessive 
phenotype. It arises not from a single mutation but from accumulation of 
more than one mutation. According to Knudson's hypothesis (Knudson, 
1985), only two mutations are rate limiting for any cancer to develop, 
either both can develop somatically or one can be inherited and other 
somatic. There appears to be at least two distinct mechanisms of 
tumorigenesis in humans, one mechanism is associated with the 
activation of growth promoting genes such as oncogenes and other being 
inactivation or loss of tumor suppressor genes. Although cervical 
carcinoma is a common malignant tumor worldwide very little 
information is available on the genetics of this cancer. The study aims to 
dissect the molecular genetic events and their interaction with 
environmental factors. According to Knudson's hypothesis at least two 
distinct mechanisms are involved in the development of human cancers, 
one is activation of oncogenes and the other inactivation or loss of tumor 
suppressor genes (TSGs). Aim of the study is to evaluate the role of 
deletion of the TSG locus, microsatellite instability, expression of erbB-
2/(Her-2neu) and other oncogenes (J3-catenin) and environmental factors 
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like HPV infection in cervical dysplasia. More than 80% of cervical 
tumors have been observed to have the evidence of HPV DNA either in 
episomal form or integrated to the Host DNA though causal relationship 
of HPV in cervical carcinogenesis is still controversial. Despite women's 
frequent exposure to HPV, development of cervical neoplasia is 
uncommon. Most cervical abnormalities caused by HPV infection are 
unlikely to progress to high grade CIN or cervical cancer, as most of 
them regress by themselves. The long time frame between initial 
infection and overt disease indicate the role of genetic factors in the 
progression of disease. 
HPV infection alone is not capable of transforming a normal epithelial 
cell to malignant one (zur Hausen 1994; Masato Nishimura et al., 2000; 
Mullokandov et al., 1996) suggesting the need for additional events. 
Various cytogenetic studies revealed genetic alterations in the form of 
various chromosomal abnormalities (Cannizaro et al., 1988; Prospeu et 
a l , 1990). Recently, with the availability of molecular cytogenetic 
techniques some frequent genetic abnormalities like losses of 
heterozygosity (LOH) consistent with the data of comparative genome 
hybridization, have been detected. Some non-random genetic lesions 
have been reported recently common in both precancerous and 
cancerous lesions. It is believed that genetic abnormalities might take 
several forms such as point mutation, amplification, viral DNA 
integrations or LOH. 
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Cytogenetic studies 
Cytogenetic studies, although limited, have revealed non-random 
chromosomal changes such as i(5p), deletion at 3p, 6q and 17p (Mitra et 
a l , 1994b; Atkin 1997), also a correlation between the common fragile 
sites and integration of HPV DNA (Cannizaro et a l , 1988). Mutations or 
deletions of a tumor suppressor gene have been shown to be frequently 
accompanied by loss of the remaining allele, leading to homozygous 
inactivation of the gene (Marshall, 1991). Several molecular studies 
(Mitra et al., 1994a; Mullokandov et al., 1996; Kersemaekers et al., 
1998) have identified a few frequent loss of heterozygosity (LOH) sites, 
suggesting possible involvement of the TSGs in the development of 
cervical cancer. 
Loss of Heterozygosity 
As reviewed earlier, several cytogenetic studies detected gross 
chromosomal abnormalities. However, it was not possible to detect 
minute genetic lesions until the introduction of molecular cytogenetic 
studies like LOH. The term loss of heterozygosity (LOH) first used by 
Dracopoli and Fogh (1983), to describe a reduced level of 
heterozygosity. LOH being a powerful approach to study the deletion or 
inactivation of the candidate TSG in precancerous lesions has been 
extensively applied leading to the identification of several chromosomal 
regions that are recurrently affected in this tumour. LOH refers to the 
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observation of single allele at particular genetic locus or loci in a biopsy 
specimen, generally a benign or cancerous lesion or precancerous lesion, 
arising in an individual who is heterozygous for the same locus or loci in 
its normal tissue. The normal or "constitutional" genotype is generally 
determined in DNA isolated from peripheral lymphocytes or from 
histologically normal tissue adjacent to the pathological lesion of 
interest. The loss of heterozygosity means that a particular DNA region 
has been lost and if the loss is recurrent in a significant number of cases 
of a particular tumor type it can be concluded that this chromosome 
region plays a role in that tumor development. Allele loss and deletion 
mapping using microsatellite markers and the detection of homozygous 
deletions represented until now the most powerful method to localize 
potential TSGs. Recently new approaches based on the analysis of 
genomic microarrays have been developed. Comparative genome 
hybridization (CGH) microarrays allow the study of copy number 
changes but not LOH, while single nucleotide polymorphism (SNP) 
microarray approaches yield LOH but not copy number changes (Pinkel 
et al., 1998; Lindblad -Toh et al., 2000). Southern Blotting to detect 
LOH is poorer when the malignant cell proportion in specimen falls 
below 70%. Therefore detection of LOH with Polymerase Chain 
Reaction is more dependable and rapid procedure. LOH for a given 
marker in 25% or more of informative cases is usually considered 
significant. A number of studies were done to perform fine mapping and 
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localize TSG more precisely, but these had low efficiency, one of which 
was that most of the studies did not use precise microdissection of tumor 
from other tissues. Thus, admixtures of stroma, blood vessels, 
lymphocytes and other normal cells in a macroscopically isolated tumor 
samples were unavoidable sources of error in LOH studies of solid 
tumors. Approach to solve this problem was to use microdissection. If 
the DNA is of high quality 50ng, if degraded 250ng to 2\ig is required. 
DNA from paraffin embedded tissue can be studied, as the biopsy 
specimens are invariably contaminated with normal tissue. 
Histologically prepared slides are used for tumor tissues DNA whereas 
adjacent tissue from the same section are used for source of 
constitutional DNA. However, such tissues should be used with caution 
since LOH in normal tissue adjacent to tumor has been reported. In 
tumors where LOH observed in normal tissue is not due contamination 
of normal tissue with tumor, this observation may represent the 
phenomenon of "Field Cancerization" where independent genetic events 
predispose an entire region of exposed tissue to transforming events 
(Slaughter et al., 1953). Wistuba et a l , (2000) performed detailed study 
on microdissected material on lung cancer and preneoplastic 
microdissected respiratory epithelial samples. Allelic losses of 3p were 
detected in 96% of the lung cancer and 78% of the preneoplastic lesions. 
LOH is being detected with increasing frequency in a wide variety of 
human tumors. The clearest example of the use of LOH analysis to gain 
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insight into tumor progression is in colorectal cancer, which offers a 
prototype approach to delineating the sequence of functional loss of 
tumour progression of malignancy. El-Naggar et al., (1995) noted high 
frequency LOH on chromosome 3p (47%) in invasive HNCC but no 
significant 3p loss (0.5%) in preinvasive lesions while Mao et al., (1996) 
reported allelic loss (36%) for 3p in oral leukoplakia. Studies in breast 
cancer have revealed several regions where LOH is predictive of 
outcome independent of standard clinico-pathological classification. 
Frequent LOH at a given locus implies the existence of a Tumor 
Suppressor Gene that is important in the pathogenesis of the particular 
cancer under study. LOH is believed to represent inactivation of one 
allele of a tumor suppressor gene by chromosomal or subchromosomal 
deletion (Mitra et al., 1994a). LOH studies through Southern Blotting 
require large quantities of intact, high molecular weight DNA and 
sensitivity of These LOH were detected in both SCC (68%) and AC 
(42%) (Larson et al., 1997) as frequent LOH at a given chromosomal 
locus implies the existence of a TSG that is important in the 
pathogenesis of the particular cancer study. LOH analysis has been done 
with a panel of probes for chromosomal arms 3p and 5p. LOH at 3p 
might be an indicator of progression since its frequency increases from 
25% in FIGO stage I to 100% in stage IV cases (Larson et al., 1997). 
Several studies agree that within the region 3p 14-22 there are two 
subregions where the LOH are concentrated and frequently both are 
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altered in the same tumor. These two regions are 3pl4.2 and 
3p21(Kohno et al.,1993; Chu et al). The data suggest that two TSGs are 
located in this chromosomal region (Huettner et al., 1998). Recently the 
FHIT gene has been identified within the chromosomal region 3pl4.2 
which is altered in several types of tumours such as lung (Sozzi 
et.al.,1996), breast (Hayashi et a l , 1997), esophagus (Zou et.al.,1997), 
cervical (Pierre et al., 1998). Another study with 75 highly polymorphic 
loci located on major autosome arms was used to estimate the incidence 
of LOH in 38 cervical cancers. LOH was found to involve 19 
chromosome arms in 20-30% of the tumors. High frequency of allelic 
loss was found on 6p, 3p and 18q. Frequent deletions on 3p have been 
confirmed by many other studies. LOH at 3p were shown not only in 
cervical cancers but also in cervical intra-epithelial neoplasia. Mutation 
or deletion in a TSG is frequently accompanied by loss of the remaining 
allele, leading to homozygous inactivation of the gene (Marshal 1991). 
Chromosome deletions and loss of heterozygosity studies from a variety 
of neoplasms have identified the short arm of chromosome 3 (3p25 -
3pl4) as the location of genes involved in tumor suppression. Tumors 
with evidence of recurring chromosome abnormalities and high 
frequency allelic loss of 3p include: small cell lung cancer 
(SCLC)(3p22-p21) (Killary et al., 1992; Brauch et al., 1987), non SCLC 
(3p23-p21) (Kok et al., 1987), renal cell carcinoma (3pl4.3-pl3) 
(Kovacs et al., 1988), breast, ovarian and testicular cancer (3p23-p21) 
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(Devilee et al., 1989; Trent et al., 1985; Lothe et al., 1989), squamous 
cell carcinoma (3p24-pl2) (Gollin et al., 1994) and cervical carcinoma 
(Mitra et al., 1994a; Mullokandov et al., 1996). LOH studies using 
molecular genetic tools provided a powerful approach to identify the 
minute genetic losses. Studies reported LOH in precancerous lesions of 
uterine cervix mainly concentrates on 3p and 5p sites. Harada et al in his 
study of 457 breast cancers concluded that assessment of erb-B2 and c-
myc amplification identified a group of high risk patients because of 
variation in the number and distribution of markers used and in methods 
of specimen preparation (direct tumor preparations, microdissection) 
comparison across studies are hazardous. Though we can make some 
tentative generalizations. Loss of 17p is a frequent event occurring in 
50-90% of the tumors of epithelial origin (Kern et al., 1989; Huang et 
al., 1992). To identify the genetic events that may play a role in the 
development of cervical carcinoma detailed allelotype analysis was 
performed by Mitra et al., 1994a, LOH was observed more than 25% at 
sites on eleven chromosomal arms. In order to further understand the 
role of genetic alterations that effect in cervical carcinogenesis, status of 
microsatellite instability in precancerous lesions has been investigated 
on 5p 14-ter (Mitra et al., 1995). LOH was observed in the allelotype 
analysis at eleven chromosomal sites which included Iq (26%), 3p 
(35%), 3q (31%), 4q (46%), 5p (53%), 5q (38%), 6p (28%), lOq (28%), 
1 Ip (24%), 18p (38%) and Xq (26%) the most frequent being 4q and 5p 
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where 5p (53%) and Xq (26%) were the two novel sites that are not 
reported in any other cancers (Mitra et al., 1994a) suggesting that 
candidate TSG may be present on these arms playing a role in the 
development of cervical carcinoma. In another study conducted by Mitra 
et al., (1994b), status of microsatellite polymorphism was evaluated at 5 
loci mapped to 5pl4-5pter in precancerous and cancerous lesions. LOH 
was observed in 55.6% of invasive cancers, 20% in CIS and 21% of rest 
of the early precancerous lesions. Among the loci tested D5S406 (5p 
15.1-15.2) exhibited LOH in 48% of invasive carcinomas, 33% of CIS 
and 60% of precancerous lesions, suggesting this to be the site in 5p of 
the novel candidate TSG. Study dealing with frequent deletion sites in 
relation to HPV infection was conducted. LOH on 3p revealed 
significant association with HPV-16/18 infection, 64% of LOH at 3p 
was in HPV-16/18 positive tumors. On the other hand 78.6% of LOH at 
5p which was most frequent (56.3%) was in tumors without HPV-16/18 
infection vs. 43.7% in tumors that had infection. In another study of 38 
cases of cervical carcinoma 21% were HPV negative (Mullokandov et 
al., 1996) noted that the spectrum of allelic losses observed in both HPV 
positive and negative tumors was similar to that observed in other 
tumors of epithelial origin suggesting the similar origin and progression 
of cervical cancer as that of other epithelial tumors. LOH analysis has 
been extensively applied to cervical cancer leading to the identification 
of several chromosomal regions that are recurrently affected in this 
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cancer. LOH analysis has been extensively applied to cervical cancer 
leading to the identification of several chromosomal regions that are 
recurrently affected in this tumor. LOH analysis has been extensively 
applied to cervical cancer leading to the identification of several 
chromosomal regions that are recurrently affected in this tumor. The 3p 
region has been implicated in ovarian, breast, testis, lung and renal 
carcinoma. In cervical cancer a broad region (3p 12-24) was identified as 
a target for LOH. The data shows that LOH occurs at an average 
frequency of 48% depending on the number of marker used (Mitra et al. 
1994; Mullokandov et al., 1996; Jones et al., 1992; Kohno et al., 1993; 
Ku et al., 1997; Karlsen et al., 1994; Huettner et al., 1998). These LOH 
were detected in squamous cell carcinoma and adenocarcinomas. 
The expected exception was LOH on 17p. LOH for 17p a presumed 
marker for loss of function of p53 is observed in 50-90% of most tumors 
of epithelial origin but was seen only in 15% of HPV positive cervical 
cancer. 
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Table 3.3 Recurrent LOH in cervical cancer 
[Courtesy P.A.Lazo. The molecular genetics of cervical carcinoma. 
British J. Can. (1990)] 
Chromosomal %age 
Region 
References 
3pl4.1-22 
4pl6 
4q21-31 
5pl3-15 
6p21.3-22 
l l p l 5 
l lq23 
17pl3.3 
18ql2.2-22 
48 
40 
32 
17 
41 
28 
38 
24 
24 
Yokota et al, 1989, Nakamura, 1992, 
Mitra et al, 1994, Kersaemaeker, 1998b 
Mullokandov et al, 1996. 
Hampton et al,1996, Kersaemaeker 1998b, 
Mullokandov etal 1996 
Mitra etal 1994, Kersaemaeker etal 1998b 
Mullokandov et al 1996 
Mitra et al 1994, Kersaemaeker1998b, 
Mullokandov etal 1996. 
Mitra et al 1994, Kersaemaeker 1998b, 
Mullokandov etal 1996. 
Mitra et al 1994, Kersaemaeker 1998b, 
Mullokandov etal 1996. 
Hampton et al 1994, Kersaemaeker 1998b, 
Mullokandov etal 1996 
Fujita et al 1992, Kersaemaeker 1998b, 
Mitra et al. 1994, Mullokandov etal 1996. 
Mitra et al 1994, Mullokandov etal 1996, 
Kersaemaeker et al 1998b 
Thus, while viral inactivation of p53 and its degradation through 
ubiquitin pathway is a vital step in HPV mediated cervical 
carcinogenesis, other genetic changes leading to malignancy in HPV 
positive tumors appear to be similar to those occurring in HPV negative 
tumors, as also reported by Mitra et al., (1995) and Pierre J.F., et al , 
(1998). Study of microsatellites in a number of tumors show genomic 
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instability which could apparently be because of a gene mutation that 
causes multiple errors in DNA replication (Aaltonen et al., 1993; 
Mironov et al., 1994). It has been found that instability of simple di and 
tri nucleotide repeats might be associated with the function of a gene 
which determines the predisposition to colorectal cancers (Thibadeau et 
al., 1993; Aaltonen L.A., et al., 1993; Peltomaki et al., 1993). These 
changes consisted of shifts in the electrophoretic mobility of (CA)n 
dinucleotide repeat fragments, suggesting that replication error had 
occurred in the sequences during tumor development. 
Microsatellite Instability 
The addition of novel microsatellite alleles in the tumor DNA is called 
microsatellite instability. Microsatellites are tandem repeat of simple 
DNA sequences, highly polymorphic and randomly interspersed 
throughout the human genome. They consist of 10-15 copies of 1-6 base 
pair motifs and it is estimated that there are on the order of 50,000 to 1 
lakh (CA)n elements scattered throughout the human genome and are 
replicated faithfully at each cell division with a new mutation rate of 10'^  to 10"^  
(Weber J.L., et al., 1993). Variations in such microsatellite regions is 
generated by errors in DNA replication. These errors are thought to 
result from a defect in the mismatch repair system. About 60,000 
proteins are required for a complete and proper functioning of an 
individual and its blueprint lies in the DNA. The estimated error rate for 
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a DNA replication in human with well functioning repair system id 10"'° 
mutations per basepair per cell generation. If DNA were copied badly 
chances of disease such as cancer will be at much higher frequency on 
the other hand if DNA were copied perfectly, there would be no room 
for evolution, the DNA repair system synchronizes the balance between 
the two. Most polymorphism occurs in the 97% of the non-coding junk 
DNA of the human genome, variations therein are functionally 
inconsequential and hence well tolerated during evolution. Much of this 
noncoding DNA consists of highly repetitive DNA segments; one such 
class in humans consists of simple tandem repeats (STRs). Such repeats 
of 2-3 nucleotide segments are known as microsatellite DNA and are 
unique to each individual. Instabilities in the microsatellite region of 
tumor DNA have been observed when compared with the normal allele 
of same patient showing either an expansion or contraction on one or 
both alleles in some tumors. Variations in such microsatellite regions is 
generated by errors in DNA replication. Since, microsatellite instability 
is one of the defects 'mismatch repair' is supposed to prevent, indicates 
a defective mismatch repair system. Cheng and Loeb, (1993) postulated 
that mutations within critical pathways (process of DNA replication, 
DNA repair, cell division, and cell differentiation) could lead to 
genomic instability. Clues to the mechanism underlying the molecular 
basis of tumor microsatellite instability emerged from the study of 
effects of mutations within the mismatch repair genes in bacteria and 
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yeast. The E. coli repair system requires several mut gene products; 
MutH, MutL, MutL, MutS, and MutU, along with other enzymes. The 
MutHLS mismatch repair system appears to be conserved through 
evolution as homologous proteins have been identified in both 
prokaryotes and eukaryotes. Evidences suggest that eukaryotic 
mismatch repair system is more complex than the prokaryotic MutHLS 
system. The human homologues of bacterial and yeast mismatch repair 
proteins were localized and cloned, and their role in HNPCC was 
examined. Instability in microsatellite loci was initially reported in 
familial colorectal carcinomas, later it was found in a variety of sporadic 
malignancies, including those of the colon, endometrium, stomach, 
pancreas, lung, bladder, kidney, esophagus, endometrium and ovarian 
cancer (lonov et al., 1993; Thibadeau et al., 1993; Han et al., 1993; 
Rhyu et al., 1994; Merlo et al., 1994; Shridhar et al., 1993; Gonzalez et 
al., 1993; Uchida et al., 1994; Burks et al., 1994; King et al., 1995). 
All of the proteins coding regions account for only about 3% of the 
human genome. Most non-coding regions of DNA may be located 
within genes (introns) or in between the genes. Since these regions do 
not code for any functional protein, variations in these regions are well 
tolerated during evolution allowing tremendous genetic diversity to 
develop in these regions. Clues to the mechanism underlying the 
molecular basis of tumor microsatellite instability emerged from the 
study of the effects of mutations within the mismatch repair proteins 
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were localized and cloned and their role in HNPCC was examined. 
Greater than 80% of HNPCC tumors demonstrated microsatellite 
instability (Aaltonen et al., 1994). 30% of families with HNPCC have 
germline mutations in hMSH2, while another 30% in hMLHl(Wijnen et 
al., 1996). The presence of MIN has been reported in a variety of 
malignancies. Tumor microsatellite instability can be detected in a PCR 
based assay by comparing tumor DNA to that derived from normal 
tissue of the same patient. 
Each cell loses 10,000 bases per day from, breakdown of DNA at 
body temperature, and dividing cells introduce additional errors in the 
act of DNA replication. These errors are rectified by the DNA repair 
enzymes, which are highly conserved throughout evolutionary history. 
There are two major types of DNA repair pathways, each of which has 
its own distinct function. Mismatch repair pathway detects and repair 
short segments of mismatch base pairs, these include simple 
mismatches, in which the wrong nucleotide building block is put into the 
new DNA strand. Since Microsatellite instability, a defect that mismatch 
repair is supposed to prevent, falls into this category. Disorders of the 
mismatch repair pathway lead to errors in these polymorphic segments. 
In contrast, " nucleotide excision repair" which goes awry in Xeroderma 
pigmentosa, snips out and replaces DNA damaged by chemicals and 
radiation (Jean Marx. 1994). MSI at any locus represents a potential 
clonal marker for the detection of cancer (Mao et al., 1994). These 
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markers may also provide useful prognosi^c information in adc^titon to 
establishing the diagnosis in tested patients. 
In several types of human cancer, alleles of microsatellite repeat have 
been deleted which are not present in constitutional DNA of same 
patient. Overall 8% cancers show this abnormality. The difference in 
size appears to be due to changes in the number of repeat units. The 
repeat unit sizes of repetitive sequences in the human genome range 
from one to many thousands of base pairs. Most of the studies 
investigated advanced cervical cancer, and little is known about the 
molecular pathogenesis in premalignant lesions (CIN). Microsatellite 
regions are scattered throughout the human genome. Variation in such 
microsatellite regions is generated by errors in DNA replication. These 
errors are thought to result from a defect in the mismatch repair system. 
Microsatellite instability is thought to represent a type of genomic 
instability, which, in turn, may predispose cells to the accumulation of 
other genetic alterations necessary to attain a malignant phenotype. 
Microsatellite is often observed in microsatellite polymorphisms 
because the short repeat units in these polymorphisms are susceptible to 
replication errors. Microsatellite instability has been reported in 35% 
(7/20) of invasive cervical cancers but less is known about microsatellite 
instability in CfN. We performed a detailed study in order to evaluate 
the role of microsatellite instability in precancerous lesions. Instability 
was assayed on PGR based assay by comparing the tumor DNA to that 
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with DNA derived from normal tissue of the same patient. Ahhouj h 
dinucleotide repeats have been used most frequently for these studids, 
instability has also been observed in mono, di, tri, and tetra-nucleotide 
repeats (Hong J.M., et al., 1997; Zhou X.P., et al., 1997). Selection f>f 
markers as well as the number of markers used in the study, for tike 
detection of microsatellite instability has a significant effect on tlie 
determination of MIN status. It has been recommended that for the be|st 
results it is best to utilize a combination of mono and di-nucleoti(^e 
repeats. Because of differences in marker selection and total number i)f 
markers used a comparison between various studies is quite difficult. 
We in our study tested microsatellite instability, using the Bethesda 
Consensus Conference reference panel of five markers, Bat-25, BAT-216, 
D2S123, D5S346 and D17S250 (Boland et al., 1998). 
Expression of Oncogenes in cervical cancer 
The growth of normal cells is regulated by a wide variety of gen^s 
known as cellular oncogenes (c-onc). Together with the growth factois, 
elucidation of the functions and regulation of cellular oncogenes a^e 
intimately linked through the complex communication cascade knoWn 
as signal transduction pathways. The number of c-oncs is continuousfy 
increasing. Then major currently recognized cellular oncogenes aj-e 
listed in table. 
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Table: 2.4 Major cellular oncogenes (c-onc) and their functions 
Localization and Function Oncogenes 
Growth factor related 
Receptor-related 
erbB-3 
Signal transducers 
Nuclear oncogenes 
Tumor suppressor 
Regulators of cell death 
sis, hst/int-2 
erbB-1 (EGFR), erbB-2 (HER-2/ne\^), 
Ros, blyn, fins, trk, kit, sea, LA-1 
ras, N-ras, K-ras, Ha-ras, src, fes, raf, 
abl, yes, fgr, Ick, nek, Jyn, gsp, gip, m^s, 
fps, Grb-2, mos, sos 
myc, myb, fos, jun, erb A, ets, rel, ski 
Rb, p53, WT, NF-1, FAP, DCC, PRAD 
bel-2 
Amplifcation of cellular proto-oncogenes has been associat<?d 
with tumor progression (Bishop 1991) e.g. MYCN in neuroblastonlia 
(Brodeur et al., 1984), small cell lung cancer (Wong A.J. et al. 198)) 
and various other tumour types; and erb-B2 (HER2/nue) in breajst 
(Slamon et al., 1987; Skalova et al.2003) ovarian (Slamon et a l , 1985 
Tyson et al., 1991; Hou et al., 1996), gastric (Houldsworth et al., 199p 
Al-Kasspooles et al., 1993) and bladder carcinomas (Coombs et. A 
1991) suggesting that this gene may play a role in tumorigenes^s 
(Bishop et al , 1991). The oncogene c-erbB2 located on chromosonk 
17q has been reported to be frequently amplified and over expressed n 
many adenocarcinoma and carcinoma of breast (Slamon et al., 1989), 
stomach (Yokota et al., 1988), renal (Freeman et al., 1989) and ovary 
(Slamon et al., 1989; Tyson, et al., 1991; Hou et al., 1996). 
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CerbB2 (HER 2/neu) 
It has recently been reported that CerbB2 oncogene is overexpressed in 
adenocarcinoma of uterine cervix (Kihana., et al., 1994) and in CIN and 
invasive cancer of the cervix (Mitra et al., 1994b; Soh et al., 2002}. 
Earlier studies reported by Mitra et al on frequent DNA amplification o 
cerbB-2 in primary squamous cell carcinoma was done by Southern Blct 
where chances of false negativity could be high and cell to cell analysis 
of amplified cells and heterogeneity of amplification in tumor was nc 
possible. cerbB-2 amplification was studied by same authors using nor 
fluorescence in-situ hybridization on primary untreated squamous ce 1 
carcinoma. This time cerb-B2 amplification was observed in 36.6° 
tumors as compared to the previous study using Southern Blot (14%) i.e. 
22% extra. However both the studies clearly indicate that cerbB-U 
amplification is common in cervical cancer and is considered to be on 
of the mechanisms of gene over expression and experimental evidenc€ 
indicate that cerb-B2 gene plays an important role in development c 
cancer (Zhang., et al., 1989). Gene amplification is one of tl 
mechanisms, besides transcriptional and translational controls or a sing 
point mutation in the gene which may cause an increase in tyrosii 
kinase activity. The erbB-2 gene encodes a 185-kd protein, which is 
member of the epidermal growth factor receptor (EGFR) subgroup bf 
the protein tyrosine kinase superfamily. This group of kinases is 
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involved in the regulation of a variety of vital functions including eel 
proliferation, cell differentiation, and stress response. Alteration in th< 
expression of the kinases occurs in numerous tumor types and plays ai 
important role in tumorigenesis, cancer progression, and susceptibility t 
cell killing by anticancer agents. Constitutive activation of the HER 
2/neu gene has been detected in sub-populations of many types o 
human solid tumors. In general, tumor cells, which overexpress HER 
2/nue, are intrinsically chemoresistant to DNA damaging agents. Thi 
may be a consequence of altered cell cycle checkpoint and DNA repair 
mechanisms and dysregulation of apoptotic pathways. HER-2/ne, 
overexpression can also enhance metastatic potential by promoting 
multiple steps in the invasion and metastasis process. In general, HER 
2/neu overexpression leads to a high degree of malignancy and ma 
predict a poor prognosis and shorter survival of the patients. Because 
normal critical tissues show little or undetectable expression of the gene, 
the HER-2/neu gene and its protein product are attractive targets fc 
therapeutic approach. The HER-2/neu oncogene was first identified as 
dominant transforming gene in chemically induced adrenil 
neuroblastomas of neonate mice and was referred to as neiji. 
Amplification of this gene occurs frequently in breast and ovaria 
cancer, and that it is associated with disease relapse and overall patieit 
survival. Detection of overexpression can be performed by a variety of 
methods. Immunohistochemistry (IHC) is the most time-saving an 
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cost-effective way. In addition, it offers advantage of in situ analysis. It 
is the identification of tissue constituents in situ by means of a specifi 
antigen-antibody reaction tagged by a visible label. We followed th^  
indirect method, which was more sensitive than the direct method. Th; 
procedure involved antigen retrieval, blocking of endogenous 
peroxidase, application of primary and secondary antibodies, applicatio i 
of peroxidase conjugated streptavidin and visualizing by 
diaminobenzidine (DAB) reaction. The slides were counterstained by 
harris 'hematoxylin. 
P-Catenin 
E-cadherin (epithelial cadherin) a transmembrane glycoprotein localize^ 
in the zona adherens junctions, mediates selective cell-cell adhesion i 
epithelial cells,(Takeichi et al., 1991) the cytoplasmic carboxy-domain 
of E-cadherin associates with the catenins (a-,P- & y-catenins). Both f 
catenin and y-catenin binds directly to E-cadherin in a mutual 
exclusive pattern while a-catenin binds through its amino-terminal to fi-
catenin or y-catenin, and through its carboxy terminal to the actin 
cytoskeleton (Hinck et al., 1994). The catenins also associate and forin 
E-cadherin independent complexes with other cellular proteins such as 
the epidermal growth factor receptor (Hoschuetzky et al., 1994). The 
adenomatous polyposis coli (APC) gene product (Rubinfeld et al., 199:5) 
and the protooncogenes c-erhB-2 (Ochiai et al., 1994). Cadherins a e 
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involved in homotypic calcium-dependent intercellular adhesion. 
Normal epithelial cells tightly bind to each other whereas cancer cells 
exhibit a looser association and invasive behavior. In invasion and 
metastasis of cancers the initial step is disruption of normal cell-cell 
adhesion in the epithelial tissue, coupling between adjacent cells by E-
cadherin bridges results in the transmission of antigrowth and other 
signals via cytoplasmic contacts with (3-catenin to intracellu ar 
signalling circuits that include the Lef/Tcf ranscription fac;or 
(Christofori and Semb, 1999). E-cadherin function is apparently lost in a 
majority of epithelial cancers, by mechanisms that include mutational 
inactivation of E-cadherin or P-catenin genes (Christofori and Semb, 
1999). 
The catenins (a, P andy) are ubiquitously expressed, cytoplasnjiic 
proteins associated with E-cadherin at cellular junctions, a-catenin can 
also bind P-cadherin and N-cadherin. a-catenin exhibits both acin 
binding and bundling activities. (5-catenin also binds to N-cadherin a id 
co-immunoprecipitates with APC. Cadherin/ catenin complexes £re 
linked to the cytoskeleton via a direct association between a actinin aid 
a-catenin. Increased tyrosine phosphorylation can disrupt eaten n-
cadherin complexes, influencing cellular adhesion. (5-catenin, a cent'al 
component of the cadherin adhesion system, binds to both tlie 
cytoplasmic domain of cadherin and the amino-terminal domain of i -
catenin and mediates cell adhesion. Mutated P-catenin does not link E-
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cadherin and a-catenin in gastric cancer cell-lines (Oyama et al., 1994). 
Mutation in APC or (3-catenin are associated with carcinogenesis and 
accumulation of cytoplasmic p-catenin. The role of cytoplasmic 3-
catenin has been revealed to be the formation of complexes with A 
binding proteins of the T-cell factor-lymphoid enhancer factor (Tcf-Lcf) 
family and their translocation to the nucleus, where this complex mny 
regulate cell proliferation and inhibition of apoptosis (Korinek V., et al., 
1997; Morin P.J., et al., 1997). Thus free cytoplasmic P-catenin behaves 
as an oncoprotein (Peifer et al., 1997). 
(3-catenin has two distinct roles in E-cadherin-mediated c jII 
adhesion and carcinogenesis through APC gene mutation. One occurs at 
cell-adhesion sites, where cadherins become linked to the actin-based 
cytoskeleton. The other occur in the cytoplasm and nuclei and £ re 
thought to regulate cell transformation, therefore, reduced P-cater in 
expression at the cell membrane are associated with cancer progression, 
on the other hand, P-catenin in the cytoplasm binds to the transcripti m 
factor TCF/LEF and is transferred to the nucleus where it upregulai es 
transcriptional activity (Korinek et al., 1997). The accumulation of 
cytoplasmic P-catenin is reported to result from the genetic mutation of 
APC and Axin (Ikeda et al., 1998) or that of p-catenin itself (Munemi su 
et al., 1995) Thus overexpression of beta-catenin in the cytoplasm or 
nucleus is often found in cancers of various organs, including the laige 
intestine (Takayama et al., 1998), endometrium, ovaries (Davies et <il., 
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1998), esophagus (Yukuta Kimura et ah, 1999), thyroid (Huang et all., 
1998), soft tissue (Alman et a l , 1997) and liver (Nhieu et al.,199S ). 
Therefore the localization (cell membrane, nuclei or cytoplasm) of 5-
catenin is of considerable importance. It has been reported by Yutalca 
Kimura et al., (1999) that accumulation of free soluble p-catenin in t ie 
cytoplasm and nuclei frequently occurs during carcinogenesis of 
squamous epithelium of esophagus. (5- catenin was expressed on the c(;ll 
membrane in non cancerous epithelial cells while it was frequently 
expressed in the cytoplasm and/or nucleus in cancer cells (Takehiro, et 
al 2001). P-catenin is a structural component of the E-cadherin mediat;d 
cell-cell adhesion system as well as signaling molecule of t ie 
Wnt/wingless pathway (Miller, et al., 1999). In this signaling pathway 
(Behrens, et al., 1999; Morin, et al., 1999), P-catenin functions as m 
activator of T- Cell factor (TCF)/ lymphoid enhance factor (LEF), aid 
upregulates the transcription of downstream genes including c-myc (F e, 
et al., 1998) and cyclin D1 (Tetsu, et al., 1999), which may be involvsd 
in human carcinogenesis. At present, P-catenin gene alterations aid 
abnormally accumulated P-catenin protein in tumor cell nuclei have 
been reported in variety of human malignancies, such colorectal 
carcinomas, hepatoblastomas, heptaocellular carcinomas, desmoid 
tumours, Wilm's tumor, melanomas, ovarian carcinomas, prostrate 
cancers (Murata et al., 2001; Koch et al., 1999; Kondo et al., 1999; 
Miyoshi et al., 1998; Maiti et al., 2000; Omholt et al., 2001; Ueda et al., 
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2001., Voeller et al., 1998). Mutations of P-catenin and aberrant 
expression of its protein have been identified in a number of different 
types of human malignancies. Cell-cell adhesion in tissue is mainly 
regulated by homotypic interaction of cadherin molecules, which are 
anchored to the cytoskeleton via cytoplasmic proteins, including alpt a-
and beta-catenin. Although Takayama et al., (1996) previously 
demonstrated that alpha-catenin is crucial for cadherin function in vi\ o, 
little is known about the role of beta-catenin. From m 
immunoprecipitation study, further Takayama et al., (1996) found tl at 
P-catenin forms a complex with E-cadherin not only in the nom al 
epithelium but also in cancerous tissues. Their findings suggested that P-
catenin forms a complex with E-cadherin in vivo and down-regulation of 
beta-catenin expression is associated with malignant transformaticn. 
Perturbation in the expression or function of the E-cadherin-cater in 
complex results in loss of intercellular adhesion, with possible 
consequent cell transformation and tumor progression (Huiping et al., 
2001). 
On the basis of the above review it was clear that most of the stud es 
have been directed to the invasive cancers and there were very f(5w 
reports on the precancerous lesions (dysplasia) of the uterine cervix. In 
order to elucidate the role of loss of heterozygosity and microsatellite 
instability in the process of cervical carcinogenesis, it was required 
emphasize the study of genetic alteration in preneoplastic lesions. LOH 
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to 
at 3p and 5p have previously been reported in other cancers and cervic il 
cancer, microsatellite instability analysis with the Bethesda Conference 
reference panel of five markers has not been reported in cervical cancer. 
HPV in relation to genetic factors like LOH, MSI and oncogene 
expression in cervical dysplasia could provide a better insight into the 
understanding of biological behavior of the cancer. Keeping all this 
view the present study on the genetic alterations and HPV infection w 
done on precancerous lesion of uterine cervix 
n 
iS 
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MateriaCs 
and Met fioa^ 
4. MATERIALS AND METHODS 
Collection of samples: 
Paraffin embedded tissue sections 
Paraffin embedded histology slides cut from the biopsy speciriens of 
cervical dysplasia cases were retrieved from the hospital. The histopathology 
archive materials were fixed in 10% (w/v) buffered formalin to stop further tissue 
changes after removal from body and subsequently embedded in su])porting 
material such as paraffin allowing sections (usually 1 t h i c k n e s s ) to be 
examination by microscopy. The trained cytopathologists then graded the 
and most severe areas of dysplastic epithelium were taken for microdissection 
under dissecting microscope. 
cut for 
samples 
Cervical smear for HPV testing 
Cervical smears of the women who visited for their regular check ips were 
collected in IX PBS (Phosphate buffer saline) and were transportec to the 
laboratory for HPV testing. A detailed questionnaire with proper consei t of the 
patient was also filled by the trained social workers, keeping in view the privacy 
and secrecy of the patient as per the ethical guidelines. All the samp es were 
transported in ice at 4°C and, stored at -20'^C till further processing. Cervical 
scrapes were vortexed along with the wooden spatula, and poured ip 1.5ml 
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eppendorf tubes after removing the spatula. Then the eppendorfs were ceijitrifuged 
at 2000 rpm for 2 minutes at 4°C. 
Preparation of Genomic DNA 
Microdissection and DNA Extraction for Genetic Analysis 
DNA for molecular analysis was extracted from formalin fixed paraffin 
embedded sections. Microdissection of the paraffin embedded tissue of patients 
with preneoplastic lesions was done under dissecting microscope and malignant 
and subsequent normal areas were scraped from the same section with the help of 
sterile blades taking guidance fi-om the stained slide. Cervical tissue specimens 
from 58 patients with lesions (from mild to severe dysplasia) of the cervix uteri 
were included in the study. 
From each paraffin-wax block lOji sections were taken out. One of the section was 
stained with haemotoxylene and eosin while the rest were left unstained for 
microdissection whereas the stained slide was used as a guide in scraping off all 
the normal and tumor material with a sterile scalpel. The normal areas and the 
tumor areas were collected in separate eppendorfs (1.5ml) labeled 'N' and 'T' for 
normal and tumor respectively. Then we de-paraffinized it by centrifuging it thrice 
with Xylene with the following protocols: 
1. Scraped the tumour tissue from paraffin section in 1.5ml mirofuge tube. 
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2. Deparaffinize three times with 1ml Xylene and centrifuged at 10,000 rpm 
for 10 minutes each time. 
3. Evaporated Xylene at 50V for 11/2 hours. 
4. Washed with absolute alcohol twice. 
5. Rinsed with 70% alcohol twice. 
6. Air-dried. 
7. Then we added 150|il of Digestion Buffer and Proteinase K (100|ig/ml) 
8. Then it was incubated for 24 hrs at 37°C. 
9. Next day, PK was inactivated by boiling at 90°C 
For further purification (if required) phenol chloroform extraction was done 
using following protocol. 
10. First the phenol was equilibrated with TE using P-mercaptoethanol, 8,a-
hydroxyquinoline and 1 X Tris EDTA. 
11. Equal volume of TE equilibrated phenol was added and rotated on 
overhead shaker for 15' and then centrifuged at 5000 rpm for 10' at 4°C. 
12. The upper aqueous layer was taken in another tube while rest was discarded 
in a separate discard beaker labeled "Organic Solvents". 
13. To the aqueous layer half volume of phenol and half Chloroform: iso-amyl 
alcohol (CIA) [24:1] was added and step 12 was repeated. 
14. Again aqueous layer was taken and to it was added equal volume of CIA 
and repeated the step 12. 
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15. To the aqueous layer i/io"' volume of chilled 3M sodium acetate and 2.5 
volume chilled ethanol was added and the DNA was either spooled out or 
precipitated by keeping at -20°C for 2-6 hrs and centrifuging for 45 
minutes. 
16. The pellet was air dried, washed with 70% ethanol twice and dissolved in 
IX TE at room temperature. 
17. The DNA can be stored at 4°C for further analysis and quantitation was 
done by spectrophotometer. 
DNA extraction from cervical smear for HPV Testing 
The DNA isolation involves basically two steps first washing the pellet 
twice with Tris-Triton Buffer (TTB) and PK digestion in Tris-EDTA Buffer 
(TTB). 1.5ml of the sample containing scraped cervical cells was taken in 1.5ml 
Eppendorf tube and centrifuged at 5000 rpm for 5'. The pellet was again washed 
with chilled IXPBS and cold centrifugation was done for 2 min at 2000 rpm. the 
pellet was washed twice in 1ml chilled TTB containing lOmM Tris-HCl (pH 8.0), 
lOmM MgC12, 300mM Sucrose and 0.8% Triton-X 100. The pellet was collected 
and rewashed in 0.5ml Cold TE Buffer containing lOMM Tris-HCl (pH 8.0), 
lOmM EDTA and lOmM NaCl. Finally the pellet was resuspended in 200^1 TE 
buffer supplemented with 1.25mg/ml PK and incubated at 65 degrees Celsius for 
2.5hrs. The tubes were vigorously shaken every half-hour in order to allow 
uniform lysis of the pellet. When the solution became transparent it was assumed 
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that extraction was completed was boiled at 95 degrees for 10 minutes for PK 
inactivation. Now the samples were ready for phenol chloroform extraction (if 
required). 
Analysis of microsatellite instability 
Microsatellite instability was analyzed on 58 paraffin embedded tissues from 
precancerous lesions using the Bethesda Consensus Conference reference panel of 
five markers, Bat-25, BAT-26, D2S123 (AFM093xh3), D5S346 (APC) and 
D17S250 (Mfd215 CA) (Boland et al., 1998). 
Table: Characteristics of the microsatellite markers analyzed. 
Name Chr Repeat Primer seq Tmf'C) Sizen)p) 
BAT 25 4q 1 1 1 1 .T.TTTT(T)7.A(T)25 TCG CCT CCA AGA ATG TAA GT 58 
TCT GCA TTT TAA CTA TGG CTC 
-90 
BAT 26 2P (T)5 (A)26 TGA CTA CTT TTG ACT TCA GCC 
AAC CAT TCA ACA 1 1 1 TTA ACC 
58 -80-100 
APC 5q21/22 (CA)26 ACT CAC TCT AGT GAT AAA TCG' 
AGC AGA TAA GAC AGT ATT ACT AGT T 
55 96-122 
Mfd 15CA 17q11.2-12 (TA)7....(CA)24 GGA AGA ATC AAA TAG ACA AT 
GCT GGC CAT ATA TAT ATT TAA ACC 
52 -150 
AFM093xh3 2p16 (CA)i3TA(CA)i5(T/G A)7 AAA CAG GAT GCC GCC TGC CTT TA 
GGA CTT TCC ACC TAT GGG AC 
60 197-227 
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The microdissected tumour and normal cells from 10)j,M thick unstained 
sections from precancerous lesions were taken as the source of DNA. One 
primer (usually the forward) was endlabelled with [y-^^P] ATP with a 
specific activity of greater than 500Ci/mmol (185 TBq/mmol), using 
Polynucleotide Kinase (PNK) and (O.IM) ditrio-threitol DTT at 37°C for 
one hour. 
lY-^ P^l ATP (LCP 101) 
(Board of Radiation and Isotope Technology, JONAKI Laboratory,) 
Adenosine triphosphate labelled in the y-position prepared by enzymatic 
phosphorylation of the corresponding nucleoside 5' diphosphates with very 
high specific activity ^^ P orthophosphoric acid. The triphosphates are 
purified by HPLC using strong anion exchange column. 
End labelling Mix 
Primer (F) 
DTT l^L 
DTT (O.IM) l^L 
T4 PNK S i^L 
^^P[yATP] 3|iL 
Incubated at 37°C for one hour 
Polymerase chain reaction 
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A standard polymerase chain reaction was carried out in a 25|iL reaction 
volume containing 30-50ng DNA, 20pmol of primers. Amplification 
reactions were carried out for 35 cycles at annealing temperatures ranging 
from Sl'^-SeV using 1 Unit of Taq DNA Polymerase {Roche, Applied 
Biosystems), 2.5mM MgC12 and 200^M dNTPs {New England Biolab). 
The amplification was first checked on 2% agarose and finally resolved on 
6% denaturing Polyacrylamide/ Urea gel (40cm x 20cm x 0.5mm) i.e. 
slightly thicker than the usual sequencing gel. Gel was polymerized in the 
presence of urea and formamide that suppresses base pairing of nucleic 
acids, alkali was not used as denaturing agent because it deaminates 
acrylamide. The DNA was denatured by heating the PGR products at 95®G 
and immediately placed in ice to prevent base pairing. Denatured DNA 
migrates through these gels at a rate that is completely independent of its 
base composition and sequence. In the presence of free radicals usually 
supplied by APS and stabilized by TEMED, a chain reaction is initiated in 
which monomers of acrylamide are polymerized into long chains whereas 
N,N' methylenebisacrylamide is included in the polymerization reaction, 
the chain becomes cross linked to form a gel. 
Preparation of glass plates 
• Plates were washed properly 
72 Materials ar d Methods 
• Cleaned the plates first with distilled water then with alcohol 
• Applied siliconizing solution (Sigma Cote) on one of the plates 
• Sealed the glass plates with tapes placing appropriate spacers (0.5mm) 
• Placed the tabs on the two upper edges with clamps 
Preparation of the Sequencing mix 
• 1 OOmL of the Acrylamide stock was taken 
• To it was added 700^L of 10% APS. Mixed well, taking care of the 
aeration of the sample. APS provides the free radicals that drive 
polymerization of acrylamide and bisacrylamide. APS decomposes 
slowly, and fresh solutions should be prepared weekly. 
• 40^L of TEMED (N,N,N', N ' - tetramethylethylenediamine) was added 
immediately before pouring, mixed the solution by swirling. TEMED 
accelerates the polymerization of acrylamide and bisacrylamide by 
catalizing the formation of free radicals from ammonium persulphate. 
• Gel was poured keeping the plates at an angle of 45° slowly, from the 
middle taking that care no air bubble is trapped inside 
• The comb was inserted and allowed the gel to polymerize for one hour 
at room temperature, additional acrylamide was added if the gel retracts 
significantly. When he gel was completely polymerized, a schieren 
pattern becomes visible just beneath the teeth of the comb. 
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• After the polymerization was complete the comb and the tapes were 
removed carefully and the wells were rinsed with water immediately 
and the small amounts of acrylamide trapped in the wells are flushed out 
with IX TBE which if not cleansed create distorted bands which are 
difficult to interpret. 
• Plates were fixed on sequencing gel apparatus 
• Poured 0.5 X TBE in both the chambers of sequencing apparatus 
Pre Heating of the gel 
• Gel was pre heated for about 10 minutes with loading dye in 2-3 lanes 
prior to loading of the samples. 
Conditions for running the gel 
2000V, 170W, 90mA 
Preparation of samples 
• The samples were diluted with 50^L dilution buffer 
• The samples are then mixed with 6X buffers (loading dyes), they 
increase the density of the sample ensuring that the DNA was dropped 
evenly into the well and they add colour which make tracking easier and 
they contain dyes that move towards anode at predictable rates. 
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Denatured the samples at 95°C for 5 minutes and place immediately in 
ice. 
Loading of samples 
• The wells were gently cleaned by flushing out air bubbles from each 
well with the help of dropper 
• Samples were loaded (2-3|j.L/well) immediately after taking out from 
ice, total time in loading should not exceed 20 minutes. 
• Electrophoresis was carried out by connecting the electrodes to the 
power pack. 
• The gel was run (for 2.5 hrs) until the marker dyes have migrated to the 
desired distance. Electrophoresis buffer was discarded from the 
reservoirs after disconnecting the power supply and glass plates were 
detached. 
Removal of the glass plates 
• After disconnecting the power supply the buffer was drained carefully 
as it contained radioactivity. 
• The plates were rested on working table and allowed to cool (RT) 
• The smaller plate was lifted by placing a spatula in between, spacers 
were also separated. 
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• A 3MM Whatman paper was placed over the gel, pressed gently and 
uniformly all over and lifted up along with the gel carefully taking care 
of the sequence of the wells by cutting a small comer at the site of the 
first well 
• Cellophane or saran wrap was wrapped over the gel, avoiding bubbles 
or folds in the Saran wrap. 
• The gel was placed on the gel drier 
• Dried the gel for one hour at 80°C 
Gel was dried in under vacuum at SO'^ C in gel drier (Biorad) for 1 hour and 
autoradiography was done by exposing the gel on X-ray film {Kodak) for 
24 to 48 hours. 
Autoradiography 
• The dried gel was placed in the cassette 
• Film (Kodak) was placed on to the gel in dark room making a mark 
(fold or cut) at the comer to indicate the start of loading 
• The cassette along with the film was kept in -20°C for exposure 
• After 24-48 hours of exposure the film was developed and fixed in dark 
• The film was ready for analysis 
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Autoradiography produces permanent images on photographic film. The 
two isotopes most commonly used for autoradiography are ^^ S and ^^P, both 
of which emit P-particles. The energies of these particles are very different. 
^^ S emits a particle with a maximum energy of 0.167MeV that can 
penetrate film emulsion only to depth of 0.25mm (although sufficient for 
the interaction between the emitted P-particle and the silver halide crystals 
in the film emulsions). ^^ P emits a particle with comparatively high energy 
(1.71 MeV) that can pass completely through an X-ray film. To increase the 
efficiency, an intensifying screen is applied below the film in the cassette 
and exposed at low temperatures (recommended = -70°C). 
Increase and decrease in the size of repeats as compared to their normal 
counterpart was considered evidence of instability. Two common band 
patterns were observed, either a novel discrete band in tumor DNA not 
observed in the corresponding normal DNA or as a marked alteration of 
repeat length, often heterogenous in nature and appeared as a ladder. RMA 
for individual primers were also calculated. [RMA = Number of cases with 
microsatellite instability/ total number of cases]. 
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LOH Analysis 
In addition to microsatellite instability, a detailed analysis of loss of 
heterozygosity was performed on the 58 dysplasia cases with a panel of five 
different polymorphic markers of chromosomes 3p (3p 14.2 to 5pl4.12) 
and 5p (5pl5.1-15.3). 
MARKERS AMPLIMER AMPLICON 
SIZE 
D3S1234 5'-CCTGTGAGACAAAGCAAGAC-3' l l l bp 
5'-GAC ATT AGG CAC AGG GCT AA-3' 
D3S1300 5'-AGCTCACATTCTAGTCAGCCT-3' 236bp 
5'-GCC AAT TCC CCA GAT G 
D3S1313 5'-CCCCTTGGAAAATCACTG-3' 
5'-CCA TGA ATA AGC CTT GCC-3' 
233b 
D5S208 5'-ACCTGA GTC TTC ATC AAT A C - 3 ' 186bp 
5'-TCC AGA ATC ATC CAT GTT GT-3' 
D5S406 5 '-CCT GCC AAT ACT TCA AGA AA-3' 185bp 
5'-GGG ATG CTA ACT GCT GAC TA-3' 
End labeling of one of the two (usually forward) primer was done 
with [y-^ ^P] ATP using T4 Polynucleotide Kinase (PNK) and (O.IM) ditrio-
threitol DTT at 37°C for one hour as described earlier. Amplification was 
done in the thermal cycler {Ependdorf/ Perkin Elmer) using 1 Unit of Taq 
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DNA Polymerase with 95° of initial denaturation, 52°-56°C annealing and a 
final extension of 72°C. The amplified products were resolved on 6% Urea 
Polyacrylamide (denaturing) gel at 2000 Volts, 170 W and 90mA for 2.5 
hrs. Steps involving preparation of glass plates, sequencing mix, 
preparation and loading of samples and autoradiography were similar to 
that described in microsatellite instability analysis. 
Absence or decrease in signal intensity by more than 50% of one 
allele in tumour DNA compared with constitutional allele was considered 
evidence for LOH. The cases, which were homozygous for the allele, were 
taken as non-informative and were not included in the study. 
HPV Detection by PCR 
PCR is an invitro method for primer directed enzymatic 
amplification of specific target DNA sequences over a million times in a 
few hours (Saiki et al 1985, Mullis et al 1987, Morris et al 1988). The 
detection level of PCR for HPV DNA has been estimated to be 10-100 
HPV DNA molecules among 5x 10"^  cells. Several studies have been 
performed to assess the sensitivity of PCR to detect HPV in clinical 
samples. Dallas et al 1989 estimated the sensitivity of PCR to be 10 copies 
of virus (0.08fg of DNA) in a 10,000-cell sample subjected too 36 cycles 
with Taq Polymerase. Similar sensitivities have been reported by a number 
of subsequent studies. To exclude false positive results appropriate negative 
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controls are mandatory. False negativity due to factors inhibiting 
polymerization can be avoided by proper DNA extraction. 
All samples proved positive for P-globin amplification, the internal 
amplification control, and were therefore considered suitable for HPV 
analysis, extra precautions were taken to avoid cross contamination of the 
amplified products. The samples were screened for the presence of HPV, 
with positive and negative controls, by amplifying them with consensus 
primers (MY09-CGTCCMARRGGAWACTGATC and MYll-
GCMCAGGGWCATAAYAATGG; (Manos at al., 1989) from the LI 
region of HPV genome, which detects a broad spectrum of HPV types. 
[Where, M - A/C; W=A/T; Y=C/T; R=A/G] 
l|il of the DNA was amplified in Thermal Cycler (Eppendorf), with MY09 
and MY 11 consensus primers (Microsynth) of LI region of HPV genome, 
covering both low and high-risk HPV types. The amplification was done 
using Taq DNA Polymerase lOX Buffer with 2.5mM MgCb, and dNTPs 
(Bangalore Genei), at initial denaturation of 95° for 5 minutes following 35 
cycles of; 
94° 30 sec 
56° 30 sec 
72° 30 sec each 
and a final extension of 72° for 10 minutes 
lOfiL of the samples were loaded for resolution on 2% agarose with 
ethidium bromide staining. 
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Detection of HPV types 
All the positive cases were amplified individually with type specific 
primers for each type viz. 6, 11, 16, 18 and 33 in order to check the efficacy 
of the RFLP technique, using following primers: 
HPV Type Primer Sequence Amplicon Size (bp) 
Type 6 ( F ) 5'-TAGTGGGCCTATGGCTCGTC-3' 280 
(R) 5'-TCCATTAGCCTCCACGGGTG-3' 
Type 11(F) 5'-GGAATACATGCGCCATGTGG-3' 360 
(R) 5'-CGAGCAGACGTCCGTCCTCG-3' 
Type 16 (F) 5'-AAGGCCAACTAAATGTCAC-3' 217 
(R) 5'-CTGCTTTTATACTAACCGG-3' 
Type 18 (F) 5'-ACCTTAATGAAAAACCACGA-3' 100 
(R) 5'-CGTCGTTGGAGTCGTTCCTG-3' 
Type 33 (F) 5'- ATGATAGATGATGTAACGCC-3' 456 
(R) 5'-GCACACTCCATGCGTATCAG-3' 
Each sample was amplified with every primer to see detect the above five 
types using following cycles: Initial denaturation 95°C for 5 minutes 
followed by 35 cycles of 94°C for 30 sec, for 30 sec and 72°C for 30 
sec each and a final extension of I'fO, for 7 minutes. The samples were 
then resolved on 3% agarose (2% agarose + 1% Nuisive) alongwith (j)X174 
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(Hae III) digested marker and stained with EBr. The gel was visualized 
under UV. 
Detection of HPV Variants using Single stranded conformational 
polymorphism (SSCP) 
Single strand conformational polymorphism analysis is one of the most 
widely used gene mutation scanning system. The technique developed in 
Hayashi's laboratory and first reported in 1989, involves PCR amplification 
of the region of the gene to be studied, denaturation of the double stranded 
amplicon by heat and electrophoresis on a non denaturing polyacrylamide 
gel ((Desaintes C., et al., 1992). During electrophoresis the single stranded 
DNA fragments fold into a three-dimensional shape according to their 
primary sequence. The separation then becomes the function of the shape of 
the single stranded molecules. If wild type and mutant PCR products differ 
in their sequence, even by order of single nucleotide, they are likely to 
adopt different three-dimensional structures and exhibit different 
electrophoretic mobility. 
In order to prevent the two single strands from reannealing to form double 
stranded DNA, the concentration of DNA in the loading buffer is kept very 
low. Thus in order to visualize the bands, radioactive labeling of DNA is 
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typically required. However, as an alternative, silver staining seems to give 
adequate sensitivity and is increasing in popularity. 
The most important advantages of PCR-SSCP analysis is that it can detect 
single substitutions of unknown positions of target DNA fragments. The 
efficacy of detection of single base substitutions in fragments of less than 
300-350 bp is estimated to more than when both strands are labeled and 
separated in gel containing glycerol. 
Therefore, the lower primers should be set to amplify a target region of 
DNA fragment having an estimated length less than 300-350 bp. The 
efficiency will be decreased gradually in DNA fragment with increasing 
lengths above 300-350bp. 
The temperature of gel during electrophoresis is also an important factor for 
determining single base substitutions. In some sequences mobility shift, due 
to a single base substitution observed after electrophoresis at 4-10°C, but 
not at room temperature. At low temperature polyacrylamide gel without 
glycerol should be used, because of the extremely slow mobility of single 
stranded DNA fragments in the presence of glycerol. Thus the mobility of 
single stranded DNA fragments in polyacrylamide gels is influenced by 
temperature and therefore an electrophoresis apparatus equipped with 
cooling system is recommended. 
The extensive application of PCR-SSCP analysis, especially in clinical 
laboratories has been hampered by its requirement for radioactive 
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nucleotides. To overcome this, non-isotopic detection of SSCP by silver or 
ethidium bromide staining of single stranded DNA in polyacrylamide gel 
has been developed (Oshima J., et al., 1993; Phelps w.C., et al , 1988; 
Lamberti C., et al., 1990). 
Working protocol for SSCP 
Reaction Mix (lOOuU 
10 X Buffer lO^L 
dNTPs 
Primer 1 
Primer 2 
8.O11L 
l.OiiL 
l.O^L 
Taq(3U) 0.3 |iL 
D.Water 79.8^1 
Total lOO^L 
25|iL each was aliquoted in separate tube and 50-100ng of tumour DNA 
was added and was subjected to amplification under following cycling 
conditions 
Initial denaturation 940 4 minutes 
Denaturation 940 30 seconds 
Annealing 55° 30 seconds 
Extension 72° 30 seconds 
Final extension i f 3 minutes 
30 cycles 
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After amplification, 10|iL aliquot of the PGR product was run on 3% 
agarose gel containing ethidium bromide and observed under the UV 
transilluminator/ Gel Doc. SSGP was performed by radiolabelling the PGR 
products where dGTP was replaced with [a-^^P] dGTP 
Reaction Mix 
10 X Buffer lO^L 
dNTP 
(except dGTP) 
Primer 1 1.0)iL 
Primer 2 l.O^iL 
a-^^PGTP l.O^L 
Taq 0.3^L 
D Water 84.2^L 
Total lOO i^L 
1.5|iL 
was aliquoted in separate tube 
1 |iL PGR product was added in the tube 
Amplified in thermal cycler for 10-15 cycles under following conditions 
Denaturation 94° 30 sec 
Annealing 55° 30 sec 
Extension 72° 30 sec 
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After amplification, 1 ^L of the radiolabelled PCR product was diluted with 
dye (95% formamide, 20mM EDTA, 0.05% xylene cyanol and 0.05% 
bromopphenol blue) 
SSCP Gel (6% non denaturing polyacrylamide 80mL) 
40% acrylamide 12mL 
lOXTBE 4mL 
Glycerol 4niL 
D Water 60mL 
Total 80niL 
10% APS 540 |iL 
TEMED 40^L 
1. Both the plates of the apparatus were washed properly as described 
earlier. Spacer (0.4mm) was placed between the two plates and the 
plates were sealed properly with brown tape. 
2. Gel was poured immediately after adding TEMED taking care that no 
air bubble was trapped inside. 
3. Gel was kept for one hour for polymerization. 
4. After polymerization the plates were connected to the power supply 
{Stratagem) for pre run (30 minutes) in 0.5 X TEE at 250 V, 17*^  ±1°C. 
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5. The SSCP-PCR product were denatured at 940C for 5 minutes and 
immediately placed in ice. 
6. 2-3)aL was loaded. 
7. The gel was run at 200V, 17°±1°C for 12 hours. 
8. After the gel was run to the desired distance and time, the plates were 
removed and the gel was taken on 3 MM Whatman paper, placed saran 
wrap and dried in gel drier at 80°C for one hour. 
9. Saran wrap was removed and the gel was placed in cassette alongwith 
the X-ray film for exposure at -70°C for 48 hours. 
10. The film was developed to see he mobility shift. 
Expression of cerbB2/Her-2 neu, P-catenin by 
immunohistochemistry 
Paraffm-embedded specimens of 58 precancer cases examined 
microscopically, were obtained on Poly-L-Lysine coated shdes. Cellular 
localization and expression of HER-2/neu and P-catenin was investigated 
by immunohistochemistry in all samples. 
c-erbB-2 (cellular localization cell membrane) is a receptor tyrosine kinase 
of the c-erbB family, P-catenin is a structural component of the E-cadherin 
mediated cell-cell adhesion system as well as signaling molecule of the 
Wnt/wingless pathway. 
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Coating slides with Poly -L-Lysine 
Poly -L-Lysine is an adhesive solution used in adhering tissue sections in 
glass slides, particularly useful with immunohistochemical techniques. 
The Poly -L-Lysine solution Sigma (Cat # P8920) was diluted 1:10 with 
deionized water prior to coating slides. 
The Microscope slides were washed with SDS and then dipped in 1%HC1 
prepared in 70% alcohol for 5' and dried to make the slides grease free 
before coating with Poly-L-Lysine and dipped in diluted Poly -L-Lysine 
solution for 5' at 18-26°C. The slides were then incubated at 60°C for one 
hour or 18-26°C overnight. The coated sUdes can then be stored at 4'^ C. 
Immunohistochemical staining procedure 
Deparqffinization 
1. The slides were dipped in Xylene for 10 minutes (3 changes) 
2. Then 5-10 dips were given in acetone 
3. 5-10 dips in 95% ethanol 80% ethanol and 70% ethanol 
4. The slides were kept in slowly running tap water for 15 minutes 
5. Microwave antigen retrieval technique was applied, i.e. the slides 
were boiled resting flat with sections facing up in lOmM citrate buffer 
for 30 minutes using microwavable glass container, then allowed to cool 
to room temperature and the slides were washed briefly with Tris-HCl 
buffer (twice). 
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6. To block the endogenous peroxidase the sUdes were immersed in 
coplin jar containing 96mL methanol and 4mL hydrogen peroxide for 
25-30 minutes at room temperature. Endogenous peroxidase blocking 
solution must be prepared fresh, immediately before use. 
7. The slides were then washed in two changes of Tris HCl buffer for a 
total of around 20 minutes. Tapping off excess buffer the slides were 
wiped around the specimen with filter paper. 
8. The slides were kept in moist chamber and the primary antibody was 
applied covering the entire specimen. 
9. The slides were incubated at 4°C overnight in the humid chamber. 
10. After removing from the moist chamber the slides were washed in 
two changes of Tris HCl at the intervals of 10 minutes. 
11. Biotinylated secondary antibody was applied and incubated at 
room temperature for one hour. 
12. Again with two changes of Tris HCl the slides were washed at the 
interval of 10 minutes. 
13. Peroxidase conjugated streptavidin was applied and kept at room 
temperature for one hour. (It is used in a labeled streptavidin-biotin 
immunoenzymatic antigen detection system. This technique involves 
the sequential incubation of the specimen with unconjugated primary 
antibody specific to the target antigen, a biotinylated secondary 
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antibody that acts with the primary antibody, enzyme labelled 
streptavidin and substrate-chromogen). 
14. Slides were washed in two changes of Tris HCl buffer for 20 
minutes. 
15. DAB solution was prepared (immediately before use) and applied 
controlling the intensity under microscope using known positive 
control as guide. 3-3'Diaminobenzidine (DAB) is a widely used 
chromogen for immunohistochemical staining and immunoblotting. 
In the presence of peroxidase enzyme, DAB produces a brown 
precipitate that is insoluble in alcohol. This product is available in 
two component form DAB chromogen and DAB substrate. The 
standard working dilution is 40|j,L (0.9mg) of DAB chromogen per 
ImL of DAB substrate. Once the two components are combined the 
reagent can be used for upto six hours.Combine 1-2 drops (40-
lOOjiL) of DAB chromogen with each ImL of DAB substrate and 
apply mixture to the tissue section. Incubate for 5-15 minutes. 
16. The DAB reaction was stopped by immersing the slide in distilled 
water and then it was washed thoroughly (with distilled water). 
17. The slides were then counterstained lightly with Harris' 
hematoxylin and dried thoroughly at room temperature. 
18. Then it was mounted with coverslip using DPX, a mounting medium 
and labeled appropriately. 
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19. The slides were then observed under microscopes with positive and 
negative controls that were run during every batch of staining. 
20. Positive control = Appropriate tissue sections known to express a 
particular antigen. 
Negative control = Eliminate the step of primary antibody 
application rest remaining unaltered. 
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MicrosateCCite 
InstaBiRty 
5. MICROSATELLITE INSTABILITY 
Introduction 
Microsatellites are tandem repeat of simple DNA sequences, highly 
polymorphic and randomly interspersed throughout the human genome. 
They consist of 10-15 copies of 1-6 base pair motifs and it is estimated that 
there are on the order of 50,000 to 1,00,00 (CA)„ elements scattered 
throughout the human genome. They are replicated faithfully at each cell 
division with a new mutation rate of 10'^  to 10"^  (Weber et al, 1993). 
Variations in such microsatellite regions is generated by errors in DNA 
replication. These errors are thought to result from a defect in the mismatch 
repair system. About 60,000 proteins are required for a complete and 
proper functioning of an individual and its blueprint lies in the DNA. The 
estimated error rate for a DNA replication in human with well functioning 
repair system id 10"'° mutations per basepair per cell generation. If DNA 
was copied badly chances of disease such as cancer will be at much higher 
frequency, on the other hand, if DNA was copied perfectly, there would be 
no room for evolution, the DNA repair system synchronizes the balance 
between the two. Most polymorphism occurs in the 97% of the non-coding 
junk DNA of the human genome, variations therein are functionally 
inconsequential and hence well tolerated during evolution. Much of this 
noncoding DNA consists of highly repetitive DNA segment, one such class 
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in humans consists of simple tandem repeats (STRs). Such repeats of 2-3 
nucleotide segments, known as microsatellite DNA are unique to each 
individual. All of the proteins coding regions account for only about 3% of 
the human genome. Most non-coding regions of DNA may be located 
within genes (introns) or in between the genes. Since these regions do not 
code for any functional protein, variations in these regions are well 
tolerated during evolution allowing tremendous genetic diversity to develop 
in these regions. Clues to the mechanism underlying the molecular basis of 
tumour microsatellite instability emerged from the study of the effects of 
mutations within the mismatch repair proteins were localized and cloned 
and their role in HNPCC was examined. Greater than 80% of HNPCC 
tumours demonstrated microsatellite instability (Aaltonen et al, 1994). 
30% of families with HNPCC have germline mutations in hMSH2, while 
another 30% in hMLHl (Wijnen et al, 1996). The presence of MIN has 
been reported in a variety of malignancies. Colorectal cancer was the first 
type of human malignancy in which MSI was described (Aaltonen et al., 
1993; Thibodeau et al., 1993; lonov et al.). The reported genomic 
instabilities involved mono-d- and tri-nucleotide repeats and occurred in 
hereditary non-polyposis as well as sporadic colorectal cancer. Tumour 
microsatellite instability can be detected in a PCR based assay by 
comparing tumour DNA to that derived from normal tissue of the same 
patient. Alterations of length of simple repetitive genomic sequences 
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(microsatellite instability) characterize a distinct mechanism of 
carcinogenesis. MSI analysis has become an attractive method for both 
diagnostic and tumoribiological purposes (Dietmer et al., 1997). 
Instabilities in the microsatellite region of tumour DNA have been observed 
when compared with the normal allele of same patient showing either an 
expansion or contraction on one or both alleles in some tumours. Variations 
in such microsatellite regions are generated by errors in DNA replication. 
Since, microsatellite instability is one of the defects 'mismatch repair' is 
supposed to prevent, indicates a defective mismatch repair system. 
Each cell loses 10,000 bases per day from, breakdown of DNA at 
body temperature, and dividing cells introduce additional errors in the act 
of DNA replication. These errors are rectified by the DNA repair enzymes, 
which are highly conserved throughout evolutionary history. There are two 
major types of DNA repair pathways, each of which has its own distinct 
function. Mismatch repair pathway detects and repair short segments of 
mismatch base pairs, these include simple mismatches, in which the wrong 
nucleotide building block is put into the new DNA strand. Since 
Microsatellite instability, a defect that mismatch repair is supposed to 
prevent, falls into this category. Disorders of the mismatch repair pathway 
lead to errors in these polymorphic segments. In contrast, " nucleotide 
excision repair" which goes awry in Xeroderma pigmentosa, snips out and 
replaces DNA damaged by chemicals and radiation (Jean Marx. 1994). In 
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December 1997, the National Cancer Institute sponsored a workshop on 
"Microsatellite Instability and RER Phenotypes in Cancer Detection and 
Familial Predisposition" and recommended the Bethesda Guidelines 
developed in 1996 to assist in selection of tumors for MSI analysis. Over 
the past five years the scope of MSI has been expanded to encompass a 
unique form of genetic instability broadly involved in the genesis of cancer 
(Boland etal., 1998). 
Materials and Methods 
Materials and Methods used in the study have been described in Chapter 3 
in detail, briefly described as follows: 
Tissue samples 
Microdissection of the paraffin embedded tissue of patients with 
preneoplastic lesions was done under dissecting microscope and malignant 
and subsequent normal areas were scraped from the same section with the 
help of sterile blades taking guidance from the stained slide. 
Method 
DNA isolation was done from the normal and dysplastic tissue separately 
after deparaffinizing three times, followed by PK digestion and phenol-
chloroform extraction. 30-50ng DNA was used as template for the PCR. 
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Table 5.1 (Primer used in the analysis of microsatellite instability): 
Name Chr Repeat Motifs Primer seq Tm 
BAT 25 4q TTTT.T."nTT(T)7.A(T)25 TCG CCT CCA AGA ATG TAA GT 58 
TCT GCA TTT TAA CTA TGG CTC 
BAT 26 2p (T)5 (A)26 TGA CTA CTT TTG ACT TCA GCC 58 
AAC CAT TCA ACA TTT TTA ACC 
(D2S123) 2pl6 (CA)I3TA(CA),5(T/G A)7AAA CAG GAT GCC GCC TGC CTT TA 60 
GGA CTT TCC ACC TAT GGG AC 
APC 5q21/22 (CA)26 ACT CAC TCT AGT GAT AAA TCG" 55 
(D5S346) GC AGA TAA GAC AGT ATT ACT AGT T 
Mfd15CA 17q11.2-12 (TA)7....(CA)24 GGA AGA ATC AAA TAG ACA AT 52 
RD17S250) GCT GGC CAT ATA TAT ATT TAA ACC 
Polymerase Chain Reaction 
A standard Polymerase chain reaction was carried out in a 25|iL reaction 
volume containing 30-50ng of DNA as template, 20pmol of primers. One 
primer was end-labeled with [y^^P] ATP using O.IM DTT and incubating at 
37°C for one hour. The amplification reactions were carried out for 35 
cycles at annealing temperatures ranging from 52°-56°C using 1 Unit of 
Taq DNA Polymerase {Roche, Applied Biosysterns), 2.5mM MgC12 and 
200|iM dNTPs (New England Biolab). The amplification was first checked 
on 2% agarose then finally resolved on 6% denaturing Polyacrylamide/ 
Urea gel. After autoradiography analysis of microsatellite instability was 
done. 
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MSI Analysis 
MSI was characterized by small deletions or expansions within short 
tandem repeats in tumor DNA as compared with matching normal DNA. It 
was detected in PCR-based assay by comparing the DNA derived from 
tumor (dysplastic) to that derived from normal tissue. Two common band 
patterns were observed, either a novel discrete band in tumor DNA not 
observed in the corresponding normal DNA or as a marked alteration of 
repeat length, often heterogenous in nature and appeared as a ladder. The 
tumors with MSI was divided into two groups: the first is characterized by 
MSI-H (MSI exhibited by two or more markers) and MSI-L (MSI exhibited 
by one marker) and a third group lacking instability (when none of the 
markers exhibit instability) was MSS. However the separation between 
MSI-H&L was highly dependent on both the type and number of 
microsatellites analyzed, for proper selection of markers to identify MSI-L 
and MSI-H phenotypes the committee recommended a reference panel of 
five microsatellite markers for colorectal cancers. In the present study, 
same reference panel of the five markers were used for the first time for 
MSI analysis on 58 untreated cervical dysplasia. Using this reference panel 
MSI-H tumors are defined as having instability in two or markers, whereas, 
MSI-L tumors are defined as having instability in one marker. Microsatelite 
Index for the five markers [Instabilty observed by the primers/number of 
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markers usedjand RMA for individual primers were also calculated. [RMA 
= Number of cases with microsatellite instability/ total number of cases]. 
Results 
Microsatellite instability was tested using the Bethesda Consensus 
Conference reference panel of the above five markers, Bat-25, BAT-26, 
D2S123, D5S346 and D17S250 (Boland, et al. 1998). Tables 5.2 and 5.3 
showed analysis of markers and in relation to severity of pathological 
lesions. Chart 5.1 shows primer information of status of MSI in individual 
tumors. The percentage of MSI ranged from 0 to 27.5. Maximum MSI was 
found at D2S123 and nil at D5S346 (Table 5.2). Some sites showed both 
MSI and LOH. The representative photographs of MSI are shown in Fig 5.1 
Microsatellite instability was found in 31/58 (53.4%) of the precancer cases 
[MSI-H =15.5% and MSI-L = 37.9%]. 48% (12/25) of the cases with mild 
dysplasia showed instability [MSI-H = 8.0% and MSI-L = 40%]. In 
contrast to mild dysplastic lesions an increased frequency of microsatellite 
instability was observed in severe dysplasia showing 57.5% (19/33) MSI 
[MSI-H = 21.2% and MSI-L = 36.3%]. However, 52.0% of the mild 
dysplasia and 42.4% of the severe dysplasia cases did not show any 
instability with any of the five markers tested and were considered 
microsatellite stable (MSS). Maximum microsatellite instability (25.8%) 
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was found in the 2pl6 region (D2S123). In addition to MSI, 7.7% cases 
showed LOH at the same site, BAT 25 showed instability in 20.6% cases, 
low instability (8.6%) was exhibited by the primer BAT 26 in the 
precancerous lesions and D17S250 showed 13.8% instability, however, no 
MSI was observed with D5S123 whereas, 6.3% LOH was found in this 
region. MSI was significantly higher (p<0.01) in HPV positive cases as 
compared to HPV negative cases. 
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BAT 26 D2S123 
N D 
BAT 25 D17S250 
FiguresS j Showing Microsatellite instability in cervical dysplasia using 
Bethesda Consensus reference panel of five markers. Arrows indicate 
increased or decreased size of repeats in tumour DNA [N= normal; D= 
dysplasia] 
Results and Discussion 
Table 5.2 Showing microsatellite status with five polymorphic markers 
in precancer (MI Index = 0.8) 
Primers 
No. of 
Cases 
i % I 
No. of 
MSI+ 
(%) 
No. of 
LOH/Inf.cases 
RMA 
BAT-25 58 12/58 
(20.6) _ ' 0.20 
BAT-26 58 5/58 
(8.6) - 0.086 
D2S123 58 16/58 
(27.5) (3.5) 0.27 
D5S346 58 0 
(0 .00) (1.8) 0.00 
D17S250 58 8/58 
r i3 .8 ) (6.3) 0.137 
[RMA = Number of cases with microsatellite instability/ total number of cases] 
Table 5.3 Showing microsatellite instability (MSI-L & H) in mild 
moderate and severe dysplasia 
Clinical Stage MSI-L 
(%) 
MSI-H 
(0/ 
MSS MSI (%) 
(Vo) (MSI-L + H) 
Mild & Moderate* 10/25 2/5 
Dysplasia (40.0) (8.0) 
(n-25) 
Severe Dysplasia 12/33 7/33 
(n=33) (36 .3) (21 .2) 
13/25 
(52 .0 ) 
14/33 
(42 .4 ) 
12/25 
(48 .0 ) 
19/33 
(57 .5 ) 
Mild & Moderate* 22/58 9/58 
+ Severe (n=58) (37.9) (15.5) 
27/58 
(46 .5 ) 
31/58 
(53 .4 ) 
* Only one case of moderate dysplasia was studied, hence it was included 
in early lesion (mild dysplasia) 
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Discussion 
Instability in microsatellite loci was initially reported in familial colorectal 
carcinomas, further it was found in a variety of sporadic malignancies, 
including those of the colon, endometrium, stomach, pancreas, lung, 
bladder, kidney, esophagus, endometrium and ovarian cancer (lonov et al, 
1993; Thibadeau et al, 1993; Han et al, 1993; Rhyu et al, 1994; Merlo et 
al, 1994; Shridhar et al, 1993; Gonzalez et al, 1993; Uchida et al, 1994; 
Burks et al, 1994; King et al, 1995 respectively). Hye-Jung et al., 1994 in 
the study of pancreatic cancer and poorly differentiate type of gastric cancer 
suggested that mechanism of instability during the progression of 
carcinogenesis could be defined more clearly, a test for alterations in 
microsatellite loci might provide useful prognostic information. Nishimura 
et al., (2000) found microsatellite instability to be a late event in the process 
of cervical carcinogenesis. Incidence of MSI in precancers have been 
reported to be 14.9% (Jimenes et al., 1998), 26.3% (Mitra et al., 1995) and 
41.7% (Wistuba et al., 1997). Since, selection of markers as well as the 
number of markers used in the study has a significant effect on the 
determination of MIN status, similarly, the comparison between studies is 
difficult, it has been recommended to utilize a combination of mono and di-
nucleotide repeats for MSI analysis. Dinucleotide repeats have been used 
most frequently for these studies, instability has also been observed in 
mono, di, tri, and tetra-nucleotide repeats (Hong et al, 1997; Zhou et al, 
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1997), indicating that both mono and dinucleotide repeat markers were 
susceptible to instability. On the basis of studies performed till date it was 
decided in the National Cancer Institute Workshop for Cancer and Familial 
Predisposition to use a "reference" panel of markers for the study of 
microsatellite instability in colorectal cancers. The recommended panel 
validated by Ruschoff and Fishel (1997) is composed of two 
mononucleotide repeats (BAT25 and BAT 26) and three dinucleotide 
repeats (D5S346, D2S123 and D17S250). To analyze the status of 
microsatellite instability in different grades of precancerous lesions of 
uterine cervix, a detailed study on 58 dysplasia cases, including 25 mild and 
33 severe dysplasia, was performed using the same "Bethesda Consensus 
Conference reference panel" of five markers, Bat-25, BAT-26, D2S123, 
D5S346 and D17S250 (Boland et al. 1998) which have so far not been used 
for the study of microsatellite instability in cervical dysplasia. 29% 
instability was observed with mononucleotide repeat primers whereas, 
markers with dinucleotide repeat motifs showed a higher (41%) instability. 
Dietmer et al , 1997 in HNPCC reported high frequency of MSI with mono-
nucleotide repeats followed by di-nucleotide repeats. Maximum 
microsatelHte instability (27.5%) was observed at D2S123, where the 
repeat motifs were (CA)i3 TA (CA)i5 (T/GA)ii , in addition to MSI, LOH 
was observed in 7.7% at the same site. BAT 25 (mononucleotide repeat 
marker) which amplifies the (A)n tract located in the intron of c-kit 
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oncogene also showed instability in 20.6% cases, primer (BAT26) from 
the intron 5 of hMSH2 gene, showed little instability (8.6%) in the 
precancerous lesions. Both BAT25 and BAT26 have been reported to be 
highly effected by instability in colorectal cancer (Parsons, et al., 1995). 
The susceptibility of mononucleotides to instability in MSI tumors was first 
described by lonov et al., 1993, where replication errors occurred most 
requently in Alu repeats that had undergone deletions in their poly (A) 
tails. D17S250, a dinucleotide repeat marker, showed 13.8% instability, 
however, no MSI was observed with D5S123, instead, 6.3% LOH was 
found in this region. Overall instability in precancers was 53.4% (31/58) 
whereas 46.5% (27/58) were microsatellite stable (MSS). Percentage of 
MSI was high in severe dysplasia (57.5%) as compared to mild dysplasia 
(48%), though the difference was not significant, the status of MSI showed 
an increasing trend with the high grade lesions. Chi-square test/ Fisher 
exact test were applied as per the requirement. Our findings clearly indicate 
that MSI is an early event in the process of cervical carcinogenesis, for 
which a hereditary predisposition has never been described, suggesting that 
this kind of instability might be common to sporadic human cancers, and 
that replication error phenotype might not be unique to HNPCC. 
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6. LOSS OF HETEROZYGOSITY 
Introduction 
The term loss of heterozygosity (LOH) first used by Dracopoli and Fogh 
(1983), to describe a reduced level of heterozygosity. LOH being a 
powerful approach to study the deletion or inactivation of the candidate 
TSG in precancerous lesions has been extensively applied leading to the 
identification of several chromosomal regions that are recurrently affected 
in this tumor. Loss of heterozygosity (LOH) refers to the observation of 
single allele at particular genetic locus or loci in benign or cancerous, or 
precancerous lesion, arising in an individual who is heterozygous for the 
same locus or loci in its normal tissue. Loss of heterozygosity is being 
detected with increasing frequency in a wide variety of human tumors 
(Yokota et al., 1989; Vogelstein et al., 1988; Wagata et al., 1991; Meltzer et 
al., 1987; Simon et al., 1991; Khosla et al., 1991; Fey et al., 1989; 
Vogelstein et al., 1989; Kovacs et al., 1988; Lee et al., 1990). Frequent 
LOH at a given chromosomal locus implies the existence of a tumor 
suppressor gene that is important in the pathogenesis of the particular 
cancer under study. LOH is believed to represent inactivation of one allele 
of a tumor suppressor gene by chromosomal or subchromosomal deletion. 
The first evidence of the existence of a tumor suppressor gene (TSG) on 
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chromosome 11 came from the suppressor of tumorigenesity as a result of 
transfer of a normal copy of chromosome 11 into HeLa cell (Saxon et at, 
1986). Subsequently, frequent LOH have been detected on 3p and 5p 
(Kohno et al 1993, Mullokandov et al 1996 and Karlsen et al 1994 etc). 
Several tumor suppressor genes have been reported to be located at 3p. 
Whereas, 5p (D5S406) showed high incidence of LOH (66.7%) in cervical 
cancer, suggesting the presence of candidate tumor suppressor gene (Mitra 
et al., 1995). To elucidate the role of LOH at 3p and 5p regions in the 
process of cervical carcinogenesis, we evaluated 58 cervical dysplasia cases 
(25 mild to moderate and 33 severe dysplasia). 
Materials and Methods 
Materials and Methods used in the study have been described in detail in 
Chapter-IL Briefly described as follows. 
Tissue samples 
58 archival paraffin blocks of precancerous lesions were used in the study. 
The tissue blocks included 25 mild dysplasia and 33 severe dysplasia. 
Paraffin embedded tissue sections (10|i) were microdissected under 
dissecting microscope and malignant and subsequent normal areas were 
scraped from the same section with the help of sterile blades taking 
guidance from the stained slide. Areas of stroma that contained the highest 
density of infiltrating lymphocytes were used as constitutional normal DNA 
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for each case. Dysplastic cells and normal cells were collected separately in 
l.S^iL microfuge tubes for further process for DNA extraction. 
Method 
DNA isolation was done from the microdissected material, samples were 
deparaffinized with Xylene, followed by PK digestion and phenol-
chloroform extraction. 30-50ng DNA was used as the template for PGR. 
Table 6.1 (Primer details for LOH analysis) 
MARKERS AMPLIMER AMPLICON SIZE 
D3S1234 5'-CCT GTG AGA CAA AGC AAG AC-3' 
5'-GAC ATT AGG CAC AGG GCT AA-3' 
l l lbp 
D3S1300 5'-AGC TCA CAT TCT AGT CAG CCT-3' 
5'-GCC AAT TCC CCA GAT G 
236bp 
D3S1313 5'-CCC CTT GGA AAA TCA CTG-3' 
5'-CCA TGA ATA AGC CTT GCC-3' 
233b 
D5S208 5'-ACC TGA GTC TTC ATC AAT AC -3' 
5'-TCC AGA ATC ATC CAT GTT GT-3' 
186bp 
D5S406 5'-CCT GCC AAT ACT TCA AGA AA-3' 
5'-GGG ATG CTA ACT GCT GAC TA-3' 
185bp 
Polymerase chain reaction 
Standard Polymerase chain reaction was carried out in a 25|iL reaction 
volume containing 30-50ng of DNA as template, 20pmol of primers (table 
6.1). One primer was end-labeled with [y^^P] ATP using O.IM DTT and 
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incubating at for one hour. The amplification reactions were carried 
out for 35 cycles at annealing temperatures ranging from 52°-56°C using 1 
Unit of Taq DNA Polymerase {Roche, Applied Biosystems), 2.5mM MgC12 
and 200|iM dNTPs {New England Biolab). The PCR products were 
denatured in sequencing stop buffer and subjected to electrophoresis in 6% 
denaturing Polyacrylamide gels, and the dried gels were autoradiographed 
for 6-18 hrs. 
LOH Analysis 
To evaluate LOH in cervical dysplasia, a panel of five markers were used 
covering the following chromosomal regions 3pl4.1-14.2 (D3S1234, 
D3S1300, D3S1313) and 5pl5.1-15.2 (D5S208 and D5S406). Markers that 
identified two distinguishable alleles of different sizes but similar intensity 
in the lane having constitutional normal DNA were termed "informative" 
(heterozygous). Markers that gave a single major band in the normal DNA 
were termed "noninformative" (homozygous). Complete absence of upper 
or lower allele compared with constitutional alleles was considered 
evidence for LOH. FRL (FRL =the number of patients with LOH in that 
region/the number of patients informative in that region) was also 
calculated. LOH was considered significant if the frequency was above 
25%. 
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Results 
Out of the 58 precancer cases studied, maximum (11.42%) LOH was 
observed with the marker D3S1300, in the region 5pl5.1-15.2 (D5S406) 
LOH was significantly higher (13.3%), though the number of informative 
cases in that region were low (eight). Microsatellite instability was also 
observed with two markers used for LOH study i.e. D3S1234 and 
D3S1300. LOH was present in low frequency in precancers (maximum 
13.3% in 5pl5.1-15.2 and 10.7% at 3p)(table 6.2). There was no significant 
difference in the pattern of LOH in mild or severe dysplasia. 
Table 6.2 Showing LOH at chromosomal arms 3p and 5p in precancers 
No. of No. of cases No. of 
Primers Cases Informative MSI LOH FRL 
studied (%) 
D3S1234 58 52 1 4/52 
(7.7) 
0.076 
D3S1300 58 56 1 6/56 
(10.7) 
0.107 
D3S1313 58 2,1 0 i m 
(5.4) 
0.054 
D5S208 58 34 0 3/34 
(8.8) 
0.088 
D5S406 58 15 0 2/15 
fl3.3) 
0.1 
No significant relationship was observed between LOH and human 
papillomavirus infection in precancers. 
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Figures^)Representative photographs showing loss of heterozygosity (LOH) 
in patients with cervical dysplasia. Arrows indicate loss of allele in the 
tumour DNA. [N= normal; D= dysplasia]. 
Results and Discussion 
Discussion 
In the present study a panel of five markers were used covering the 
following chromosomal regions 3pl4.1-14.2 (D3S1234, D3S1300, 
D3S1313) and 5pl5.1-15.2 (D5S208 and D5S406). These regions 3pl4.1-
14.2 and 5pl5.1-15.2 were selected on the basis of previously obtained data 
and for their reported high LOH rate. LOH was scored insignificant (<25%) 
both at 3p and 5p in precancers with no significant correlation in the 
fi-equency of LOH in mild dysplasia and severe dysplasia. 
LOH at 3p 
LOH at 3p have been found to be involved in different human cancers. In 
cervical cancer also, frequent LOH at 3p site have been reported. In our 
present study of 58 cervical dysplasia cases LOH at 3p was found to be 
maximum 10.7% (D3S1300). Among chromosome 3-specific TSGs some 
probably confirms the classical two hit model requiring inactivation/ loss or 
silencing of both alleles of the gene (homozygous, -/-, phenotype), while 
others may function as haploinsufficient TSGs one allele of which is still 
expressed in the tumor (hemizygous, -/+, phenotype). Since the acquisition 
of other genetic modifications still rate limiting in causing cancer 
(Knudson, 1995), another mutation in a different gene would appear to be 
required in the haploinsufficient cancer model. Chromosome 3p contains 
several tumor suppressor genes, some of them are cancer specific and 
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others are common for different cancer types. Mullokandov et al. 1996 
found LOH at 3p in 39% of tumors. LOH of D3S32 locus was found in 
32% of the tumors of uterine cervix (Mitra et al., 1994). Because these are 
located at 3p21 and 3p21.33-21.1 respectively, a putative tumor suppressor 
gene would be expected to be located within p22.1 as this is the only band 
of overlap with the D3S1298 probe that maps to p22.1-24.1 (Mullokandov 
et al., 1996). In the present study three markers were used for the region 
3pl4.1-14.2, maximun 10.7% LOH was found (D3S1300 other two 
markers (D3S1234 and D3S1313) showed 7.7 and 5.5% LOH respectively. 
Chung et al., 1992 found 83% LOH at the RAF locus (3p25) and 90% at 
D3S locus (3pl4), Jones and Nakamura et al., 1992,. also found LOH at 
3pl3-3pl4.3 in 75% cervical cancer and 3p21.2-22 in cervical, ovarian and 
endometrial cancers. Kohno et al, 1993 found LOH at the 3pl3 region in 
47% of the cervical cancers. Karlsen et al , 1994 found 70% LOH at 3p21 
and 56% in 3p21.1-22. 3p contains several tumor suppressor genes, two of 
which was also reported to be involved with renal cancer. The 3p 13.21.1 
region is often involved in LOH in cancers of breast, lung, kidney and some 
other cancers (Seizenger et al , 1991). The fragile site FRA 3B at 3pl4.2 is 
one of the most frequent and most sensitive sites induced by the carcinogen 
aphidicolin. A number of investigators (Jones and Nakamura, 1992; Mitra 
et al., 1994a; Mullokndov et al., 1996; Kersemaekers et al., 1998) have 
reported frequent LOH at 3p mapped to 3p21-22, where the P-catenin is 
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located, representing a downstream modulator of adenomatous polyposis 
activity (Trent et al., 1995). Mullokandov et al 1996 reported high LOH 
(39%) at 3p. Further Mullokandov et al., (1996); Jones and Nakamura et al 
(1992), using several probes for loci 3p found LOH for segment 3pl3-14.3 
in 75%of cervical cancers and in endometrial cancers, and of 3p21.2 - 22 in 
cervical and ovarian cancers. Kohno et al 1993 also found LOH at 3p 21 in 
cervical cancers. Karlsen et al (1994) found 70% LOH at 3p21 in cervical 
carcinomas. The 3p 13-21.1 region often showed LOH in cancers of the 
breast, lung, kidney and some other cancers. Michael Lin et al. (2000), 
found LOH at FHITgene (3pl4.2) was significantly higher in the recurrent 
group than in the non-recurrent group and MSI were more frequent in the 
recurrent group as compared with the non-recurrent group of cervical 
dyplasia. LOH at 3p might be an indicator of progression since its 
frequency increases from 25% in FIGO stage I to 100% in stage IV cases 
(Larson et al., 1997). Several studies agree that within the region 3p 14-22 
there are two sub regions where the LOH are concentrated and frequently 
both are altered in the same tumor. 
LOH at 5p 
In the present study of 58 cervical dysplasia, the percentage of LOH was 
significantly low (<25%) both at 3p and 5p, as compared to data obtained in 
invasive cancers (Mitra et al. 1994a). Maximum LOH was found on 
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chromosome 5p (D5S406) [13.3%; FRL= 0.13] supporting the hypothesis 
of possibility of candidate tumor suppressor gene at that locus. Mitra et al., 
(1995) reported high incidence of LOH (53%) at 5p (D5S406) in cervical 
cancer, which was not reported in other cancers, suggesting the possible 
location of a novel candidate tumor suppressor gene. It was further 
suggested by Mitra et al , (1994a) that allelic loss and microsatellite 
instability in the region 5pl5 (D5S406) might play a role in the 
development of cervical cancers and could be a potential marker for the 
progression of precancerous cervical lesions. Out of the 58 precancerous 
cases studied we observed 13.3% LOH at 5pl5. Mullokandov et al., 1996, 
reported similar findings for the adjacent region 5pl3.1-14 where the 
incidence was found to be 20% consistent with the findings of Mitra et al., 
1994, of 27.6% at 5pl4 in invasive cervical cancer. 
Since, all dysplasia cases do not progress to cancer and the process of 
cervical carcinogenesis may take several pathways, where LOH could be a 
late event. These could be the possible reasons for the low incidence of 
LOH in precancer. 
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7. HUMAN PAPILLOMAVIRUSES 
Introduction 
Infection of human papillomavirus (HPV) is sexually transmitted 
infection (STI) known to be the main causative agent of cervical 
preinvasive and invasive neoplasia. Therefore, detailed, knowledge 
regarding the epidemiology and biological properties of HPV is important 
for the global public health. From both biological and epidemiological 
standpoints there are compelling evidences, which conclude that human 
papillomaviruses are carcinogenic in humans (lARC Working Group, 
1995). Hildesheim et al.,(1994) has shown that persistence of HPV is 
higher among older women. More over persistence has been reported to be 
higher among women infected with high-risk HPV types (viz. 16, 18, 33 
etc) as compared to the low risk types. Persistent high levels of HPV DNA 
were more predictive of persistent cervical lesion (CIN). Similar results 
were obtained by Remmink and colleagues 1995 in a study that aimed to 
evaluate the predictive value of HPV genotyping for progressive CIN 
disease. They concluded that persistence of HR-HPV types leads to 
progression of cervical lesions, which is not observed in the absence of 
HPV DNA or in presence of low risk types. These findings suggest that 
only persistent infection of the cervical epithelium trigger tumour 
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development. Type specific prevalence is presented for the eighteen most 
common HPV types as identified by Clifford et al; Lechner et al., 1992 in 
meta-analysis of HPV types in invasive cervical cancers are: HPV types 6, 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 and 82 in order 
of descending prevalence for each subgroup analysis. Nubia Munoz et al 
2003 in their epidemiologic classification of human papillomavirus types 
grouped fifteen HPVs as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73 and 82); three as probable high-risk types (26, 53 and 66) 
and 12 were classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 
72, 81, and CP6108). 
Materials and Methods 
HPV detection was done by Polymerase chain reaction using MY09/11 
consensus primers. Detection of HPV types was done using type specific 
primers. DNA for PCR was isolated from cervical swabs fi-om the females 
using Ayer's spatula and transferred to the vials containing phosphate 
buffer saline. The DNA was isolated fi"om the exfoliated cervical cells. 
DNA extraction method involved incubation of cell nuclei in higher 
concentration of Proteinse-K at 65°C for 2.5hrs.following prolonged 
incubation at higher temperature, the enzyme is autoinactivated and the 
DNA isolated can be used directly for analysis without further purification 
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(Gopalkrishna et al., 1992). 0.5-l)^L of DNA was used as template for 
PGR. 
Polymerase Chain Reaction 
P-globin primers PC04 and GH20 (Saiki et al., 1988), which produces a 
268bp PGR product, were used as an internal amplification control. All the 
samples proved positive for P-globin amplification (figure 7.2) were 
considered for HPV analysis. DNA was amplified using MY09/11 
consensus primers (Manos., et al, 1989) (figure 7.3), in thermal cycler The 
amplification reactions were carried out for 35 cycles at annealing 
temperatures ranging from 56® G to 58° G using 1 Unit of Taq DNA 
Polymerase {Roche, Applied Biosystems), 2.5mM MgG12 and 200)liM 
dNTPs {New England Biolab). Positive and negative controls were also 
taken with every round of amplification. The PGR products were resolved 
on 2% agarose, stained with ethidium bromide and visualized under 
transilluminator or Gel Documentation system (BioRad). All the positive 
samples were further subjected to HPV typing with type specific primers 
for HPV types 6, 11, 16, 18 and 33 (figure 7.4 to 7.6). A new low cost 
PGR-RFLP method was developed for the detection of above five different 
HPV types discussed in chapter 8. 
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Table 7.1 Primers used in HPV analysis 
Primer Primer Sequence (amplimer) Amplicon (bp) 
PC04 
GH20 
5 '-CAACTTCATCCACGTTCACC-3' 
5 '-GAAGAGCCAAGGACAGGTAC-3' 
268 
MY09 
MYll 
5'- CGTCCMARRGGAWACTGATC- 3' 
a/c a/g a/t 
5'- GCMCAGGGWCATAAYAATGG -3 ' 
a/c a/t c/t 
-450 
HPV 
Type 6 
(F) 
(R) 
5'- TAGTGGGCCTATGGCTCGTC -3' 
5'- TCCATTAGCCTCCACGGGTG -3' 
280 
HPV 
Type 11 
(F) 
(R) 
5'- GGAATACATGCGCCATGTGG-3' 
5'- CGAGCAGACGTCCGTCCTCG-3' 
360 
HPV 
Type 16 
(F) 
(R) 
5'- AAGGCCAACTAAATGTCAC -3' 
5'- CTGCTTTTATACTAACCGG -3' 
217 
HPV 
Type 18 
(F) 
(R) 
5'- ACCTTAATGAAAAACCACGA -3' 
5'- CGTCGTTGGAGTCGTTCCTG -3' 
100 
HPV 
Type 33 
(F) 
(R) 
5'- ATGATAGATGATGTAACGCC -3' 
5'- GCACACTCCATGCGTATCAG -3' 
456 
Results 
To see the prevalence of HPV infection among different grades of lesions, a 
comprehensive study was carried out on 473 females visiting gynecological 
out patient department and cancer clinics, which included 264 women with 
normal cervix, 64 chronic cervicitis, 25 mild & moderate dysplasia, 33 
severe dysplasia, 61 squamous cell carcinoma and 3 adenocarcinoma. Out 
of 473 cases (median age 32 years), 178 (37.6%) were found HPV positive 
by consensus primers (MY09/11), HPV positivity in normal cervix was 
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24.7%, chronic cervicitis 37.5%, mild dysplasia 36.0%, moderate & severe 
dysplasia 57.5%), squamous cell carcinoma 85.2%, and adenocarcinoma 
100% (Table 7.2 and graph 7.2) Of the above 473 cases examined 
Maximum infection in all categories was found between the ages 30 and 50 
years. HPV infection was observed highest among the females of age group 
30-40 years which is considered to be the fertile period of women's life 
cycle. Epidemiological studies point to suggest the persisting infections to 
be a high risk factor for cer^dcal cancer development in older women. HPV 
infection among women with normal cytology showed increase in 30 to 40 
year interval and was maximum in 40-50 years, women with chronic 
cer\dcitis showed maximum percentage of HPV in the age group of 30-40 
years, whereas, HPV positivity in dysplasias was maximum between the 
age group 30-50 years and decreased after 50 years. Overall positivity 
showed a declining trend with the advancement of age group. 
Graph 7.1 Showing HPV infection with respect to age, among females 
with normal cervix, chronic cervicitis, mild dysplasia and severe 
dysplasia. 
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Fig. 7.1 Representative photograph •f DNA extracted by TTB method, 
resolved on 1% agarose (lanes 1-6) with X (Hind III digested) marker (M) 
268 bp 
Fig. 7.2 Photograph of ^-goblin gene amplification, used as internal 
amplification control. Resolved on 2% agarose with ^X 174 (Hae III 
digested) marker (M) 
- 450 bp 
Fig. 7.3 Photograph showing HPV positive (lanes 3-5 aad 7,8) and negative 
(lane 6) samples with positive and negative controls (lane 1 and 2 
respectively) amplified •sing MY09/11 consensus primers, resolved on 2% 
agarose with (j)X 174 (Hae III digested) marker (M). 
M 1 2 3 4 5 6 
B 
360bp 
280bp 
Fig 7-M 
Figr A. Showing Type 11 and B.HPV Type 6 positive samples, positive control 
(Lane-1) and negative control (Lanes -2) resolved on 2% agarose with (j)X174 
Hae III Digested marker (M), 
M 1 2 3 4 5 6 7 
B 
lOObp 
216bp 
Fig 
Fig. A. Showing HPV Type 18 and B. Type 16 cases with positive controls 
(Lane-IA & 2B) and negative controls (Lanes 2A & IB) resolved on 2% 
agarose with (j)X174 Hae III Digested marker (M). 
Results and Discussion 
M 1 2 3 
456bp 
Fig 7.6 Showing HPV types 33 resolved on 2% agarose with ^X 174 
(Hae III digested) marker (M) and negatives and positive controls 
(lanes 1 2 respectively). 
Table 7.2 Showing the HPV infection in the females at different clinical stages visiting 
gynecological out patient department and cancer clinic. 
CUnical 
Stages 
No. Of 
Cases 
HPV 
P o ^ v e 
(MYOWII) 
Type 06 Type 11 Type 16 Type 18 6/11 6/16 11/16 6/11/16 
Normal 287 71 
(24.7%) 
35 
(12.2%) 
23 
(8.0%) 
- - 17 
(6.0%) 
- - -
Chronic Cervicitis 64 24 
(37.5%) 
12 
(18.7»/i>) 
8 
(12.5%) 
2 
(3.1%) 
- 6 
(9.3%) 
- I 
(1.5%) 
-
Mild & Moderate 
Dysplasia 
25 9 
(36.0%) 
6 
(24.0%) 
4 
(16.2%) 
- - 3 
aim'o) 
- -
Severe Dysplasia 33 19 
(57.5%) 
8 
(24.2%) 
5 
(15.1%) 
3 
(6.06%) 
- 1 
(3.03%) 
2 
(6.1%) 
- -
Squamous Cell 
CarcinMiia 
61 52 
(85.2<»'o) 
46 
(75.4%) 
16 
(26,2%) 
26 
(42.6%) 
- 5 
(8.2%) 
16 
(26.2%) 
- 12 
(19.6%) 
Adenocarcinoma 3 3 
(100%) 
1 
(33.3%) 
- 1 
(33.3%) 
2 
(66.6%) 
- 1 
(33.3%) 
- -
Total n=473 178 
(37.6%) 
108 
(22.8%) 
58 
(12.2%) 
32 
(6.7%) 
2 
(0.42%) 
32 
(6.7%) 
19 
(4.0%) 
1 
(0.2%) 
12 
(Z5%) 
[Note: Co-infections are also included separately with individual types] 
Graph 12 Showing the HPV infection in the females at different clinical stages visiting 
gynecological out patient department and cancer clinic. 
120 T 
Chr.Cwr. Mod/Sev 
—ear— 
•L1 Pos 
-Type 6 
Type 11 
-Type 16 
-Type 18 
Co-inf6/11 
-Co-inf6/16 
-Co-inf 11/16 
-Co-inf6/11/16 
123 
Human papiliomavmises 
HPV type 6 considered to be a low-risk type showed the maximum 
prevalence in all grades of lesion including females with normal cervix 
(12 %); chronic cervicitis (18.7%); mild dysplasia (24%); severe 
dysplasia (24.2%); SCC (75.4%) and adenocarcinoma (33.3%). 
Infection with high-risk HPV type 16 was low in precancer and 
altogether absent in normal and mild dysplasia, in SCC percentage of 
HPV type 16 was 42.6%. 
Discussion 
Infection with HR-HPV types was low in preneoplastic lesions. HPV 16 
which is the most prevalent HPV type commonly associated with 
cervical cancer was present in 6.7% of severe dysplasia, whereas it was 
altogether absent in normal cervix and mild dysplasia, in chronic 
cervicitis HPV 16 was 3.1%. However, type 16 was significantly higher 
(p<0.01) in invasive cancer (42% in SCC and 33% in adenocarcinoma) 
as compared to preneoplastic lesions. HPV 16 have been found to be the 
most prevalent HPV types associated with cervical carcinoma. Earier 
studies reported HPV- 16 infection in more than 80% of cancers of 
uterine cervix (Das et al., 1992). In the present study HPV type 16 was 
fond in 42.6% of SCCs. Bosch et al., 1995. in the study of HPV 
prevalence in different countries have found the HPV-16 prevalence to 
be 33-50% in African countries; 34-59% in South America; 31-59% in 
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South east Asia; 54-76.5% in Europe; 76.5% in Germany and overall 
percentage of HPV-16 in cervical cancer was 49.9% worldwide. Munoz 
et al., (2003) found HPV-16 to be present in 54.6% of cancers. HPV 
type 18 was present in 66% cases of adenocarcinoma (see table 7.2). 
The incidence of low-risk HPV type (especially type 6) was quite high 
dysplasia (18.2% in mild dysplasia and 22.2% in severe dysplasia) and 
invasive cancers (75% in SCC and 33.3% in AC). Most of the reports 
show low prevalence of LR-HPV types in invasive cancers. In the 
present study co-infection of type 6 and 16 was significantly high 
(p<0.01) in SCC (26.2%) as compared to precancer. Reports on multiple 
infections suggest that co-infection increases the chance of tumor 
development. E6 protein of low risk HPV type 6 augments the ability of 
E7 to immortalize cells, the E6 and E7 proteins of HPV type 6 alone are 
weak at promoting immortalization, but coupled are potent, greater 
potency was seen when E6 of HPV 16 is coupled with E7 of HPV 6 or 
E7 of HPV 16 is coupled with E6 of HPV6 (Halbert, et al., 1992). The 
studies show that the LR-HPV types have the capability to transactivate 
cells. Foster and coworkers (1994) argue that there is no linear sequence 
that convincingly distinguishes the high risk from low-risk HPV E6 
proteins (Foster, et al., 1994). Further, binding ability of high-risk 
HPV's E7 for pRB complex is 10 folds higher than that of LR-HPV 
(Huibregste, et al., 1993). This difference results apparently from a 
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single amino-acid modification at the position 21 (Heck, et al , 1992) 
affecting its oncogenicity. Incidence of HPV 16 was low as compared to 
HPV type in dysplasia, e.g. in mild dysplasia HPV 6 was 18.2% 
whereas there was no infection of HPV type 16, in severe dysplasia also 
percentage of HPV 6 was high (22%) as compared to HPV 16 (6.9%) 
and co-infection of Types 6 and 16 was also low. The data obtained 
show a marked decline in the HPV 16 infection in the presence of HPV 
type 6 (6.9%). In invasive cancer percentage of HPV 6 was significantly 
high (75.4%) (p<0.01) as compared to type 16 (42.6%) co-infection of 
types 6 and 16 was also high (22.2%) in SCC i.e. Only 30% of the cases 
are there that have infection of type 6 only. On the basis of the data 
obtained and the previous reports based on the serological evidences 
(Sillins, et al, 1999) we can suggest that HPV 6 might be providing 
immunity against HPV 16 infection in women already infected with 
HPV type 6, or those with history of warts etc. on the other hand 
regarding co-infections of types 6 and 16 both the types together 
appeared to have an antagonistic interference causing relative excess 
risk due to Interaction (Halbert, et al , 1992). Therefore LR-HPV type 6 
also seems to play an intermediary role in the pathogenesis of the 
disease hence detection of HPV 6 along with other high-risk types is of 
considerable importance. It has been reported that there is difference of 
single amino acid in the E7 protein of HPV type 6 and that of HPV type 
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16 (Heck, et al., 1992), and since the oncogenic potential of HR- HPV 
types lie in E6 and E7 proteins, HPV type 6 could also act as IR-HPV 
(intermediate risk type). 
Variants of HPV Type 16 
High-risk human papillomaviruses especially type 16 are considered to 
be the most important risk factors in the development of cervical 
neoplasias (zur Hausen, 1991; Walboomers et al., 1999). Variation in 
the DNA sequence was found in the HPV type 16 present in patients 
with chronic cervicitis, severe dysplasia and squamous cell carcinoma. 
Nevertheless, further studies are required to determine whether 
particular variants of high-risk HPVs can predict the risk of cervical 
neoplasia. This question has also implications in the design of vaccines 
directed against HPVs. In the present study 25 different samples of HPV 
type 16 obtained from females with different grades of lesions were 
analyzed. To see the polymorphism in the URR region of HPV 16, SSCP 
of all 25 cases was performed. SSCP analysis revealed four different 
band patterns or band shifts (fig. 7.7), Most of the cases showed a 
common pattern (similar to lanes 3 and 4) and the sequences were 
similar to the European prototype. This pattern was present in one 
sample with chronic cervicitis and 17 SCC cases. The second pattern 
shown in lanes 2, 5 and 6 was present in four cases only (one chronic 
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cervicitis, one severe dysplasia and two SCC), the third pattern (lane 1) 
was present in single chronic cervicitis sample, whereas, the fourth 
pattern (lane 8) was also unique showing marked difference and was 
present in two SCC cases. 
CC SD SCC 
1 2 3 
SCC CC CC SD SCC 
4 5 6 7 8 
Fig 7.7 Representative photograph showing SSCP of HPV type 16 
with different conformational changes in the URR region. [CC: 
chronic cervicitis; SD: Severe dysplasia or CIN III; SCC: squamous 
cell carcinoma] 
Four samples (from lanes 1, 2, 4 and 8) with shifts in the mobility of 
bands as observed by SSCP (one sample was picked randomly from 
each category) were selected for DNA sequencing (URR region). 
The results of sequencing (fig. 7.8), as compared by the European 
prototype showed sequence variations: 
CC-1 showed deletion at base pair position 7839 and A to G substitution 
at 7866, mutation (A to G substitution) at 7866 was also observed in. 
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SD-2 and SCC-8, in addition to which substitution of T to A at 7840 
and C to G at 7885 was also found in SCC-8 (which showed marked 
difference in band pattern in SSCP). Thus out of 25 cases of HPV type 
16 we found four different mutant forms. 
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Fig 7.8. Pherograms showing mutations in a portion (7828-7904bases) of URR 
region of HPV 16 genome in chronic cervicitis (1), severed dysplasia (2), SCC (4 and 
8). Sequence of squamous cell carcinoma (4) was similar to the persistent European 
prototype commonly found in cervical cancers. 
Genetic Alterations and HPV infection in Cervical Dysplasia 
Since allelic losses are associated with HPV infection and analysis of 
mono and dinucleotide repeats might contribute to improved risk 
assessment for cervical cancer. HPV infection was found to be high in 
cases exhibiting microsatellite instability as compared to the 
microsatellite stable (MSS) cases. Whereas, there was no significant 
correlation between human papillomavirus infection and LOH in 
precancerous lesions of uterine cervix. HPV positivity in precancer was 
48.2% (36% in mild dysplasia and 57.5% in severe dysplasia). In both 
mild dysplasia and severe dysplasia, HPV positivity was significantly 
higher (p<0.01) among cases exhibiting MSI (64.5%) as compared to 
microsatelhte stable (MSS) cases (29.6%). In 58 precancer cases 
studied, 53.4% (31/58) of the cases exhibited microsatellite instability, 
of which, 64.5% were HPV positive. Whereas, 46.5% (27/58) cases 
were microsatellite stable (MSS) and HPV positivity was low (29.6%). 
Study shows that HPV was predominantly present in cases exhibiting 
microsatellite instability (58.3% in MD and 68.4% in SD), as compared 
to microsatellite stable (15.3% in MD and 42.8% in SD) (table 7.3). We 
found a significant correlation between the microsatellite instability 
status and HPV infection in the precancerous lesions of uterine cervix 
(p=0.02). The results suggested that microsatellite instability is an early 
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event in the process of cervical cancer from its predefined precursor 
lesions and HPV infection could be a major factor in the pathogenesis of 
the disease (Kersemackers et al., 1998; Bosch et al., 1995). 
Table 7.3 showing human papillomavirus infection with respect to 
the microsatellite status in different grades of precancerous lesions 
Clinical 
Stage 
MSI-L MSI-H MSS MSI 
(MSI-L+ H) 
Mild & Mod* 
Dysplasia 
(n=25) 
40.0% (10/25) 
HPV 70.0% 
(7/10) 
8.0% (2/25) 
HPVO 
52.0% (13/25) 
HPV 15.3% 
(2/13) 
48.0% (12/25) 
HPV 58.3% 
(7/12) 
Severe 
Dysplasia 
(n=33) 
36.3% (12/33) 
HPV 58.3% 
(7/12) 
21.2% (7/33) 
HPV 85.7% 
(6/7) 
42.4% (14/33) 
HPV 42.4% 
(6/14) 
57.5% (19/33) 
HPV 68.4% 
(13/19) 
Mild, 
Moderate & 
Severe 
(n=58) 
37.9% (22/58) 
HPV 63.6% 
(13/22) 
15.5% (9/58) 
HPV 66.6% 
(6/9) 
46.5% (27/58) 
HPV 29.6% 
(8/27) 
53.4% (31/58) 
HPV 64.5% 
(20/31) 
*Moderate dysplasia was included with early dysplastic lesion (mild) as only one 
moderate dysplasia case was reported 
Graph 7.3 HPV In Mild and Severe Dysplasia with 
respect to their Microsatellite Status 
-f-
CZ3MildDys 
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Mitra et al., (1995) reported high frequency of HPV in cases with LOH 
at 3p and 5p (77.8 to 100%). LOH at 3p was significantly more (64.3%) 
in HPV positive tumors than in HPV negative tumors (23.2%). No 
significant correlation was found with LOH and HPV in the precancers, 
however, high frequency of genomic alterations (microsatellite 
instability) with the HPV infection was found in precancers which may 
provide a molecular basis for the epidemiologic observation of 
increased progression risk for advanced preneoplastic lesions. . Over 
40% of the HSIL lesions and 64% of LSILs regress during follow up 
(Syrjanen et al., 1992), rest persist or progress to cancer. Since MSI 
represents defective mismatch repair system and HPVs are involved in 
the pathogenesis of the disease, it could be possible to categorize 
individuals, exhibiting MSI and HPV infection together, to be at a 
higher risk of developing cancer, and both, MSI and HPV infection 
together appears to be a prognostic indicator for categorizing females in 
dysplastic stage, which are at higher risk of developing cancer. 
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8. LOW COST DETECTION TEST FOR 
COMMON HPV TYPES 
Introduction: 
Since detection of HPV is not enough to study the pathogenesis or 
prognosis, the detection of particular HPV types that play important role in 
the pathogenesis of the disease is essential. The cost for typing and 
detection for any particular HPV type will be very high for DHCA and time 
consuming by PCR, we developed a new low-cost technique that detects 
five important HPV types that are predominantly present in cervical cancers 
and could be useful for the prognostic purpose. The technique utilizes 
RFLP of the same ~450bp amplicon that had been amplified while 
screening HPV by MY09/MY11 Primers. The technique has advantage 
over the DHCA or individual typing by PCR that it reduces the time and 
cost of second PCR or the cost of individual probes in DHCA-II. RFLP 
detects the five HPV types that are predominantly present in cervical 
dysplasia and cancer and their co-infections in just one experiment whereas, 
individual typing was found to be more combursive and time consuming. 
RFLP analysis for the detection of HPV types have been done using various 
other enzymes but the difference being that in our study RFLP was done 
using single enzyme, and benefit of Rsa-1 over other REs is that it detects 
the five most prevalent HPV types associated with cervical lesions and the 
134 Low cost HP V detection 
bands showing co-infection of the above five types can be resolved are far 
apart and are easily visible on 8% PAGE. Uncut bands in some instances 
may be present due to incomplete digestion at 450bp position that has to be 
overlooked. 
DNA Extraction From The Cervical Smear For HPV Testing 
Cervical scrapes were vortexed along with the wooden spatula, and 
poured in 1.5ml eppendorf tubes after removing the spatula. Then the 
ependdorfs were centrifuged at 2000 rpm for 2 minutes at 4°C. 
The DNA isolation involves basically two steps first washing the 
pellet twice with Tris-Triton Buffer (TTB) and PK digestion in Tris-EDTA 
Buffer (TTB). 1.5ml of the sample containing scraped cervical cells was 
taken in 1.5ml Ependdorf tube and centrifuged at 5000 rpm for 5'. The 
pellet was again washed with chilled IXPBS and cold centrifugation was 
done for 2 min at 2000 rpm. the pellet was washed twice in 1ml chilled 
TTB containing lOmM Tris-HCl (pH 8.0), lOmM MgC12, 300mM Sucrose 
and 0.8% Triton-X 100. The pellet was collected and rewashed in 0.5ml 
Cold TE Buffer containing lOMM Tris-HCl (pH 8.0), lOmM EDTA and 
lOmM NaCl. Finally the pellet was resuspended in 200|il TE buffer 
supplimented with 1.25mg/ml PK and incubated at 65 degrees Celsius for 
2.5hrs. The tubes were vigorously shaken every half-hour in order to allow 
uniform lysis of the pellet. When the solution became transparent it was 
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assumed that extraction was completed was boiled at 95 degrees for 10 
minutes for PK inactivation. 
Amplification of viral DNA with consensus primers detects a broad 
spectrum (more than 40) of HPV types. Detection of types using type 
specific primers is a combursive and time consuming process where each 
sample has to be amplified individually by type specific primers. We 
developed a low cost method for the detection of five most prevalent types 
of HP Vs. The technique involves RFLP of the LI amplicon with Rsa 1 
(recognition sequence GT'AC) restriction enzyme and resolving on 8% 
non-denaturing polyacrylamide gel. 1 unit of enzyme was used to cut 10|iL 
of the PGR product in one hour at 37°C with the buffer provided (NEB). 
The bands after analyzing on gel documentation system revealed the sizes 
specific for their respective types. Though the approximate size of the LI 
amplicon was -450 base pairs but it varied for different HPV types which is 
difficult to be distinguished in lower concentration of gels viz. the amplicon 
size of the MY09 and MYll consensus primer for HPV-06 is 447 base 
pairs for HPV-11 it is 449 base pairs for HPV-16, 452 base pairs for HPV-
18, 455 base pairs and for HPV-33, 449 base pairs. Therefore after 
digestion with Rsa 1 different band pattern can be observed which are quite 
distinguishable from the following five HPV types. 
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LI CONSENSUS PRIMERS (M=A+C ; R=A+G; W=A+T; Y=C+T) 
a/c a/t c/t 
MY 11 GCMCAGGGWCATAAYAATGG 
MY09 CGTCCMARRGGAWACTGATC 
a/c a/g a/t 
HPV 6b (447 bp) 
gcccaggg acataacaat ggtatttgtt ggggtaatca actgtttgtt actgtggtag 
ataccacacg cagtaccaac atgacattat gtgcatccgt aactacatct tccacataca 
ccaattctga ttataaagag tacatgcgtc atgtggaaga gtatgattta caatttattt 
ttcaattatg tagcattaca ttgtctgctg aagtaatggc ctatattcac acaatgaatc 
cctctgtttt ggaagactgg aactttgggt tatcgcctcc cccaaatggt acattagaag 
atacctatag gtatgtgcag tcacaggcca ttacctgtca aaagcccact cctgaaaagg 
aaaagcca tccctataag aaccttagtt tttgggaggt taatttaaaa gaaaagtttt 
ctagtgaatt ggatcagtat cctttgggac g 
HPVl l (449 bp) 
gctc agggacataa caatggtatt tgctggggaa accacttgtt tgttactgtg gtagatacca 
cacgcagtac aaatatgaca ctatgtgcat ctgtgtctaa atctgctaca tacactaatt 
cagattataa ggaatacatg cgccatgtgg aggagtttga tttacagttt atttttcaat 
tgtgtagcat tacattatct gcagaagtca tggcctatat acacacaatg aatccttctg 
ttttggagga ctggaacttt ggtttatcgc ctccaccaaa tggtacactg gaggatactt 
atagatatgt acagtcacag gccattacct gtcagaaacc cacacctgaa aaagaaaaac 
aggatcccta taaggatatg agtttttggg aggttaactt aaaagaaaag ttttcaagtg 
aattagatca gtttcccctt ggacg 
HPV 16 (452 bp) 
gcacagggc cacaataatg gcatttgttg gggtaaccaa ctatttgtta ctgttgttga 
tactacacgc agtacaaata tgtcattatg tgctgccata tctacttcag aaactacata 
taaaaatact aactttaagg agtacctacg acatggggag gaatatgatt tacagtttat 
ttttcaactg tgcaaaataa ccttaactgc agacgttatg acatacatac attctatgaa 
ttccactatt ttggaggact ggaattttgg tctacaacct cccccaggag gcacactaga 
agatacttat aggtttgtaa cccaggcaat tgcttgtcaa aaacatacac ctccagcacc 
taaagaagat gatcccctta aaaaatacac tttttgggaa gtaaatttaa aggaaaagtt 
ttctgcagac ctagatcagt ttcctttagg acg 
HPV18 (455 bp) 
gca cagggtcata acaatggtgt ttgctggcat aatcaattat ttgttactgt 
ggtagatacc actcccagta ccaatttaac aatatgtgct tctacacagt ctcctgtacc 
tgggcaatat gatgctacca aatttaagca gtatagcaga catgttgagg aatatgattt 
gcagtttatt tttcagttgt gtactattac tttaactgca gatgttatgt cctatattca 
tagtatgaat agcagtattt tagaggattg gaactttggt gttccccccc ccccaactac 
tagtttggtg gatacatatc gttttgtaca atctgttgct attacctgtc aaaaggatgc 
tgcaccggct gaaaataagg atccctatga taagttaaag ttttggaatg tggatttaaa 
ggaaaagttt tctttagact tagatcaata tccccttgga eg 
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HPV 33 (449bp) 
gc acaaggtcat aataatggta tttgttgggg caatcaggta tttgttactg tggtagatac 
cactcgcagt actaatatga ctttatgcac acaagtaact agtgacagta catataaaaa 
tgaaaatttt aaagaatata taagacatgt tgaagaatat gatctacagt ttgtttttca 
actatgcaaa gttaccttaa ctgcagaagt tatgacatat attcatgcta tgaatccaga 
tattttagaa gattggcaat ttggtttaac acctcctcca tctgctagtt tacaggatac 
ctataggttt gttacctctc aggctattac gtgtcaaaaa acagtacctc caaaggaaaa 
ggaagacccc ttaggtaaat atacattttg ggaagtggat ttaaaggaaa aattttcagc 
agatttagat cagtttcctt tgggacg 
After digestion products were resolved on 8% Polyacrylamide gel at 
200 V for 2.5 hrs and stained with ethidium bromide for 30 min. the gel 
was visualized under transilluminator or gel documentation system (Bio-
Rad) using the software Quantity One (Figure 8.3). The bands show the 
types of HPV present as well as the co-infections. 
The degenerate primers MY09/11 used for amplifying LI region, 
accepts certain degree of mismatch between primers and target DNA, 
accomplished by reducing the stringency of primer annealing, there being 
always a difference of few bases in the amplicon for different HPV types, 
which are not distinguishable in lower concentration of agarose gels. The 
product (amplicon) sizes amplified by MY09/11 primers for HPV type 6 
was 447bp; HPVll-449bp; HPV16-452bp, HPV18-455bp and for HPV33 
was 449bp, which after digestion with Rsa 1 (recognition sequence GT'AC) 
gives the following band sizes (Table 8.1 and Figure 8.1). 
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Table 8.1 Showing the number of possible cuts as well as size of the 
fragments of different HPV types after the digestion of LI amplicon with 
Rsa-L The bold values indicate the distinguishing bands after resolving on 
8% PAGE and staining with ethidium bromide. 
Type No, of cuts Fragment sizes 
HPV6 3 72,67,149 and 159 
HPV 11 3 72,216,26 and 135 
HPV 16 2 72,70 and 310 
HPV 18 4 72,38, 85,125 and 135 
HPV 33 3 72,39,236 and 102 
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Figure showing schematic representation of the Rsa I restriction sites for 
different HPV types in the amplicon of LI region of HPV genome, amplified 
using MY09 and MY 11 primers. 
M 1 2 3 4 6 7 8 9 10 11 12 
450bp 
Figs; Representative photograph showing HPV Positive cases amplified using 
MY09/MY11 consensus primers (amplicon size ~450bp) resolved on 2% 
agarose alongwith (j)X174 (H»e III digested) marker. Lanes 1«& 2 are positive 
and negative controls respectively. 
M 1 2 3 4 5 
603bp • 
310bp — • 
72bp 
Fig. Showing RFLP of LI amplicon using Rsa 1 [recognition 
sequenceGT'AC] resolved on 8% PAGE and stained with EBr. Lanes 1, 2, 3, 
4, 5 are HPV types 6, 11, 16, 18 and 33 respectively [M= (|)X174 (Hae III 
digested marker)]. 
Results and Discussion 
Comparing the two techniques, RFLP with restriction enzyme Rsa 1 
and PCR with type specific primers, we found that RFLP using Rsa-lean 
detect co-infections simultaneously and more consistently than individual 
typing with type specific primers and was cost effective as it saves the total 
cost of second PCR for HPV typing with type specific primers (Aadrian et 
al., 1990). Use of nested PCR with degenerate primers have been described 
by various workers to be extremely sensitive means of detecting a wide 
range of HPV types (Broker et al., 2001; Pizzighella et al., 1995). RFLP of 
the inner nested PCR product of MY09/11 primers using Bst Ell and a 
double digest of Pst 1 and Bgll (Patti et al., 2002) detected ten high-risk 
anogenital HPV types. Both the methods were able to detect broad range of 
HPV types. Most of the PCR-RFLP studies show either use of multiple 
restriction enzymes with two rounds of amplification. Whereas, method 
described in this paper, was found to be precise, with only one round 
amplification, followed by RFLP using single restriction enzyme, detected 
the five most prevalent HPV types commonly associated with cervical 
abnormalities and cancer. In conclusion, this method is less combursive, 
low-cost and user-friendly for the detection of HPV DNA from cervical 
swabs, both at clinical and research level. 
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9. EXPRESSION OF c erb B-2 AND y0- CATENINm 
CERVICAL DYSPLASIA 
Introduction 
Involvement of various oncogenes has been reported in several human 
cancers. About twenty genes can produce cancer in humans, acting on 
the same pathway of cell proliferation. These genes were first identified 
from oncogenic R.NA viruses called retroviruses. These oncogenes are 
named after the viral strain from which they were isolated: e.g. rel, src, 
myb, erb-A, erb-B, fps, yes, ros, mos, ras, abl, fes, fms and sis. Another 
agent that stimulates proliferation, epidermal growth factor, like src 
increases phosphorylation of membrane proteins at tyrosines, and so it is 
thought that this tyrosine phosphorylation somehow controls cell 
proliferation. Cancer cells contain ten times more phosphotyrosine than 
normal cells. 
cerbB2 
The erb-B oncogene has been found to be a truncated version of the 
gene coding for epidermal growth factor receptor. The tyrosine kinase 
domain in the viral erb-B viral oncogene, is intact but its catalytic 
activity is increased because of a shorter extracellular domain.however 
expression of genes may occur by various pathways like gene mutation, 
amplification etc. Although the oncogene c-erbB2 located on 
chromosome 17q has been reported to be frequently amplified and 
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overexpressed in many adenocarcinomas and carcinoma of breast 
(Slamon et al., 1989), stomach (Yokota et al., 1988), renal (Freeman et 
al., 1989) and ovary (Slamon et al., 1989; Tyson et al., 1991; Hou et al., 
1996). It has recently been reported that cerb-B2 oncogene is 
overexpressed in adenocarcinomas of uterine cervix (Kihana et al., 
1994) and in CIN and invasive cancer of the cervix (Mitra et al., 1994b; 
Soh et al., 2002). Expression of oncogenes, including ras, myc and 
erbB-2 have been reported in a high proportions of 
cholangiocarcinomas. The expression of cerbB2/ Her-2 neu was found 
to be insignificant in cervical dysplasia. Though it has been reported in 
invasive cervical cancer (Mitra et al., 1994b) and many other cancers of 
epithelial origin. Overexpression of erbB2 in over 60% of the invasive 
cancer patients was found (Pinion et al., 1991). Sharma et al., (1999) 
reported frequent amplification of cerbB-2 (Her-2/neu) oncogene in 
cervical carcinoma using non fluorescence in-situ hybridiaztion 
technique on paraffin sections which has preciously been reported using 
Southern Blot technique. Mitra et al., (1994b) studied 22 
protooncogenes for amplification in 50 primary untreated squamous cell 
carcinoma of uterine cervix belonging to clinical stages II and III and 
histologically all moderately to well differentiated, high expression of 
erbQ-2 was observed. 
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P-catenin 
^catenin has two distinct roles in E-cadherin mediated cell adhesion 
and carcinogenesois through APC gene mutation. One occurs at cell 
adhesion sites where cadherins become linked to the actin based 
cytoskeleton, the others occur in the cytoplasm and nuclei and are 
thought to regulate cell transformation. In order to evaluate the role of fi-
catenin during the progression of cervical cancer, we studied expression 
of both cytoplasmic and membranous jS-catenin in the precancerous 
lesions of uterine cervix. 
Materials and Methods 
Paraffm-embedded specimens of 58 precancer cases examined 
microscopically, tissue sections were obtained on Poly-L-Lysine coated 
slides. Cellular localization and expression of erbB-2 (HER-2/neu) and 
P-catenin was investigated by immunohistochemistry. 
3'Diaminobenzidine (DAB) was used as chromogen for staining. 
Prmary antibodies, biotinylated secondary antibody and peroxidase 
conjugated streptavidin were obtained from Neomarker [LSAB Kit, 
(Ready to use)]. 
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Results 
erbB-2 
We studied 58 cervical dysplasia cases (25 were mild dysplasia and 33 
severe dysplasia) for the expression of erbB-2 oncogene. erbB-2 
expression was found to be 8% (2/25) in mild dysplasia and 9% (3/33) 
in severe dysplasia (Chart 2). No significant correlation was observed in 
relation to HPV status (Fig 9.1). 
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fi-catenin 
Expression of P-catenin in 58 cervical dysplasia cases (including 25 
mild to moderate and 33 severe dysplasia) and 11 healthy controls were 
immunohistochemically investigated. The Membranous staining 
observed in healthy specimens was used as control (Fig. 9.2). For 
purpose of data analysis all cases, with reduction in membranous 
distribution of staining or increase in cytoplasmic staining in more than 
50% of epithelial cells, were classified as abnormal. Staining was scored 
independently by two observers and a high level of concordance (95%) 
was achieved. 24% (8/25) of the mild dysplasia showed abnormal 
expression (Fig. 9.3) whereas in severe dysplasia it was 54% (18/33) 
(Fig. 9.4). Results showed that the abnormal expression of /^catenin 
increases during the progression of mild to severe dysplasia. Out of 58 
dysplasia cases studied, abnormal expression of P-catenin was 
significantly high (p = 0.03) in severe dysplasia as compared to 
mild/moderate dysplasia (see Chart 2). In severe dysplasia HPV P-
catenin expression was also higher in HPV positive cases as compared 
to HPV negative cases. 
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Discussion 
Expression of erbQ-2 was found to be low in precancers 8% in mild and 
9% in severe dysplasia). cerbB-2 overexpression has recently been 
reported in adenocarcinomas of uterine cervix (Kihana et al., 1994). It 
was reported by Mitra et al., (1994b) in squamous cell carcinoma of 
uterine cervix by Southern blot technique and by non-flurscence in-situ 
hybridization (Mitra et al., 1999). 36.6% tumors revealed cerbB-2 
amplification experimental evidences indicate that erbB-2 gene plays an 
important role in development of cancers (Zhang et al., 1989). 
Overexpression of erbB-2 gene was reported in over 60% of patients 
with CIN III and invasive cancers (Pinion et al., 1991). Reduced erbB-2 
expression indicate the involvement of other oncogenes also in the 
development of cervical cancer. 
In our study, cytoplasmic expression of P-catenin was found 
significantly higher (p=0.03) in severe dysplasia as compared to mild 
dysplasia of uterine cervix. Since, it has been reported by Yutaka 
Kimura et al., (1999) that accumulation of free soluble /3-catenin in the 
cytoplasm and nuclei frequently occurs during carcinogenesis of 
squamous epithelium of esophagus. f3- catenin was expressed on the 
cell membrane in non cancerous epithelial cells while it was frequently 
expressed in the cytoplasm and/or nucleus in cancer cells (Takehiro et al 
2001). We also observed the same pattern where the expression of P-
catenin in membrane gradually decreased and cytoplasmic ^-catenin 
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increased significantly in severe dysplasia as compared to mild dysplasia 
Our results indicate that abnormal beta- catenin expression in cytoplasm 
may promote malignant transformation by triggering cyclin D1 
expression in cervical cancers. In order to investigate the cause of 
increased cytoplasmic staining of P-catenin in cervical dysplasia, it is 
suggested to analyze the P-catenin gene (CTNNBl) using PCR-SSCP 
analysis. Exon 3 of fi-catenin gene with nuclear overexpression has 
already been investigated and was found that mutations in CTNNB1 can 
increase free cytoplasmic P-catenin in colon cancers (Morin et al., 
1997). Cytoplasmic P-catenin staining was found to be significantly 
high in severe dysplasia than mild dysplasia. Therefore it is likely that 
accumulation of P-catenin in cytoplasm starts in late dysplasia and could 
pass into the nucleus (nuclear translocation) and interact with 
transcription factors causing progression to cancer. In severe dysplasia 
cytoplasmic P-catenin expression (69%) was significantly higher 
(p<0.01) in HPV positive samples as compared to HPV negative (35%), 
whereas, in mild dysplasia no such correlation was observed (table 8.1). 
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(generaC 
ConcCusion 
GENERAL CONCLUSION 
Cervical cancer develops from its predefined precursor lesions, 
which occur a decade earlier than does the invasive cancer, accumulating a 
number of mutations. Epidemiologic studies reveal multiple etiologic 
factors responsible for the development of cancer, these include infection 
with certain oncogenic types of human papillomaviruses (HPV), and other 
socio-economic factors like, multiparity, multiple sexual partners etc. 
Studies indicate that HPV infection alone is not capable of transforming a 
normal cell into tumorous, a number of genetic factors are also responsible 
for the progression of the disease. Cervical lesions accumulate a number of 
mutations as they progress towards malignancy and invasion. Therefore the 
identification of recurrent chromosomal locations is important for the 
understanding of the biology of cancer. The genetic alterations in cervical 
cancer might be either a consequence of biological selection for specific 
chromosome locations containing integrated HPV DNA or result from 
other alterations that are recurrently effected in this tumor. The recurrent 
genetic alterations can take several forms such as point mutation, viral 
DNA integration or LOH. On the other hand mutations in DNA mismatch 
repair genes result in the accumulation of mutations. The cell with a defect 
in any of these genes will invariably progress to develop cancer (Kinzler 
and Voglstein, 1998). In the present study, ten different polymorphic 
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markers were used to detect LOH and microsatellite instability. LOH and 
MSI were found to be two independent events occurring during the process 
of cervical carcinogenesis. Markers were selected for chromosomal arms 3p 
and 5p for their reported high LOH rate in other cancers and cervical cancer 
(Ku et al., 1977; Yokota et al , 1989; Jones and Nakamura, 1992; Kohno et 
al., 1993; Karlsen et al, 1994; Mitra et al , 1994a; Mullokandov et al, 1996; 
Larson, 1997; Chu et al, 1998) suggesting the possibility of several TSGs 
located in the region 3pl4.1-p22 and 5pl5.1-15.2. LOH scored 
significantly low {<15%) in precancer, possibly because not all dysplasia 
cases progress to cancer and carcinogenesis may take several pathways. 
LOH was thought to be a late event in the pathogenesis of the disease. 
Though LOH was maximum (13.3%) at 5p (D5S406) supporting the study 
of Mitra et al , (1994a) for the possibility of a novel candidate TSG at 5p, 
3p (D3S1300) showed 10.7% LOH. Microsatellite instability was tested 
using the Bethesda Conference reference panel of five markers for both 
mono and dinucleotide repeats (BAT 25, BAT 26, D2S123, D5S346 and 
D17S250). These markers were applied for the first time to cervical 
dysplasia. MSI was present in 48%) in mild and moderate and 57.5% in 
severe dysplasia indicating replication error phenotype. MSI and MSS 
appear to characterize two different pathways of cervical carcinogenesis. 
Marker D2S123 showed maximum (27.5%) instability. BAT25 located in 
the intron 5 of c-kit oncogenes also showed instability in 20%) cases. HPV 
155 General conclusion 
infection also showed a different trend. HPV type 6 was significantly 
higher in both precancer and cancer as compared to four other HPV types 
that are commonly associated with cervical abnormalities. HPV type 16 
which was considered to be high-risk type for the pathogenesis of cervical 
dysplasia was present in 42% of cervical cancer (SCC), whereas HPV type 
^ (LR-HPV) was present in 75% in SCC and 24% in precancers, co-
infection of HPV type 6 and 16 was also present which itself is a risk factor 
for the development of cervical cancer, as E6 of HPV type 6 augments the 
capability of E7 of HPV type 16 and E7 of type 6 promotes the potential of 
HPV type 16 in immortalizing normal cell. However, several serologic 
evidences suggest the interaction of different HPV types. Both HPV types 6 
and 16 have antagonistic interference in the respect that HPV type 6 
provides immunity against HPV 16 infection. Further, it was also found 
that HPV infection was significantly higher in the dysplasia exhibiting 
microsatellite instability as compared to MSS cases. Microsatellite 
instability in preneoplastic lesions was found to be 53.4% (31/58) whereas 
46.5% (27/58) were MSS. Overall HPV positivity in mild dysplasia was 
36% whereas in severe dysplasia it was 57.5%. In severe dysplasia, HPV 
positivity was significantly high (p<0.01) with MSI (64.5%) as compared to 
MSS (29.6%). Thus microsatellite instability, which was an early event in 
the process of cervical carcinogenesis and together with HPV infection, it 
appears to be a good prognostic indicator for categorizing females who are 
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at higher risk of developing cancer. Whereas, oncogene cerbB-2, which has 
been reported to be over expressed in adenocarcinoma of uterine cervix and 
squamous cell carcinomas of uterine cervix, did not show any significant 
expression in cervical dysplasia. However, present study showed that in 
cytoplasmic P-catenin expression was more in severe dysplasia as 
compared to early preneoplastic lesions (mild dysplasia). In order to 
investigate the cause of increased cytoplasmic staining of fi-catenin in 
cervical dysplasia, PCR-SSCP analysis of p-catenin gene (CTNNBl), 
could be done in cases where cytoplasmic expression was observed. Exon 3 
of /3-catenin gene with nuclear overexpression has already been 
investigated and was found that mutations in CTNNBl can increase free 
cytoplasmic P-catenin in colon cancers (Morin et al., 1997). In present 
study, cytoplasmic P-catenin staining was found to be significantly high in 
severe dysplasia than mild dysplasia. Further, in severe dysplasia 
cytoplasmic P-catenin expression (69%) was significantly higher (p<0.01) 
in HPV positive samples as compared to HPV negative (35%), whereas, in 
mild dysplasia no such correlation was observed (table 8.1). It is likely that 
accumulation of P-catenin in cytoplasm starts in late dysplasia and could 
pass into the nucleus (nuclear translocation) and interact with transcription 
factors causing progression to cancer. 
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Summary 
Detection of human papillomavirus (HPV) types 6, 11, 16, 18 and 33 including co-
infections among females attending gynaecological out patient department and 
cancer clinics, was done by restriction fragment length polymorphism (using Rsa-
1), of approximately 450bp amplicon, obtained by the amplification of the LI 
region of HPV genome with consensus primers MY09 /I l(Manos., et al., 1989). 
The results were further tested with HPV type specific primers (Van den Brule). 
The technique was found to be low-cost and less time consuming. The advantage 
of Rsa 1 over other enzymes was that it detects the five most prevalent HPV types 
commonly associated with warts, cervical dysplasia and cancer. 
Key words: HPV, RFLP, Rsa 1, cervical dysplasia, cancer 
Method 
i DNA extraction = 3 hours 
ii Polymerase chain reaction for detection of HPV infection by MY09/11 
primers = 2 hours. 
iii Electrophoresis= 45 minutes 
iv Preparation of polyacrylamide gel = one hour 
V RE digestion = one hour 
vi Electrophoresis on polyacrylamide gel= 2.5hrs 
vi Staining with ethidium bromide = 25 minutes 
Total time in detection = 11 hours 
Human papillomaviruses are small non-enveloped tumorigenic double stranded 
DNA viruses of about 8kbp. More than 100 HPV types have been identified and 
characterized on the basis of DNA sequences. Human papillomaviruses cause 
warts (Schwarz et al, 1983), papillomas (Gissmann et al, 1982) and certain 
cancers including cancer of the uterine cervix (Bosch et al, 1995, Benndenon et al 
1986, Cole et al 1986). Cervical intraepithelial neoplasia and cervical cancer both 
are strongly associated with persistence presence of some types of human 
papillomavirus. Over 90% of the cervical carcinoma have been shown to contain 
some high-risk HPV types (Nieminen et al, 1991). The genital HPVs are 
classified into two groups high and low risk based on whether or not the lesions 
with which they are associated are at significant risk for malignant progression. 
The low risk HPVs such as HPV-6 and 11 are generally associated with genital 
warts (condyloma accuminata and flat genital warts), lesions that only rarely 
progress to cervical cancer. The high-risk viruses, such as HPV-16 (Favre et al, 
1989; Seedorf et al, 1985), HPV18 (Cole ST et al, 1987) and HPV 33 (Benndenon 
et al, 1987; Cole et al 1986), and few other are associated with CIN and cervical 
cancer. HPV 16, 18, 33 and 45 account for more than 90% of the high risk types. 
The MY09/MY11 primer set mediated PCR (MY-PCR) (Hildesheim et al., 1994; 
Manos., et al., 1989) and the GP5+/GP6+ primer set mediated PCR (GP+-PCR) 
(de Roda et al., 1995) are the most frequently used amplification systems for the 
detection of HPV DNA in clinical samples and genotyping by type specific 
primers (Van Den Brule et al , 1989). There was differential amplification 
sensitivity of HPV types between the two systems. MY-primer set was found to be 
inefficient for HPV type 35 detection but was proved to be more sensitive than 
GP+-PCR primer set in the amplification of multiple HPV DNA types within a 
given sample (Qu et al., 1997). According to a recent meta-analysis (Clifford et 
al., 2003), it was found that HPV prevalence vary little between geographical 
regions. The most common high-risk HPV types in cervical squamous cell 
carcinoma was HPV 16 whereas, HPV 18 was predominant in adenocarcinomas 
and adenosquamous carcinomas followed by HPV 16. The MY09/11 primer set 
has been used predominantly in epidemiologic studies in North and South 
America and Asia (Bosch et al., 1995; Liaw et al., 1995) whereas the GP5+/GP6+ 
has been used primarily in Europe (de Rod Husman et al., 1995). Furthermore, 
various studies indicated frequent co-infections of HPV 16 and HPV6, suggesting 
interaction between different HPV types in multiple infections. HPV 16 and 6 
appeared to have antagonistic interference in cervical carcinogenesis. Serological 
evidences indicate protection by HPV type 6 infection against HPV type 16 
cervical carcinogenesis (Sillins et al., 1999), whereas in co-infections the E6 
protein of low-risk HPV (type 6) augments the ability of E7 of HPV type 16 or E7 
of HPV type 6 coupled with E6 of type 16 increases the potency and ability to 
immortalize cells (Halbert et al., 1992). These studies suggest the detection of 
low-risk HPV types and their co-infections alongwith HR-HPVs to be important 
for understanding the pathogenesis of the disease and the biological behavior of 
HPVs during cervical carcinogenesis. Infection of multiple HPV DNA types is a 
risk factor for cervical intraepithelial neoplasia (Liaw et al., 1995). These 
observations demand for an early detection of virus types, especially those 
associated with cervical dysplasia and cancers, with an easy, cost-effective and 
simple diagnostic procedure. We, developed a new rapid and cost-effective PGR-
RFLP technique, using restriction digestion with Rsa 1, of the amplified products 
of LI region (by MY09/11 consensus primers). It detects five different HPV types 
and their co-infections simultaneously (Table 1.1), commonly associated with 
warts, precancerous and cancerous lesions. Cervical scrapes from the women, 
attending the Outpatient department of Gynaecology, were obtained after taking 
their proper consent. Scrapes were taken by scraping the ectocervix or the surface 
of the portio with Ayer's spatula and put in 5mL of 1 X PBS (Phosphate buffer 
saline). The samples were transported to the laboratory at 4°C and stored at -20°C 
till further processing. The DNA isolation from the exfoliated cervical cells 
involves basically two steps: first washing the pellet twice with Tris-Triton Buffer 
(TTB) and PK digestion in Tris-EDTA Buffer (TTB) (Gopalkrishna et al 1992), 
total time required in DNA isolation was 3 hours. Cervical scrapes were agitated 
along with the wooden spatula, and poured in 1.5mL tubes after removing the 
spatula. Then the tubes were centrifuged at 2000 rpm for 2 minutes at 4°C. The 
pellet was rewashed with chilled IXPBS and cold centrifugation was done for 2 
min at 2000 rpm. the pellet was washed twice in 1ml chilled TTB [lOmM Tris-
HCl (pH 8.0), lOmM MgCh, 300mM Sucrose and 0.8% Triton-X 100]. The pellet 
was collected and rewashed in 0.5ml Cold TE Buffer [lOMM Tris-HCl (pH 8.0), 
lOmM EDTA and lOmM NaCl]. Finally the pellet was resuspended in 200|il TE 
buffer supplimented with Proteinase K (PK =1.25mg/ml) and incubated at 65^C 
for 2.5hrs. The tubes were shaken vigorously every half-hour in order to allow 
uniform lysis of the pellet till the solution became transparent. PK inactivation was 
done by boiling at 95°C for 10 minutes, p-globin primers PC04 (5'-
CAACTTCATCCACGTTCACC-3')and GH20 (5'-
GAAGAGCCAAGGACAGGTAC-3') (Saiki et al., 1988), which produces a 
268bp PGR product, were used as an internal amplification control. Precautions 
were taken to avoid cross contamination of samples and the amplified products. 
The samples were then screened for the presence of HPV using proper controls. 
The detection of HPV was done by PGR amplification of the LI region of HPV 
genome using degenerate primers, MY09/ll(Manos et al 1989) (Fig 1.1). PGR 
using MY09/11 primers have been proved to be a valid tool for the detection of a 
wide spectrum of genital HPVs (Gravitt et al, 1998). The ampHfication was done 
using Taq DNA polymerase (0.6U/25)iL, Catalog No. MME 5J), lOX Buffer with 
2.5mM MgCl2 and dNTPs 200|iM/25|aL (New England Biolab; Catalog No. 
N0442S), with initial denaturation of 95° for 4 minutes followed by 35 cycles of 
94°, 56° and 72°C each for 30 seconds and a final extension of 72° for seven 
minutes. 8|iL of the sample was loaded for electrophoresis on 2% agarose (Sigma; 
Catalog No. A9539), stained with ethidium bromide, for the screening of HPV 
positive cases (Fig 1.1). RFLP of the PGR products of all the HPV positive 
samples was done using 1 Unit of Rsa 1 (New England Biolab; Catalog No. 167 
L) with NEB reaction buffer, and incubating at 37°C for 1 hour. After digestion 
the products were resolved on 8% polyacrylamide non denaturing gel with TBE 
buffer, after 30 minutes of staining with ethidium bromide, the products were 
visualized under UV/gel documentation system (BioRad) using the software 
Quantity One. The bands show the types of HPV present including their co-
infections (Fig 1.2). 
The degenerate primers MY09/11 used for amplifying LI region, accepts certain 
degree of mismatch between primers and target DNA, accomplished by reducing 
the stringency of primer annealing, there being always a difference of few bases in 
the amplicon for different HPV types, which are not distinguishable in lower 
concentration of agarose gels. The product (amplicon) sizes amplified by 
MY09/11 primers for HPV type 6 was 447bp; HPVll-449bp; HPV16-452bp, 
HPV18-455bp and for HPV33 was 449bp, which after digestion with Rsa 1 
(recognition sequence GT'AC) gives the following band sizes (also see Fig 1.3). 
Type No. of cuts Fragment sizes 
HPV6 3 72,67,149 and 159 
HPV 11 3 72,216,26 and 135 
HPV 16 2 72,70 and 310 
HPV 18 4 72,38, 85,125 and 135 
HPV 33 3 72,39,236 and 102 
Table 1.1 shows the number of possible cuts and the sizes of the fragments 
resolved after the digestion of LI amplicon with Rsa 1 for different HPV 
types. The bold values indicate the distinguishing bands. 
To confirm the results obtained by RFLP, all positive cases were amplified using 
type specific primers. (Table 1.2). 1-2|liL DNA was used for amplification with 
type specific primers, temperature profile for the amplification was same for each 
type, initial denaturation 95°C for 5 minutes, followed by 35 cycles (95°C for 30 
sec, 5 6 ^ for 30 sec and 72°C for 30 sec) and a final extension at 72°C for 7 
minutes. The products were resolved on 2% agarose after ethidium bromide 
staining (Fig. 1.3; A-E). 
HPV Type Primer Sequence 
Type 6 (F) 5'-TAGTGGGCCTATGGCTCGTC-3' 
(R) 5'-TCCATTAGCCTCCACGGGTG-3' 
Type 11 (F) 5'-GGAATACATGCGCCATGTGG-3' 
(R) 5'-CGAGCAGACGTCCGTCCTCG-3' 
Type 16 (F) 5 '-AAGGCCAACTAAATGTCAC-3' 
(R) 5'-CTGCTTTTATACTAACCGG-3' 
Type 18 (F) 5 '-ACCTTAATGAAAAACCACGA-3' 
(R) 5'-CGTCGTTGGAGTCGTTCCTG-3' 
Type 33 (F) 5'- ATGATAGATGATGTAACGCC-3' 
(R) 5'-GCACACTCCATGCGTATCAG-3' 
Table 1.2 Primers used for PCR 
Amplimer details for type specific PCR and P-globin taken from previously 
published papers and were obtained through Microsynth. 
Comparing the two techniques, RFLP with restriction enzyme Rsa 1 and PCR with 
type specific primers, we found that RFLP using Rsa-lean detect co-infections 
simultaneously and more consistently than individual typing with type specific 
primers and was cost effective as it saves the total cost of second PCR for HPV 
typing with type specific primers (Aadrian et al., 1990). Use of nested PCR with 
degenerate primers have been described by various workers to be extremely 
sensitive means of detecting a wide range of HPV types (Broker et al , 2001; 
Harwood et al., 199; Pizzighella et al, 1995). RFLP of the inner nested PCR 
product of MY09/11 primers using Bst Ell and a double digest of Pst 1 and Bgll 
(Patti et al., 2002) detected ten high-risk anogenital HPV types. Both the methods 
were able to detect broad range of HPV types. Most of the PCR-RFLP studies 
show either use of multiple restriction enzymes with two rounds of amplification. 
Whereas, method described in this paper, was found to be precise, with only one 
round amplification, followed by RFLP using single restriction enzyme, detected 
the five most prevalent HPV types commonly associated with cervical 
abnormalities and cancer. In conclusion, this method is less combursive, low-cost 
and user-fiiendly for the detection of HPV DNA from cervical swabs, both at 
clinical and research level. 
M 1 3 4 5 6 7 8 9 1 0 1 1 1 2 
450bp 
Fig 1.1. Representative photograph showing HPV Positive cases amplified 
using MY09/11 consensus primers (amplicon size ~450bp) resolved on 2% 
agarose with (|)X174 (Hae III digested) marker. Lanes 1& 2 are positive and 
negative controls respectively; 3 & 4 mild dysplasia; 5-7 severe dysplasia; 8-
11 squamous cell carcinoma and 12 adenocarcinoma of uterine cervix. 
10 
M 1 2 3 4 5 
Fig 1.2. Rsa 1 digest of LI amplicon resolved on 8% PAGE showing HPV 
types 6, 11, 16, 18 and 33 in lanes 1 to 5 respectively [M, (|)X174 (Hae III 
digested) marker]. 
11 
M 1 2 3 4 5 6 7 M 1 2 3 4 5 6 
360bp 
M 1 2 3 4 
456bp 
E 
Fig 1.3 Showing HPV types 18, 16, 11 and 6 and 33 (A to E respectively) 
amplified using type specific primer, resolved on 2% agarose with (()X 174 
(Hae III digested) marker with positive controls (lanes 1 in A, C and D) and 
lane 2 in B & E) and negative controls (lanes 2 in A, C , D and lane 1 in B & 
E). 
12 
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